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Hepatocellular carcinoma (HCC) is the third most lethal cancer due to late detection, 
high recurrence and limited therapeutics. Although genetic alterations have been 
recently studied by whole genome or whole exome next generation sequencing, a 
comprehensive analysis of HCC relevant genes on lesions with low and high grade of 
dedifferentiation is missing. Herein, I aimed to study the nuclear and mitochondrial 
genomic alterations in order to characterize HCC development and clonality. 
First, for target enrichment of HCC relevant genes and mt-genome, gene loci of 
relevance had to be selected and primer sets designed. Subsequent ultra-deep 
sequencing revealed that in accordance with previous studies, the β-catenin gene 
(CTNNB1) was shown to be the most frequently mutated oncogene, whereas the 
TP53 and AXIN1 genes were the most frequently mutated tumour suppressor genes. 
Interestingly, CTNNB1 mutations were detected in lesions with early as well as 
advanced HCC stage, confirming its role in hepatocarcinogenesis. In contrast, TP53 
mutations were only detected in nodules with advanced HCC stage. In addition, non-
protein damaging mutations in the AXIN1 gene were detected in higher frequency in 
non-tumour than in tumour lesions; indicating the loss of heterozygosity (LOH) in 
some tumour samples. Since AXIN1 alterations effect as well as β-catenin mutations 
the WNT signalling, my study supports new therapeutical strategies targeting 
components of the WNT pathway. 
Furthermore, this study addressed the intra-tumour clonal structure by ultra-deep 
sequencing of the entire mitochondrial (mt) genome for better understanding how 
HCC originate, develop and progress. Since, the mt-genome is highly susceptible to 
DNA alterations due to the lack of protective histones and a limited DNA repair 
system, the mutations of the mtDNA are ideal targets to be used for follow up of 
tumour progression and analysis of tumour clonality. Therefore, I established a NGS 
approach for a rapid and sensitive mutation screening analysis of the entire mt-
genome as a novel tool for tumour cell tracking. 
Beside a high mt-mutation rate in tumour areas, also frequent mt-mutations were 
observed in peri-tumour area suggesting that mt-genome is susceptible at earliest 
stage of hepatocarcinogenesis. Furthermore, most HCC nodules of individual sample 




increasing numbers and frequency of a particular mt-hotspot mutation refer to the 
progression of the HCC dedifferentiation. 
In summary, I established a fast pipeline of mutation analysis for simultaneous 
testing of a tumour specific, hotspot gene panel covering diagnostic relevant loci of 
HCC, and could assist in the selection of currently available treatments likely to be 
most effective for HCC patients. Notably, effective targeting of the Wnt signalling 
pathway is considered as a potential target for pharmacological therapy that is 
eagerly awaited.  
Additionally, our mt-genome screening based approach representing rapid and 






Das hepatozelluläre Karzinom (HCC) ist die dritthäufigste tödliche Krebsart, da es 
spät erkannt wird und es nur limitiert therapierbar ist. Obwohl in jüngster 
Vergangenheit genetische Veränderungen im HCC durch neue Sequenzieransätze 
des gesamten Exoms und Genoms analysiert wurden, fehlen umfangreiche 
Kenntnisse über tumortreibende Mutationen in HCC in Abhängigkeit der 
Dedifferenzierung. In der vorliegenden Arbeit sollte daher der Mutationsstatus in der 
Entwicklung von HCC untersucht und genomische Unterschiede zwischen frühen 
und fortgeschrittenen Tumoren betrachtet werden.  
Zunächst wurden HCC relevante Genloci für die Studie festgelegt und ein 
entsprechendes Primerset für die Anreicherung und nachfolgende Analyse der 
Zieldomänen durch Tiefensequenzierung entworfen. Übereinstimmend mit früheren 
Daten konnte in der vorliegenden Studie dargelegt werden, dass das β-Catenin-Gen 
(CTNNB1) das am häufigsten mutierte Onkogen in HCC ist, während TP53 und 
AXIN1 die meist mutierten Tumorsuppressorgene sind. Hierbei konnte herausgestellt 
werden, dass CTNNB1-Mutationen insbesondere bereits in frühen HCC-Stadien 
nachgewiesen werden konnten, was die tumortreibende Rolle von β-Catenin in der 
Hepatokarzinogenese unterstützt. TP53-Mutationen wurden dagegen vermehrt in 
HCC mit hohem Dedifferenzierungsgrad gefunden. Daneben wurden Veränderungen 
im AXIN1-Gen nachgewiesen, die aufgrund der Frequenzunterschiede zwischen 
peritumoralen und Tumorgeweben in einigen Fällen auch auf einen Verlust der 
Heterozygotie (LOH) schließen lassen. Da AXIN1 ebenfalls wie β-Catenin im WNT-
Signalweg anzusiedeln ist, unterstützen die vermehrten AXIN1-Veränderungen in der 
Hepatokarzinogenese, dass neue Therapieansätze besonders auf den Wnt-
Signalweg zielen sollten. 
Darüber hinaus adressierte diese Studie die intratumorale klonale Struktur des HCC. 
Aufgrund der fehlenden Histone und einem begrenzten Reparatursystem ist das 
mitochondriale (mt) Genom sehr anfällig für DNA-schädigende Agenzien und daraus 
hervorgehende Mutationen. Das mt-Mutationsmuster kann daher genutzt werden, um 
die Tumorevolution zu verfolgen und die Klonalität zu beurteilen. Hierfür wurde die 
Anreicherung und Ultra-Tiefensequenzierung ganzer mitochondrialer (mt) Genome 






Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and 
represents the fifth most common cancer worldwide. HCC ranks as one of the 
most critical global health problems due to its increasing incidence and mortality 
rate over the years. In 2000, HCC was estimated to be the third most common 
cause of cancer deaths, with 500,000 deaths worldwide each year [1, 2]. Due to its 
increasing incidence, it was estimated in 2012 to be the second most important 
cause of cancer deaths, and caused approximately 750,000 deaths annually [3]. 
The incidence of HCC has striking global variations; it is particularly high in 
developing countries (East Asia and sub-Saharan Africa), and lower in developed 
regions (North America and most of Europe), though here the incidence is 
increasing [4, 5]. These regional differences mainly depend on the complex 
aetiology of HCC and associated risk factors. The most prominent factors 
associated with HCC are chronic viral hepatitis B (HBV) and hepatitis C (HCV), 
alcohol abuse, aflatoxin-B1 consumption, and virtually all cirrhosis-inducing 
conditions. These factors drive HCC incidence rates in different regions [6]. In 
addition to regional tendencies of HCC incidence, HCC is notably more prevalent 
in males, with an average ratio of between 2:1 and 4:1 male patients to female 
patients [5]. 
 
1.1 HCC aetiology and pathophysiology 
HCC is a heterogeneous disease and is associated with various risk factors.  80%-
90% of all HCC cases are associated with liver cirrhosis, which represents the 
major single risk factor. Chronic infections of HBV and HCV are also main risk 
factors [5, 7]. HBV infections are responsible for 50%-80% of HCC cases 
worldwide, whereas 10%-25% of cases are thought to be a result of HCV infection. 
The mechanisms by which HBV contributes to HCC carcinogenesis are unclear. 
Chromosomal integration of HBV-DNA in a critical location within the host genome 
can promote cellular proliferation and an increased risk of HCC [8]. In addition, the 
viral expression of the transcriptional activator, the HBV Xgene (HBx), is 
suggested to promote an important cellular pathway that is implicated in 
hepatocarcinogenesis as the RAS-RAF-MAPK kinase pathway [9, 10], while the 




transcriptional activator NS5A [11], and also to the viral core protein [12]. 
Furthermore, the oncogenic role of aflatoxin B1 is linked to somatic mutation in the 
TP53 tumour suppressor gene [13]. 
HBV-related HCC and non-alcoholic liver fatty liver disease (NAFLD) can occur in 
the absence of cirrhosis, while almost all cases of HCV-related HCC occur with 
cirrhosis [14], but mostly HCC is based on chronic inflammation and cirrhosis. 
Cirrhosis is characterised by an increase in fibrous tissue and a destruction of liver 
cells, which stimulates cellular proliferation and in turn leads to the development of 
precancerous nodules. 
Besides of viral infections, also non-viral risk factors occur, which include chronic 
alcohol abuse, aflatoxin intake, diabetes, obesity, or certain hereditary conditions 
such as hemochromatosis [15]. 
Both diabetes and obesity are implicated in the development of non-alcoholic 
steatohepatitis (NASH), which can progress to cirrhosis and its related 
complications, including HCC [16]. Hereditary hemochromatosis, mostly due to 
homozygous HEF-C282Y mutations, is associated with an increased risk for HCC 
as a result of increased iron stores stimulating the carcinogenesis [17]. 
 
1.2 Molecular pathogenesis of HCC 
1.2.1 Altered signalling during HCC development 
Hepatocarcinogenesis is a multi-step process that is mostly linked to chronic liver 
damage as described above. Accumulated genetic and epigenetic alterations 
result in the activation of tumour enhancer genes (proto-oncogenes) and their 
mitogenic signalling pathways, as well as the inactivation of tumour suppressor 
genes, leading to autonomous cellular proliferation. Main pathways contributing to 
HCC development include the Wnt/β-catenin, insulin growth factor (IGF), 
PI3K\AKT\mTOR, and MAPK pathways and growth factor-regulated angiogenic 
signalling. 
The Wnt\β-catenin pathway is suggested to be one of the main drivers of 
hepatocarcinogenesis [18]. β-catenin is a structural protein that acts as a regulator 
in the cadherin-mediated cell-cell adhesion system and in the Wingless\Wnt signal 




the mutation of the phosphorylation domain targeted by glycogen synthase kinase 
3b (GSK3b) and subsequent inhibition of ubiquitin-proteasome degradation. 
Furthermore, mutations in the genes whose products activate β-catenin signalling, 
such as APC and AXIN1, lead to β-catenin accumulation [18, 21-23].  
Accumulated β-catenin translocates to the nucleus and forms a complex with T 
cell-factor (TCF)\lymphoid enhancer-factor (LEF), activating transcription activity of 
target genes such as cyclin D1, c-Jun, and c-Myc [21, 24]. The expression of 
these potential β-catenin targets play a critical role in regulating cellular growth, 
differentiation, and apoptosis in liver cancer [25, 26]. 
Another important pathway that is involved in HCC is the IGF signalling. This 
pathway is reactivated in HCC and mainly occurs at the level of IGF-II expression. 
Activation of the IGF-signalling pathway is triggered by receptor phosphorylation 
and ultimately leads to the activation of MAPK, PI3K\AKT\mTOR pathways [27]. 
The IGF-signalling pathway regulates several cellular processes, including 
proliferation, motility, and inhibition of apoptosis [28].  
The PI3K\AKT\mTOR pathway plays a significant role in HCC progression by 
promoting neoangiogenesis [29]. Activated AKT phosphorylates several 
cytoplasmic proteins, such as mTOR and BCL-2 associated death promoter 
(BAD), leading to increased cellular proliferation, decreased apoptosis, and 
increased cell survival [30]. This pathway is negatively regulated by phosphatase 
and tensin homolog (PTEN), which dephosphorylate the lipid products of PI3K 
[31]. Therefore, any anomalies in PTEN function result in over activation of the 
PI3K\AKT\mTOR pathway in HCC. 
The ERK\MAPK pathway is a ubiquitous signal transduction pathway that 
regulates crucial cellular processes, including proliferation, differentiation, 
angiogenesis, and survival [32]. Activation of this pathway usually occurs by 
oncogenic mutations within the RAS gene: up to 30% of N-RAS mutation has been 
reported in HCC [33]. Furthermore, B-RAF activation resulting from dysregulated 
overexpression of growth factors and their receptors has been demonstrated [32]. 
A number of angiogenic growth factors, including members of the vascular 
endothelial growth factor (VEGF) family, have been detected to be upregulated at 




factors induce the angiogenic signalling through the activation of previous above 
signalling pathways [31]. 
Furthermore, epigenetic changes are suspected to occur early in the pre-
neoplastic stage, leading to quantitative alteration of gene expression in the 
absence of detected structural changes of genes or chromosomes [35]. Elevated 
expression of DNA methyltransferases has been detected in higher levels in HCC 
than it has in chronic hepatitis and cirrhosis [36]. In addition, microsatellite 
instability has been observed in some chronic hepatitis, cirrhosis, and HCC [36, 
37]. Other structural genetic alterations, such as amplification, deletion, and 
mutation, occur in some genes and chromosomal loci during the early pre-
neoplastic stage, and increase markedly in dysplastic lesions and HCCs [38]. 
Tumour suppressor genes, such as TP53 and RB, are often located in frequently 
deleted chromosomal regions, and are inactivated by deletion or mutation during 
HCC. Likewise, some of the areas of chromosome regional gain contain 
oncogenes, like the MYC gene, which is overexpressed in most HCCs [39]. 
 
1.2.2 Mitochondrial genomic alteration 
The mitochondria are the main intracellular generator of ATP, which has a crucial 
role in the regulation of cellular function, metabolism, and apoptosis [40, 41] 
Human mitochondrial DNA (mtDNA) is a small circular, self-replicating 
chromosome of approximately 16.6 Kb, which encodes 13 essential subunits of 
oxidative phosphorylation (OXPHOS) complexes (complexes I, III, IV, and V), as 
well as two rRNA and 22 tRNA genes [42]. Due to the high rate of Reactive 
Oxygen Species (ROS) generation as well as a lack of protective histones and 
inefficient DNA repair activities, mtDNA are predisposed to a high mutational rate 
in comparison to nuclear DNA (nDNA) [43]. Mutated mtDNA copies may confer a 
selective growth advantage and are likely to survive through selection during 
cellular development. Mutated mtDNA may expand to all intracellular mtDNA 
copies (homoplasmy) or only to a proportion of them (heteroplasmy) [44, 45]. 
In 1924, Warburg hypothesised that cancer cells cause a defect in mitochondria 
and impair aerobic respiration, leading to glycolytic metabolism regardless of the 




Warburg effect’ [46]. Several published studies have addressed the role of mtDNA 
mutation in cancer initiation and metastasis, including for liver cancer [47], breast 
cancer [48], prostate cancer [49], and other solid tumours [50-52]. 
HCC is usually preceded by chronic inflammation, repeated destruction, and 
regeneration of liver tissue, leading to increased oxidative stress and ROS 
generation. ROS overproduction results in mtDNA mutations and subsequent 
mitochondrial respiratory defect [53, 54]. A study by Nishikawa et al. found that 
accumulated mtDNA mutations were markedly increased in cancerous and 
noncancerous tissue of HCC patients [55]. In addition, the frequency of mtDNA 
mutations correlated with the degree of tumour dedifferentiation [55]. In HCC, 
decreased the mtDNA copy number was shown to significantly correlate with large 
tumour size, liver cirrhosis, and poor five-year survival [56]. Furthermore, mtDNA-
deplete hepatoma cells displayed chemoresistance and cell migration mediated by 
nuclear-dependent pathways [57-59]. These findings support the contribution of 
mtDNA mutation and mitochondrial dysfunction to malignant progression of HCC. 
Due to the resulting high mutation rate, combined with the presence of hundreds 
of mtDNA copies within each cell and the homoplasmic nature of somatic mtDNA 
mutations [44, 45], the mitochondrial genome (mt-genome) is an ideal target to 
use for tumour cell tracking[47-49, 52, 60-62]. Since clonal expansion and the 
dynamic evolution of cancer are areas of unmet need for development of precise 
anti-tumour therapy [63], the mt-genome plays a major role in examining the 
evolutionary history of human cancer. 
 
1.3 HCC management 
The Barcelona Clinic Liver Cancer (BCLC) staging classification summarizes the 
criteria for HCC management. The BCLC classification includes five stages: 0, A, 
B, C, and D. These stages are determined according to tumour factors (size, 
number, vascular invasion, lymph node, and extrahepatic metastasis), liver 
function (Child-Pugh score), and patient health status [64]. Briefly, patients at 
stage 0, the very early stage, have a single tumour nodule which is less than <2cm 
in diameter, and are optimal candidates for a hepatic resection. Patients at stage 
A, the early stage, have a single tumour nodule >2cm in diameter or three tumour 




liver transplantation, or percutaneous treatments). Patients at stage B, the 
intermediate stage, have multinodular tumours and may benefit from 
chemoembolisation. Patients at stage C, the advanced stage, have lymph node 
and extrahepatic metastasis, and may receive targeted therapy (sorafenib). 
Patients at stage D, the end stage, have tumour-related disability, and may receive 
symptomatic and palliative treatment [64]. 
HCC is a therapy-refractory tumour. Early diagnosis and transplantation will result 
in the best treatment options, but transplantations are mostly not possible due to 
donor shortage. Furthermore, despite successful hepatic resection, the remnant 
pre-neoplastic cirrhotic liver frequently develops new HCC lesions. Sorafenib is a 
palliative therapy, and is the only systemic targeted treatment available for HCC 
patient who can no longer be treated with potentially more effective therapies. 
Therefore, there is an urgent need to develop an efficient radical management 
strategy for HCC, including eliminating the HCC risk factors, enhancing early 
screening strategies, and developing tolerable molecularly targeted agents.  
 
1.3.1 Eliminating chronic hepatitis-related cirrhosis 
Antiviral therapy significantly decreases the risk of HCC in patients infected with 
viral hepatitis. HBV vaccination programs have also been started in many 
countries and dramatically reduce the rates of mother-to-infant transmission of 
HBV, thereby reducing the rate of HCC among children [65]. Furthermore, antiviral 
therapy against HBV has a beneficial role in decreasing the serum level of HBV-
DNA, and reducing the risk of HCC development among patients with chronic HBV 
[8]. 
Previous advances have been made in managing chronic HCV infections with 
effective protease inhibitors. In the past few years, interferon and ribavirin were the 
only two drugs approved by the Food and Drug Administration (FDA) for HCV 
treatment. Recently, however, the FDA granted a new anti-HCV drugs called 
direct-acting antivirals (DAAs) as a gold standard for HCV infection treatment [66]. 
The DAAs are once-daily pills, used for 12 weeks with a cure rate greater than 
90% [66, 67]. These new, effective, and well tolerated drugs induce a dramatic 





In other efforts to decrease the risk of HCC, health education programs may have 
a prime impact on diabetes, obesity, and NASH, which are becoming increasingly 
important HCC risk factor in the United States and Europe. 
 
1.3.2 HCC surveillance 
The determination of serum alpha-fetoprotein (AFP) for defining HCC risk lacks 
adequate sensitivity and specificity for efficient surveillance [68]. Ultrasound 
examination is an optimal tool for HCC surveillance and highly recommended to 
be performed in an interval of six months. The HCC diagnosis should be based on 
imaging techniques and biopsy. The application of dynamic imaging criteria should 
be applied only to patients with cirrhosis of any aetiology and to patients with 
chronic HBV who may not have fully developed cirrhosis or who have regressed 
cirrhosis. Interpretation of biopsies and distinction between high-grade dysplastic 
nodules (H-DN) and HCC is challenging. Further diagnostic techniques are 
reinforced by staining for glypican 3, heat shock protein 70, and glutamine 
synthetase, because positivity for two of these three stains confirms HCC [69]. 
 
1.3.3 HCC histopathology 
Advances in imaging techniques and development of surveillance protocols for 
those patients at high-risk of HCC development, result in early detection of small 
hepatic nodules. However, the histopathology of these nodules has a wide range 
of diagnostic entities, some benign and some with malignant potential, that needs 
to distinguish for clinical management. 
Macroscopically HCC forms soft mass of nodular or invasive pattern, with a 
heterogeneous macroscopic appearance, and foci of haemorrhage or necrosis. 
HCC could be a single or multiple nodules ranging from less than <1 cm to over 
>30 cm in size. Microscopically, HCC shows different histological patterns: the 
trabecular pattern, the acinar or pseudoglandular pattern, and the solid or compact 
pattern. Cytologically, tumoural hepatocytes are polygonal, displaying an 
eosinophilic granular cytoplasm, rounded nuclei and prominent nucleoli. 
In 1995, an International Working Party (IWP) of the World Congresses of 




into large regenerative nodule, low grade dysplastic nodule (L-DN), high-grade 
dysplastic nodule (H-DN), and HCC [70]. The IWP defined a small HCC as a 
tumour measuring less than <2 cm. Small HCC have been classified into early 
HCC that is well differentiated, and progressed HCC that is moderately 
differentiated with evidence of microvascular invasion [71]. The diagnostic 
challenge was to differentiate the H-DNs from early HCC. Detection of stromal 
invasion is a hallmark for diagnosis of well-differentiated HCC [72]. Furthermore, 
appearance of nodule-in-nodule lesion suggests the presence of HCC. 
Edmondson and Steiner system divided HCC into four grades based on the 
histological differentiation [73]. In grade I (G1), the tumour cells are small and 
arranged in thin trabeculae. In grade II (G2), cells are larger with abnormal nuclei 
and glandular structures may be present. In grade III (G3), nuclei are large and 
hyperchromatic, with an eosiphilic granular cytoplasm. In grade IV (G4), tumor 
cells are much less differentiated with hyperchromatic nuclei and loss of trabecular 
pattern. In fact, most of HCC present as G2 or G3. Due to heterogeneity of cell 
differentiation inside a tumour, a three-scale system including well-, moderately 
and poorly differentiated HCC was frequently applied [74]. 
 
1.3.4 Surgical intervention 
Hepatic resection and transplantation remain the first option and the most effective 
treatment for early localised HCC. Hepatic resection for small HCC in normal liver 
is the best treatment of choice. Recently, surgical outcome of hepatic resection 
have improved due to a better understanding of liver segmental anatomy, and the 
improvements in surgical techniques. The reported overall five-year survival rate is 
30%-60%. However, only 10%-30% of HCCs are amenable to cure by surgical 
resection at the time of diagnosis [75, 76]. 
Whereas, liver transplantation (LT) is the most effective therapeutic option in 
cirrhotic liver and unresectable HCC, because LT removes both the tumour and 
the underlying diseased liver. Theresults from Mazzaferro et al in Milan, 
demonstrated that patients with small tumors (i.e. a single nodule <5 cm or two or 
three nodules each <3 cm without vascular invasion)had a 4-year overall survival 
rate of 85% and a tumour-free survival rate of 92% [77]. Application of the Milan 




Due to the shortage of donor livers and the consequent increase in waiting time for 
a transplantation, hepatic resection prior to liver transplantation is recommended 
for patients with small HCC and preserved liver function[78, 79]. 
Various local therapies are widely used in patients with small localised HCC, when 
surgical treatment is no longer suitable due to poor general condition or because 
of compromised liver function [80]. These modalities include i) local ablative 
therapy: radiofrequency ablation (RFA), microwave coagulation therapy (MCT), 
and percutaneous ethanol injection (PEI); and ii) trans-arterial techniques: trans-
arterial embolisation (TAE), trans-arterial chemotherapy (TAC), trans-arterial 
chemoembolisation (TACE), and trans-arterial radioembolisation (TARE). These 
techniques result in a local area of coagulative necrosis within and around the 
tumour. 
 
1.3.5 Systemic targeted therapy 
Sorafenib is a multi-kinase inhibitor considered to be a first-line treatment in 
patients with unresectable HCC. The antitumor activity of sorafenib in HCC is 
mediated by blocking the cell proliferation through targeting the RAF\MEK\ERK 
signalling pathway, and inhibits angiogenesis by targeting tyrosine kinases (TKs), 
VEGFR-2, VEGFR-3, and PDGFR of endothelial cells [81, 82]. Sorafenib is the 
only targeted therapy approved by the FDA for clinical use, and shows significant 
improvement in overall survival and doubles the time to progression among 
patients with advanced HCC [83]. 
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2 Aim of study 
HCC is one of the most lethal cancers, worldwide. In order to better understand 
the genomic alterations characterising HCC nodules of different differentiation 
grades, a collective of well differentiated and poorly differentiated HCC nodules 
should be studied by ultra-deep sequencing of HCC-related genes. First a primer 
set had to be designed and applied to the enrichment of HCC relevant targets. 
Mutants should then be identified by ultra-deep sequencing of DNA from defined 
and well characterised macrodissected tumour areas. Furthermore, this study 
addressed the tumour history and clonality by analysis of the mtDNA mutation 
pattern. Therefore, the analysis of the entire mt-genome by ultra-deep sequencing 
had to be established. Next, the novel technology should be applied to HCC 
lesions in comparison to matching non-tumour tissues. 
 
 Materials and Methods 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Reagents and kits 
The names of all reagents and kits used in the experiments and their 
manufacturing companies are listed below (Table 1-8). All reagents for NGS are 
listed in the table 2 to 6. 
 
Table 1: Reagents for COX\SDH enzyme histrochemical staining 
Reagent Company Catalog Number 
3,3′-diaminobenzidine 
tetrahydrochloride (DAB) Vector laboratories, Burlingame, USA SK-4105 
Cytochrome C Sigma-Aldrich, Heidelberg, GER C2506 CAS: 9007-43-6 
Bovine catalase Sigma-Aldrich, Heidelberg, GER C1345CAS: 9001-05-2 
Nitroblue tetrazolium 
(NBT) Sigma-Aldrich, Heidelberg, GER N6876 CAS: 298-83-9 
Sodium succinate Sigma-Aldrich, Heidelberg, GER S2378 CAS: 6106-21-4 
Phenazine methosulfate 
(PMS) Sigma-Aldrich, Heidelberg, GER P9625 CAS: 299-11-6 
Sodium azide Merck, Darmstadt , GER 1.06688.0100 
 
Table 2: Reagents and kits for quantification of DNA templates used for target enrichment 
Reagent Reagent/Kit Company 
Fluorescence Absorbance 
QuantiFluor QuantiFluor™ dsDNA System Promega, Heidelberg, GER 
qPCR 
Master mix GoTaq® qPCR Master Mix Promega, , Heidelberg , GER 
Primer 
HFE primer forward 
5’ATG GAT GCC AAG GAG TTC GAA CC 
Eurofins Genomics, Eberstadt, 
GER 
HFE primer reverse 
5’GCC ATA ATT ACC TCC TCA GGC AC 
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Table 3: Reagents and kits used for NGS library construction of HCC related nuclear 
gene loci 




2x Ion AmpliSeq™ Primer Pool Panel 1 
IAD40623 (pool1: 153 primer pairs, pool 2: 147 
primer pairs; 100nM each) 
Life Technologies, 
Darmstadt, GER 
2x Ion AmpliSeq™ Primer Pool Panel 2 
IAD41957 (pool1: 49 primer pairs, pool 2: 45 
primer pairs; 400nM each) 
Life Technologies, 
Darmstadt, GER 
5x Ion AmpliSeq™ HiFi Master Mix 
(Ion AmpliSeq™ Library Kit 2.0) 
Life Technologies, 
Darmstadt, GER 









Agencourt® AMPure® XP Beckman Coulter, Krefeld, GER 
Adapter 
Ligation 
NEXTflex™ DNA barcodes – 48 Bioo Scientific, Austin, USA 
Switch Solution 









Platinum® PCR Super Mix 
(Ion AmpliSeq™ Library Kit 2.0) 
Life Technologies, 
Darmstadt, GER 
NEXTflex™ Primer Mix 
(NEXTflex™ DNA Barcode Kit) 
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Table 4: Reagents and kits used for NGS library construction of HCC related mt-gene loci 






PCR GoTaq® Colorless Master Mix 
Promega, Heidelberg , 
GER 
Multiplex PCR: 
GeneRead DNAseq Panel PCR Puffer, 5x (Mix-n-
Match Panel V2, Qiagen) 
GeneRead HotStar Taq DNA Polymerase (6U/µl) 
(Mix-n-Match Panel V2, Qiagen) 
Qiagen, Hilden, GER 
End Repair 
 
End-Repair Buffer, 10x (Core Kit, Qiagen) 
Qiagen, Hilden, GER 
End-Repair Enzyme Mix (Core Kit, Qiagen) 
3’ Adenylation 
A-Addition Buffer, 10x (Core Kit, Qiagen) 
Qiagen, Hilden, GER 




Agencourt® AMPure® XP Beckman Coulter, Krefeld, GER 
Adapter 
Ligation 
NEXTflex™ DNA barcodes – 48 Bioo Scientific, Austin, USA 
Ligation Buffer, 2x (Core Kit, Qiagen) 
Qiagen,Hilden, GER 
T4 DNA Ligase (Core Kit, Qiagen) 
Adapter-
Specific PCR 
HiFi PCR Master Mix, 2x (Amp Kit, Qiagen) 
Qiagen, Hilden, GER 
Primer Mix (10µM each) (Amp Kit, Qiagen, 
Hilden, GER) 
 
Table 5: Reagents and kits used for quality assessment and quantification of the generated 
libraries 
Step Reagent/Kit Company 
Quality Assessment 
Microfluidic 






Illumina Adapter Primer Forward 
5’AAT GAT ACG GCG ACC ACC GAG ATC TAC AC 
Eurofins Genomics, 
Eberstadt, GER 




Table 6: Reagents and kits used for NGS on the MiSeq platform 
Step Reagent/Kit Company 
Next Generation 
Sequencing 
MiSeq Reagent Kit v2 (300 cycles) Illumina, San Diego, USA 
PhiX Control v3 Illumina, San Diego, USA 
 
Table 7: Reagents and kits used for Sanger validation 
Reagent\Kit Company 
RedTaq®-DNA polymerase  Sigma-Aldrich, Taufkirchen, GER 
BigDye terminator sequencing kit v.3.1  Applied Biosystems, Darmstadt, GER 
 
Table 8: Reagents used for cell culture work 
Reagent Company 
Dulbecco’s Modified Eagle Medium Sigma-Aldrich, Taufkirchen, GER 
FCS Sigma-Aldrich, Taufkirchen, GER 
Trypan blue solution (0.5 %) Biochrom AG, Berlin, GER 
Trypsin GibcoBRL, Karlsruhe, GER 
 
3.1.2 Primers 
All the oligonucleotides used for mt-genome amplification, and for validation were 
ordered from Eurofins MWG Operon (Ebersberg, GER). 
 
Step Reagent/Kit Company 
qPCR of Adapter-
Carrying Amplicons 
Illumina Adapter Primer Reverse 





GoTaq® qPCR Master Mix Promega, Heidelberg, 
GER 
PhiX Control v3 Illumina, San Diego, USA 
Fluorescence 
Absorbance 
QuantiFluor™ dsDNA System Promega, Heidelberg, 
GER 
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Table 9: 108-primer sets for whole mitochondrial genome amplification. Primer name*: 
Previously published primers. 




F1 GATCACAGGTCTATCACCCT 1-162  
R162 GATAAATAATAGGATGAGGCAGG   
2 
F155* TATTTATCGCACCTACGTTC 155-285 [84] 
R285* GTTATGATGTCTGTGTGGAA  [84] 
3 
F265 TTCCACACAGACATCATAAC 265-401  
R401 TAAAATTTGAAATCTGGTTAGGC   
4 
F402* ATCTTTTGGCGGTATGCACTTT 402-599 [85] 
R599* TTGAGGAGGTAAGCTACATA  [84] 
5 
F567 ACCCCCCACAGTTTATGTAGC 567-757  
R757 ATGCTTGTTCCTTTTGATCGTGG   
6 
F741 ATCAAAAGGAACAAGCATCAAGCACG 741-878  
R878* CCAACCCTGGGGTTAGTATAGC  [85] 
7 
F866 ACCCCAGGGTTGGTCAATTTC 866-979  
R979 TCAGGTGAGTTTTAGCTTTATTGGG   
8 
F980 TCACCTGAGTTGTAAAAAACTC 980-1136  
R1136* GGCGAGCAGTTTTGTTGATT  [85] 
9 
F1135* CCAGAACACTACGAGCCACA 1335-1332 [85] 
R1332 TTGACCTAACGTCTTTACGTGG   
10 
F1320* GACGTTAGGTCAAGGTGTAGCCC 1320-1510 [85] 
R1510 AGTATACTTGAGGAGGGTGACGG   
11 
F1510 TCAAAGGACATTTAACTAAAACCCC 1510-1676  
R1676 TTTAGCTCAGAGCGGTCAAG   
12 
F1657* CTTGACCGCTCTGAGCTAAAC 1657-1769 [86, 87] 
R1769* GCCAGGTTTCAATTTCTATCG  [86, 87] 
13 
F1766 TGGCGCAATAGATATAGTACCG 1766-1924  
R1924* AGGTAGCTCGTCTGGTTTCG  [85] 
14 
F1921 ACCTAAGAACAGCTAAAAGAGCAC 1921-2115  
R2115 AGCTGTTCCTCTTTGGACTAAC   
15 
F2105* GAGGAACAGCTCTTTGGACAC 2105-2216 [86, 87] 
R2216* TGTTGAGCTTGAACGCTTTCTT  [85] 
16 
F2213 AACACCCACTACCTAAAAAATCC 2213-2338  
R2338 TTATGCGGAGGAGAATGTTTTC   
17 
F2333* GCATAAGCCTGCGTCAGA T 2333-2439 [85] 
R2439* ATGCCTGTGTTGGGTTGAC  [85] 
18 
F2432 ACAGGCATGCTCATAAGGA AAGG 2432-2630  
R2630 ATACAGGTCCCTATTTAAGGAACAAG   
19 
F2625* CTGTATGAATGGCTCCACGAG 2625-2818 [85] 
R2818* GCCCCAACCGAAATTTTTAAT  [85] 
20 F2803 AAATTTCGGTTGGGGCGACC 2803-2940  
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 R2940 TGTTATCCCTAGGGTAACTTGTTC   
21 
F2932* GGGATAACAGCGCAATCCT AT 2932-3109 [85] 
R3109 AANGTAGATAGAAACCGACCTG   
22 
F3108 TTCAAATTCCTCCCTGTACGAAA GG 3108-3259  
R3259 TATGCGATTACCGGGCTCTGC   
23 
F3241* AGAGCCCGGT AATCGCATAA 3241-3417 [85] 
R3417* GGGGCCTTTGCGTAGTTGTA  [85] 
24 
F3424 AACGTTGTAGGCC CCTACGG 3424-3521  
R3521 ATGTAGAGGGTGATGGTAGATGTG   
25 
F3518 ACATCACCGCCCC GACCTTAG 3518-3632  
R3632* GAGGTGGCTAGAATAAATAGGAGGC  [85] 
26 
F3633 TAGCCTAGCCGTTTACTCAATC 3633-3825  
R3825* CAGAGGTGTTCTTGTGTTGTGAT  [85] 
27 
F3823 TGATTACTCCTGCCATCATGACC 3823-3987  
R3987 TTCGGCTATGAAGAATAGGGCG   
28 
F3964 TCGCCCTATTCTTCATAGCCG 3964-4162  
R4162* TGAGTTGGTCGTAGCGGAATC  [86, 87] 
29 
F4163 TACACCTCCTATGAAAAAACTTCC 4163-4334  
R4334 TCCTAGAAATAAGGGGGTTTAAG   
30 
F4335 CTATGAGAATCGAACCCATCCCT 4335-4479  
R4479* GGGGATTAATTAGTACGGGAAGG  [85] 
31 
F4459 TTCCCGTACTAATTAATCCCCTG 4459-4608  
R4608 TTTTGGTTAGAACTGGAATAAAAGCTAG   
32 
F4609* AAATAAACCCTCGTTCCACAGA 4609-4676 [85] 
R4676* GATTATGGATGCGGTTGCTT  [85] 
33 
F4675 TCCTTCTAATAGCTATCCTCTTCAAC 4575-4860  
R4860 GAAGAAGCAGGCCGGATGT   
34 
F4859 TCTCACATGACAAAAACTAGCC 4859-5034  
R5034* ATCCTATGTGGGTAATTGAGGA  [85] 
35 
F5033 ATGAATAATAGCAGTTCTACCGTAC 5033-5210  
R5210* GGTGGATGGAATTAAGGGTGT  [85] 
36 
F5189 ACACCCTTAATTCCATCCACC 5189-5325  
R5325* TGATGGTGGCTATGATGGTG  [85] 
37 F5318* CACCATCACCCTCCTTAACC 5318-5500 [86, 87] 
 R5500 AGTATAAAAGGGGAGATAGGTAGG   
38 
F5487 TCCCCTTTTATACTAATAATCTTATAG 5487-5681  
R5681* GTGGGTTTAAGTCCCATTGGT  [85] 
39 
F5664* AATGGGACTTAAACCCACAAA 5664-5799 [85] 
R5799* TGCAAATTCGAAGAAGCAG  [85] 
40 
F5800 ATTCAATATGA AAATCACCTCGGAGC 5800-5994  
R5994* TGCCTAGGACTCCAGCTCAT  [88] 
41 
F5994 ACAGCTCTAAGCCTCCTTATTCG 5994-6184  
R6184 AACGCCATATCGGGGGCAC   
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F6178 TGGCGTTTCCCCGCATAAAC 6178-6359  
R6359 TAGGTGTAAGGAGAAGATGGTTAG   
43 
F6351 ACACCTAGCAGGTGTCTC 6351-6444  
R6444* TTTGGTATTGGGTTATGGCAG  [85] 
44 
F6443 ACGCCCCTCTTCGTCTGATC 6443-6642  
R6642 TAAGAATATAAACTTCAGGGTGACCG   
45 
F6636* ATTCTTATCCTACCAGGCTTCG 6636-6832 [85] 
R6832 ATGGTAGCGGAGGTGAAATATG   
46 
F6831 ATAATCATCGCTATCCCCACCG 6831-6899  
R6899* CATATTGCTTCCGTGGAGTGTG  [85] 
47 
F6899 GAAATGATCTGCTGCAGTGCTC 6899-7076  
R7076 CCTATGATGGCAAATACAGCTCC   
48 
F7075 AGGCTTCATTCACTGATTTCCC 7075-7248  
R7248* TGGTGTATGCATCGGGGTAGT  [85] 
49 
F7248 ACATGAAACATCCTATCATCTGTAGG 7248-7365  
R7365 GTTCTTCTACTATTAGGACTTTTCGC   
50 
F7366* CCTCCATAAACCTGGAGTGA 7366-7489 [85] 
R7489 TGGCTTGAA ACCAGCTTTG   
51 
F7481 TCAAGCCAACCCCATGGCC 7481-7680  
R7680 AAAATGATTATGAGGGCGTGATCATG   
52 
F7679 TTCCTTATCTGCTTCCTAGTCC 7679-7842  
R7842 ATGTAAAGGATGCGTAGGGATG   
53 
F7821* CATCCCTACGCATCCTTTACAT 7821-7980 [85] 
R7980 TCGCCTGGTTCTAGGAATAATG   
54 
F7960 ATTATTCCTAGAACCAGGCG 7960-8141  
R8141* CGGTGAAAGTGGTTTGGTTTA  [85] 
55 
F8129* ACCACTTTCACCGCTACACG 8129-8269 [85] 
R8269 CTATAGGGTAAATACGGGCCC   
56 
F8256 TATTTACCCTATAGCACCCC 8256-8378  
R8378* TTAGTTGGGGCATTTCACTGT  [85] 
57 
F8377 AAATACTACCGTATGGCCCACC 8377-8566  
R8566 TTGTGGGGGCAATGAATGAAGC   
58 
F8563 ACAATCCTAGGCCTACCCG 8563-8640  
R8640* GATGAGATATTTGGAGGTGGG  [85] 
59 
F8641 AACAACCGACTAATCACCACC 8641-8837  
R8837 ATGGCTAGGTTTATAGATAGTTGG   
60 
F8836 ATGGCCATCCCCTTATGAGC 8836-9031  
R9031* GGTGGCCTGCAGTAATGTTAG  [85] 
61 
F9032 TACTCATGCACCTAATTGGAAGCG 9032-9146  
R9146 GCGACAGCGATTTCTAGGATAG   
62 
F9143 TCGCCTTAATCCAAGCCTACG 9143-9275  
R9275 TGAGAGGGCCCCTGTTAG   
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63 F9272* CTCAGCCCTCCTAATGACCTC 9272-9376 [85] 
 R9376* CATTGGTATATGGTTAGTGTGTTGG  [85] 
64 
F9377 ATGGCGCGATGTAACACGAG 9377-9568  
R9568 ATGCCTGTTGGGGGCCAG   
65 
F9568 TCACCCCGCTAAATCCCCTAG 9568-9758  
R9758 TACTCTGAGGCTTGTAGGAGGG   
66 
F9757 TACTTCGAGTCTCCCTTCACC 9757-9940  
R9940 ACAAAATGCCAGTATCAGGCGG   
67 
F9940 TAGATGTGGTTTGACTATTTCTG 9940-10110  
R10110 TTAGTAGTAAGGCTAGGAGG   
68 
F10093 TCCTAGCCTTACTACTAATAATTATTAC 10093-10294  
R10294* AGGGCTCATGGTAGGGGTAA  [85] 
69 
F10294 TACAAACAACTAACCTGCCACT 10294-10487  
R10487 TATGTAAATGAGGGGCATTTGG   
70 
F10488 AATATTATACTAGCATTTACCATCTC 10488-10667  
R10667 AAGACTAGTATGGCAATAGGC   
71 
F10661 TCTTTGCCGCCTGCGAAG 10661-10942  
R10942* TAGGGGGTCGGAGGAAAAG  [85] 
72 
F10943 ACAACCCCCCTCCTAATAC 10943-1110  
R11110 GATAAGTGTGGTTTCGAAGAAG   
73 
F11108 TTATCCCCACCTTGGCTATC 11108-11318  
R11318 ATAGTTCTTGGGCAGTGAGAG   
74 F11319* CAAACTCCTGAGCCAACAACTT 11319-11428 [85] 
 R11428* GGCTTCGACATGGGCTTT  [85] 
75 
F11424 AAGCCCCCATCGCTGGG 11424-11627  
R11627 AAGAGTATGCAATGAGCGATTTTAGG   
76 
F11626 TCAATCAGCCACATAGCCC 11626-11768  
R11768* TGCGTTCGTAGTTTGAGTTTG  [85] 
77 
F11760* ACGAACGCACTCACAGTCG 11760-11955 [86, 87] 
R11955 TTGAGTCCTGTAAGTAGGAGAG   
78 
F11952 TCAACATACTAGTCACAGCCC 11952-12089  
R12089* TGGGGGATAGGTGTATGAACA  [85] 
79 
F12089 ATTCTCCTCCTATCCCTCAACC 12089-12210  
R12210 TCGGTAAATAAGGGGTCGTAAGC   
80 
F12194* CCCCTTATTTACCGAGAAAGC 12194-12302 [85] 
R12302* GCCTAAGACCAATGGATAGCT  [85] 
81 
F12288 CCATTGGTCTTAGGCCCCAAA 12288-12470  
R12470 TAATAAAGGTGGATGCGACAATGG   
82 
F12452* TTGTCGCATCCACCTTTATT 12452-12648 [85] 
R12648 TGAGAATTCTATGATGGACC   
83 
F12648 ACTGTGATATATAAACTCAGACC 12648-12766  
R12766* AGCCGATGAACAGTTGGAATA  [85] 
84 F12741* CAACCTATTCCAACTGTTCATCG 12741-12936 [85] 
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 R12936 TTGTTGTGGGTCTCATGAGTTG   
85 
F12936 AATAGCCCTTCTAAACGCTAATC 12936-13025  
R13025* TGGAGACCTAATTGGGCTGA  [85] 
86 
F13025 ACCCCTGACTCCCCTCAG 13025-13215  
R13215 AAGGGCGCAGACTGCTGC   
87 
F13203* AGTCTGCGCCCTTACACAAA 13203-13390 [85] 
R13390* TGTTAAGGTTGTGGATGATGGA  [85] 
88 
F13381 AACCTTAACAATGAACAAGATATTCG 13381-13559  
R13559* GCTCAGGCGTTTGTGTATGAT  [85] 
89 
F13557 AGCCCTATCTATTACTCTCATC 13557-13740  
R13740 AATGAGAAATCCTGCGAATAGG   
90 
F13741 ACTAACAACATTTCCCCCGCATCC 13741-13855  
R13855* GGTAGTTGAGGTCTAGGGCTGTT  [85] 
91 
F13835* CAGCCCTAGACCTCAACTACC 13835-13924 [85] 
R13924 GGTAGAATCCGAGTATGTTGGA   
92 
F13921 ACCCTAGCATCACACACC 13921-14077  
R14077 TTTGGGTTGAGGTGATGATG   
93 
F14058* CATCATCACCTCAACCCAAA 14058-14118 [85] 
R14118* TGGGAAGAAGAAAGAGAGGAAG  [86, 87] 
94 
F14114 TCCCACTCATCCTAACCC 14114-14312  
R14312 TAGGAAGCTGAATAATTTATGAAGG   
95 
F14271 TCAACCCTGACCCCTCTCC 14271-14448  
R14448* GAGGAGTATCCTGAGGCATGG  [85] 
96 
F14431* TGCCTCAGGATACTCCTCAAT 14431-14609 [85] 
R14609 AGCCTTCTCCTATTTATGGGG   
97 
F14609 TTAGAAGAAAACCCCACAAAC 14609-14721  
R14721* CGATGGTTTTTCATATCATTGG  [85] 
98 
F14715 ACCATCGTTGTATTTCAACTACAAGAA 14715-14902  
R14902* GGCTAGGAATAGTCCTGTGGTG  [85] 
99 
F14903 ATGCACTACTCACCAGACGCC 14903-15083  
R15083 AGGTTTCTGAGTAGAGAAATGATCCG   
100 
F15083 TGAAACATCGGCATTATCCTCC 15083-15279  
R15279 AATCGTGTGAGGGTGGGAC   
101 
F15278 TTCTTTACCTTTCACTTCATCTTGC 15278-15396  
R15396* TTATCGGAATGGGAGGTGATTC  [85] 
102 
F15396 AAATCACCTTCCACCCTTAC 15396-15585  
R15585* ATTGTGTAGGCGAATAGGAAATA  [85] 
103 
F15584 ATTCTCCGATCCGTCCCTAAC 15584-15728  
R15728* GGAGTCAATAAAGTGATTGGCTTAG  [85] 
104 
F15729 TAGCCGCAGACCTCCTCATTC 15729-15896  
R15896 TACAAGGACAGGCCCATTTGAG   
105 F15896 AGTATAAACTAATACACCAGTCTTG 15896-16042  
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Amplicon Primer Name Primer Sequence 
Targeted 
Region References 
 R16042* CTGCTTCCCCATGAAAGAAC  [85] 
106 
F16043 ATTTGGGTACCACCCAAGTATTG 16043-16230  
R16230 TAGTTGAGGGTTGATTGCTGTAC   
107 
F16227 ACTATCACACATCAACTGCAACTC 16227-16410  
R16410* GAGGATGGTGGTCAAGGGA  [84] 
108 
F16409 TCCGTGAAATCAATATCCCGC 16409-16569  
R16569 CATCGTGATGTCTTATTTAAGGG   
primer name*: Previously published primers 
 
Table 10: PCR primer of Sanger validation 
Oligonucleotide Species Sequence 
APC-F-E1317Q Human GATGTAATCAGACGACACAGGAA  
APC-R-E1317Q Human AATCCAGCAGACTGCAGGG 
ARID1A-1326+1327F Human CCTGAGGGAAACATGAGCACT 
ARID1A-1326+1327R Human TTCCTATGGCAATCAGTTCTCCA 
ARID1A-F-G1293fs Human GGTCCTTATGACAGAGTGAGGTA  
ARID1A-R-G1293fs Human ATGCCTTCCAACCCAGACTC  
ARID1A-F-G242-A243 Human CCAACCACCAGTACAACTCCTA  
ARID1A-R-G242-A243 Human TCGCTCAGCAGCGCTTCG  
ARID2-998+999F Human CATCACCTGTCCCAGCTACTAA 
ARID2-998+999R Human TTCAGCAGCCCCAACAAGTAC 
ARID2-F-Q835* Human CAGAGTACAGAACATACCAGCAT  
ARID2-R-Q835* Human TACTGTTATCATAGCACCCCCAC  
AXIN1- F-P278L Human CAGGACATGGATGAGGACGAT  
AXIN1- R-P278L Human AAGGCAGAGAGTTCAGGTGAG  
AXIN1-F-G650S Human GGATGCGGAGAAGAACCAGAAA  
AXIN1-F-T402M Human CCGCGTGGAGCCTCAGAA  
AXIN1-F-T402M Human ATGTCCTGATGTTCTTCATGGGG  
AXIN1-R-G650S Human TTCAGTGTGTGTGGCGAGTGT  
CDKN2A-F-A148T Human GAGCTGGGCCATCGCGAT  
CDKN2A-R-A148T Human TTCCAGCACAGAAAGTTCAGCC  
CTNNB1-F-L753P Human GGTATGGACCCCATGATGGAA  
CTNNB1-R-L753P Human ATCAGCTGGCCTGGTTTGATAC  
PTEN-138F Human CCAATGGCTAAGTGAAGATGACAA 
PTEN-138R Human TCCTTTCCTCTTCCTGGATCTG 
PTEN-F-L182V Human CTGTCCACCAGGGAGTAACTA  
PTEN-R-L182V Human AATGTTCAGTGGCGGAACTTGC  
TP53-207F Human GGCCTCTGATTCCTCACTGATT 
TP53-207R Human AACTGGGGTCTCTGGGAGG 
TP53-F-R337L Human GGACCAGACCAGCTTTCAAAAA 
TP53-R-R337L Human CAGGCTAGGCTAAGCTATGAT 
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3.1.3 Clinical samples 
 
Table 11: Clinical features of HCC samples included in this study.* Aetiology refers to the 
frequent risk factors: Hepatitis B (HBV), Hepatitis C (HCV), Alcohol intake(Al.), 
Hemochromatosis(HM), Hepatic adenoma (HA), Steatohepatitis (SH), Underlying HCC are not 
defined (n.d). 
Sample 
ID Age Gender Aetiology* Fibrosis Diagnosis 
Tumour 
Grade TNM 
H01 49Yrs M HCV F4 HCC G2-G3 T3NxMx 
H02 57Yrs M Toxic F0-F1 HCC G2-G3 T3NxMx 
H03 68Yrs M n.d F0-F1 HCC G1-G2 T2NxMx 
H04 55Yrs M HCV F4 HCC G2 T3NxMx 
H05 68Yrs M n.d F0-F1 HCC  G1+G3-4 T2NxMx 
H06 41Yrs M HCV F4 HCC+DN G2 T3NxMx 
H07 58Yrs M Toxic F4 HCC  G2-G3 T2NxMx 
H08 50Yrs M HA F4  HCC G2 T1NxMx 
H09 65Yrs M HBV F4 HCC+DN G2+G3 T4N1Mx 
H10 70Yrs F n.d F0-F1 HCC G3 T3NxMx 
H11 76Yrs M HCV F4 HCC G3 T3NxMx 
H12 49Yrs M HBV F4 HCC+DN G1 T1NxMx 
H13 73Yrs F HBV F4 HCC G3 T3NxMx 
H14 53Yrs F HM F0-F1 HCC G1 T3NxMx 
H15 68Yrs M n.d F0-F1 HCC G3 T3NxMx 
H16 69Yrs M Toxic F4 HCC G2 T3NxMx 
H17 65Yrs M HBV F4 HCC G4 T1NxMx 
H18 40Yrs M HBV F4 HCC G2 T1NxMx 
H19 82Yrs M n.d F0-F1 HCC G1 T1NxMx 
H20 58Yrs M HBV F4 HCC G1-G2 T1NxMx 
H21 75Yrs F n.d F0-F1 HCC G2-G3 T2NxMx 
H22 64Yrs M HCV F4 HCC G2-G3 T3NxMx 
H23 73Yrs F HM F0-F1 HCC G2 T3NxMx 
H24 44Yrs M HCV F4 HCC G2 T1NxMx 
H25 57Yrs F HBV,HDV F4 HCC G1 T1NxMx 
H26 67Yrs M HCV F4 HCC G2 T1NxMx 
H27 55Yrs M SH F0-F1 HCC G2 T1NxMx 
H28 72Yrs M SH F0-F1 HCC G2 T3NxMx 
H29 73Yrs M SH F4 HCC G1 T1NxMx 
H30 65Yrs M n.d F0-F1 HCC G2 T1NxMx 
H31 65Yrs M n.d F4 HCC G2 T1NxMx 
H32 69Yrs M HCV F4 HCC G2 T1NxMx 
H33 69Yrs M HCV F4 HCC G2 T2NxMx 
H34 69Yrs M HCV F4 HCC G2 T2NxMx 
H35 67Yrs M n.d F0-F1 HCC G2 T1NxMx 
H36 76Yrs M AI F4 HCC G2 T1NxMx 
H37 74Yrs F n.d F0-F1 HCC G2 T1NxMx 




ID Age Gender Aetiology* Fibrosis Diagnosis 
Tumour 
Grade TNM 
H38 74 Yrs M n.d F0-F1 HCC G2 T1NxMx 
H39 53Yrs M HBV F4 HCC G2 T1NxMx 
H40 53Yrs M Toxic F4 HCC G2 T1NxMx 
H41 45Yrs M HBV F2 HCC G3 T3NxMx 
H42 61Yrs M n.d F4 HCC G2 T3NxMx 
H43 66Yrs M HCV F4 HCC G2 T2NxMx 
H44 67Yrs M HBV F0-F1 HCC G2-G3 T3NxMx 
* Aetiology refers to the frequent risk factors: Hepatitis B (HBV), Hepatitis C (HCV), Alcohol 
intake(Al.), Hemochromatosis(HM), Hepatic adenoma (HA), Steatohepatitis (SH), Underlying 
HCC are not defined (n.d). 
 
3.1.4 Buffers 
All buffers were prepared using completely desalted millipore purified water 
(Millipore-Q Plus, Millipore, (Molsheim, GER)). 
 
Table 12: Buffer solutions used in various experiments 
Buffer Concentrations 
and Dilutions Substance/Company 
Lysogeny broth (LB): 1.0 % [w/v] Tryptone (Fluka, GER) 
Medium: 
0.5 % [w/v] Bacto-yeast extracts (Difco, USA) 
0.8 % [w/v] 
Sodium chloride (NaCl) 
(adjust pH value to 7.6 with NaOH) 
LB agar: 15 g /l LB medium Bacto-Agar (Difco) 
2 x TSS: 
20 % [w/v] Polyethylene glycol (PEG) 8000 (Sigma, GER) 
10 % [v/v] Di-methyl sulfoxide (DMSO) (Sigma, GER) 
70.0 mM Magnesium chloride (MgCl2) in LB, pH 6,5 
Buffer Concentrations 
and Dilutions Substance/Company 
Phosphate-buffered 74 g NaCl 
Saline (PBS) 10x 
14.2 g Di-sodium hydrogen phosphate (Na2HPO4 x H2O) 
3.62 g NaH2PO4 x 2H2O 
Add to 1L Distilled water (dH2O) mg,  pH 7.4 
TAE buffer 
40 mM Tris-acetate, pH 7.8 
5 mM Sodium acetate (CH3COONa) 
1 mM EDTA, pH 8.0 
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3.1.5 Cell lines 
Hepatoma cell lines are used as experimental models for human liver cancer. 
 
Table 13: Hepatoma cell lines 
Cell line Origin Characteristics Source 
HUH7 Human Hepato cellular carcinoma cell line U. Protzer 
Pop10 Human Hepato cellular carcinoma cell line U. Protzer 
HepG2 Human Hepato cellular carcinoma cell line ATCC 
Hep3BG* Human Hepato cellular carcinoma cell line Prof. Jonel Trebicka 
HEK-293 Human Human embryonic kidney cells ATCC 




All devices used in this study are listed below. 
 
Table 14: Devices that used in the experiments and their manufacturing companies 
Device Company 
Microscope Eclipse TE 300 Nikon, Düsseldorf, GER 
MJ Research PTC-200 Peltier Thermal PCR 
Cycler  
GMI, Minnesota, USA 
Multiscan Ascent (photometer) Thermo Scientific, Bonn, GER 
Olympus Vanos-S AH2 (Fluorescence 
microscope) Olympus, Hamburg, GER 
Precellys 24 Homogenisator Peqlab, Erlangen, GER 
BioRad CFX96 Real-time PCR Cycler Bio-Rad, Munich, GER 
Roche Lightcycler 480 Roche, Mannheim, GER 
Eppendorf BioPhotometer Eppendorf, Hamburg, GER 
Water bath Dr. Hirtz & Co, Cologne, GER 
 





3.2.1 Cell culture 
The human cell lines were cultured in Dulbecco's modified Eagles medium 
(DMEM) (Sigma, Heidelberg, GER) supplemented with 10% fetal calf serum (FCS) 
(Sigma, Heidelberg, GER) and maintained at fully humidified atmosphere at 37°C 
and 5%CO2. 
 
3.2.1.1 Passage of cells 
Medium was aspirated from the monolayer of adherent cell lines and were washed 
with 1 x PBS to remove serum which inhibits trypsin digestion. The cells were 
treated with trypsin (0.25 % trypsin / 0.02 % (w/v) EDTA in 1 x PBS) and after 10 
seconds, most of the trypsin was aspirated. The cells were incubated at 37°C for 
1-5 minutes until the adherence was abolished. Trypsin action was stopped by 
adding fresh medium to the plates. Cell clumps were broken up by vigorous 
pipetting. The cells were split and further cultivated in new cell culture plates with 
10% FCS DMEM. 
 
3.2.1.2 Cryopreservation of cells 
Monolayers of 80-90 % confluency were washed twice with 1 x PBS, trypsinized, 
suspended in fresh medium. Suspended cells were centrifuged at 800 rpm / 4 °C 
for 5 minutesin a Beckman GPR centrifuge (Beckman, Krefeld, GER).Afterwards, 
the cell pellet was resuspended in 500 µl fresh 10% FCS supplemented DMEM 
medium and mixed with DMSO to a final concentration of 10 %. The cells were 
slowly frozen at -70 °C over 24 h and finally stored in liquid nitrogen. 
In order to cultivate cryopreserved cells, frozen cells were rapidly thawed and 
incubated in a culture dish with 9 ml fresh medium. The medium was changed 
after 12hours to remove any residual DMSO. 
 
 Materials and Methods 
25 
 
3.2.2 HCC sample collection from cryoconserved liver resectates for 
genomic HCC analysis 
One hundred fifteen resected specimens with HCC or matching non-tumorous 
areas (kindly provided by Professor Dr. Schirmacher, Institute for Pathology of the 
University of Heidelberg) were used from 44 patients. In addition, four hepatoma 
cell lines (Huh7, Hep3p, HepG2, and Pop10) were enrolled in this study.  
The characteristics of the patients are shown in Table 15. The mean age was 63 
years and most patients were male. Most of tumours showed no evidence of 
lymph node or distal metastasis, and the majority of tumours showed moderately 
differentiated histology. 
 




 Years 63.11 
  
 Range 40-82 
  
Gender 
Male 37 84 
Female 7 16 
TNM 
T1NxMx 20 45 
T2NxMx 7 16 
T3NxMx 16 36 
T4N1Mx 1 2 
Differentiation 
Well 7 16 
Moderately 23 52 
Poorly 14 32 
Cirrhosis 
Yes 28 64 
No 16 36 
Aetiology 
HCV 11 25 
HBV 10 23 
Toxic 4 9 
Other* 19 43 
Total                                                                      44 
Other*: Alcoholic intake (1), Hepatic adenoma (1), Hemochromatosis (2), the 
aetiology non determined (n.d) (12), Steatohepatitis (3). 
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3.2.3 HCC sample collection from cryoconserved liver resectates for mt-
genome analysis 
In total 48 HCC nodules, representing different tumor grades, and adjacent 
noncancerous regions from ten patients out of 44, and three control liver samples 
from individuals with liver disease other than HCC (including colorectal, kidney and 
breast cancer with liver metastasis) were investigated. 
 
3.2.4 COX\SDH enzyme histochemical staining of dysplastic and HCC 
nodules 
A dual histochemical assay was applied for investigating mitochondrial dysfunction 
according to Ross et al. 2011 protocol [89]. Briefly, frozen sections were cut at a 
thickness of 15µm, and allowed to air dry at room temperature for 1 hour. 
Cytochrome C staining medium (COX) was prepared according to the protocol and 
150-200µl of medium dropped to each slide, and spread onto all section by pipette 
tip. Then, the slides incubated at 37°C for 1 hour. Next, excess solution was 
removed and the slides rinsed well with 0.1 M PBS. Afterward, 150-200µl of 
prepared succinate dehydrogenase (SDH) medium was added to each slide, and 
spread by pipette tip. Then, the slides incubated for 40 minutes at 37 °C. 
Afterward, excess solution was removed and slides rinsed with PBS. Next the 
slides dehydrated in the ascending concentrations of ethanol, and placed in xylene 
for 10 minutes. Then, the slides mounted with entellan and coverslip, and allowed 
the slides to dry overnight in a ventilated area (Table 1). 
 
3.2.5 Macrodissection of HCC nodules 
COX\SDH histochemical staining allows to clearly visualizing tumor nodules, and 
easily scraped off the individual tumor nodule. Manual macrodissection was then 
performed on fresh frozen sections (15µm) using a sterile disposable scalpel 
blade. Gross tumor nodules were scraped off with a scalpel and collected 
individually into 1,5ml Eppendorf tube which contains 300µl lysis buffer (Maxwell® 
16 LEV Blood DNA Kit, Promega, Heidelberg, GER). 
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3.2.6 Genomic DNA extraction 
Genomic DNA was extracted from samples automatically by the Maxwell® 16 
automate using the Maxwell® 16 LEV Blood DNA Kit (Promega, Heidelberg, GER) 
according to the manufacturer’s instructions. 
 
3.2.7 Analysis of DNA extracts from HCC samples 
3.2.7.1 Quality control of DNA by microfluidic electrophoresis 
The quality of DNA was determined by parallel capillary electrophoresis using the 
Fragment Analyzer (Advanced Analytical, Heidelberg, GER) according to the 
manufacturer’s protocol (DNF-474 High Sensitivity NGS Fragment Analysis Kit (1-
6,000bp)). 
 
3.2.7.2 DNA quantification by fluorescence absorption and qPCR 
Two different quantification methods were used to detect the amount of input DNA. 
Genomic DNA was quantified by fluorescence absorbance using the 
QuantiFluor™ dsDNA System (Promega, Heidelberg, GER) and the 
QuantiFluor™-ST fluorometer (Promega, Heidelberg, GER) according to the 
manufacturer’s instructions. Alternatively, the extracted genomic DNA was 
measured quantitatively by qPCR using the human hemochromatosis gene (HFE) 
as amplifying target (234 bp). DNA samples were quantified from genomic DNA 
standard curves that were prepared from native DNA extracted from human 
embryonic kidney cells (HEK-293, obtained from the American Type Culture 
Collection ATCC) (Table 16). Dilutions of HEK-293 cell DNA in a range of 0.195 to 
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Table 16: Set up of HFE qPRC and amplification conditions 
A) HFE qPCR setup 
Component Volume [µl] 
Nuclease-free water 7.4 
HFE primer forward (10 µM)*1 0.8 
HFE primer reverse (10 µM)*2 0.8 
GoTaq® qPCR Master Mix (Promega, 
Heidelberg, GER) 10.0 
Total 19.0 




5’ATG GAT GCC AAG GAG TTC GAA CC 
*2 5’GCC ATA ATT ACC TCC TCA GGC AC 
B) HFE qPCR amplification conditions 
Stage Temperature Time 
Hold 94°C 3 Minutes 
55 Cycles 
94°C 30 Seconds 
60°C 30 Seconds 
72°C 30 Seconds 
Plate read and melting curve 
 
3.2.8 Target enrichment of HCC related nuclear gene using multiplex 
PCR 
HCC target panels were designed using the Ion AmpliSeq™ algorithm of Life 
Technologies, target enrichment and library preparation followed the instructions 
of the “Ion AmpliSeq™ Library Kit 2.0” (Life Technologies,Darmstadt, GER) and 
the “NEXTflex™ DNA Sequencing Kit, Manual V11.12” (Bioo Scientific, Austin, 
USA) are briefly described below. 
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3.2.8.1 Design of HCC hotspot loci 
To select hotspot regions of genes for the target specific HCC panel, first different 
comprehensive databases as COSMIC (catalogue of somatic mutations in 
cancer) [90], BioGPS [91], UniProt [92] and EMBOSS (The European and 
Molecular Biology Open Software Suite, 2000) were screened [93]. In addition, 
most recent published data on HCC was involved [18, 94-96]. Based on the 
previous inquiry, two panels were designed (Figure 1). A first panel contained 300 
primers in two primer pools with targets covering the whole coding regions of the 
eight genes: ARID1A, ARID2, AXIN1, CDKN2A, CTNNB1, PTEN, RPS6KA3, and 
TP53. A second panel covering 94 hotspot regions in two more primer pools with 
the following 32 genes: APC, ASXL1, ATM,  BRAF, CDH1, CSF1R, EGFR, 
ERBB2, EZH2, FZD1, GNAS, HNF1A, HRAS, IL6ST, IRF2, JAK2,KDM6A, KRAS, 
MET, MLL3, MMP9, NF1, NF2, NFE2L2, NOTCH2, NOTCH3, NAS, PDGFRA, 
PIK3CA, RB, SMAD2, and SMAD4. Both two panels were designed using the Ion 
AmpliSeq™algorithm of Life Technologies (Darmstadt, GER). In total, the panels 
contained primer for 394 target regions and were delivered in four primer pools 
(Supplemental Table S1 and S2). 
 
 
Figure 1: Designed HCC gene panels for multiplex target enrichment. Two HCC gene panels 
of most relevant HCC genes. HCC targeted gene panel involving the hotspot regions of the gene. 
And HCC complete gene panel involving the whole coding sequences of the gene. 
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3.2.8.2 Multiplex PCR for HCC target enrichment 
A total of 40ng genomic DNA was amplified in four separate multiplex PCR 
reactions per sample. Table 17 showed the PCR setup and amplification 
conditions. 
 
Table 17: Multiplex PCR reaction mix and amplification conditions 






Component Volume [µl] Volume [µl] 
5x Ion AmpliSeq™ HiFi Master Mix  
(Ion AmpliSeq™ Kit 2.0, Life Technologies, 
Darmstadt, GER) 
4 2 
2x Ion AmpliSeq™ primer pool* (Life 
Technologies, Darmstadt, GER) 10 5 
gDNA, ~10ng Y Y 
Nuclease-free water 6-Y 3-Y 
Total 20 10 
*IAD40623 pool1: 153 primer pairs, pool 2: 147 primer pairs; 100nM each 
*IAD41957 pool1: 49 primer pairs, pool 2: 45 primer pair; 400nM each 
B) PCR amplification conditions 
Stage Temperature Time 
Hold 99°C 2 Minutes 
30 Cycles 99°C 15 Seconds 
60°C 4 Minutes 
Hold 10°C ∞ 
 
Then, two of the four PCR reactions per sample were pooled and subjected to 
enzymatic digestion of the primer sequences according to the manufacturer’s 
protocol (Life Technologies, Darmstadt, GER) (Table 18). 
 





50°C 10 Minutes 
55°C 10 Minutes 
65°C 20 Minutes 
10°C For up to 1 hour 
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3.2.8.3 Library construction of HCC related hotspot gene loci 
After multiplex-PCR-based target enrichment and enzymatic digestion, each 
reaction per sample was pooled and amplification products were purified from half 
of the reaction volume. All purification and size selection steps were performed in 
a 96 well format using Agencourt® AMPure® XP magnetic beads and a Biomek® 
FXp workstation (Beckman Coulter, Krefeld, GER). Each purification and size 
selection step contained two washing steps with 200 µl 80% ethanol. Purification 
step I was done with 1.6-fold reaction volume of magnetic beads to remove 
fragments <100 bp. DNA was eluted with 20 µl nuclease-free water. Subsequently, 
10-fold diluted samples were adenylated (Table 19) and ligated to NEXTflex™ 
DNA barcodes-48 (Bioo Scientific, Austin, USA) (Table 20). 
 
Table 19: Adenylation reaction mix and conditions 
Component Volume [µl] 
Purified amplicons 17.0 
NEXTflex™ Adenylation Mix (Bioo Scientific, Austin, USA) 4.0 
Total 21.0 
Incubation for 30 minutes at 37°C 
 
Table 20: Adapter ligation reaction mix 
A) Components for adapter ligation Volume [µl] 
3’ Adenylated DNA 20.0 
NEXTflex™ DNA Barcode Adapter 1-48 (Bioo Scientific, Austin, 
USA) (12.5 µM)* 2.0 
Switch Solution (Ion AmpliSeq™ Kit 2.0, Life Technologies, 
Darmstadt, GER) 4.0 
DNA Ligase (Ion AmpliSeq™ Kit 2.0, Life Technologies, Darmstadt, 
GER) 2.0 
Nuclease-free water 2.0 
Total 30.0 
*5’AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
* 5’GAT CGG AAG AGC ACA CGT CTG AAC TCC AGT CAC XXX XXX ATC TCG TAT GCC GTC TTC 
TGC TTG
 





22°C 30 Minutes 
72°C 10 Minutes 
10°C Hold 
 
Further, purification step II was done with 1.8-fold reaction volume of magnetic 
beads to remove fragments <100 bp. DNA was eluted with 40 µl nuclease-free 
water. To enrich amplicons with library sizes between 200 and 400 bp size 
selection was performed with 0.8-fold and 0.2-fold reaction volume of magnetic 
beads. The DNA was eluted with 23 µl nuclease-free water. Amplicon adapter 
ligated libraries were enriched by a final PCR step (Table 21) and purified 
afterwards. 
 
Table 21: PCR parameters for the final PCR amplification of adapter ligated DNA libraries;A) 
PCR components; B) PCR conditions 
A) Final PCR setup 
Component Volume 
[µl] 
Platinum® PCR SuperMix High Fidelity  
(Ion AmpliSeq™ Kit 2.0, Life Technologies, Darmstadt, 
GER) 
25.0 
NEXTflex™ Primer Mix (Bioo Scientific, Austin, USA) 
(12.5µM)* 2.0 
DNA library 23.0 
Total 50.0 
*5’AAT GAT ACG GCG ACC ACC GAG ATC TAC AC 
*5’CAA GCA GAA GAC GGC ATA CGA GAT 
B) Final PCR amplification parameters 
Stage Temperature Time 
Hold 98°C 2 Minutes 
10 Cycles 98°C 15 Seconds 
60°C 60 Seconds 
Hold 10°C ∞ 
 
The final purification step III was done with 1-fold reaction volume of magnetic 
beads and elution of DNA with 20 µl nuclease-free water. 
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3.2.9 Target enrichment of HCC related mt-genome 
Target enrichment of whole mt-genome performed by singleplex PCR based 
approach. One hundred-eight primer pairs were designed manually, and ordered 
from Eurofins MWG Operon (Eberstadt, GER). Library preparation followed the 
instructions of the GeneRead DNAseq Panel PCR kit(QIAGEN Inc. Hilden, GER) 
and the “NEXTflex™ DNA Sequencing Kit, Manual V11.12” (Bioo Scientific, 
Austin, USA) are briefly described below. 
 
3.2.9.1 Primer design for entire mitochondrial genome 
One hundred-eight primer sets spanning the whole mtDNA were designed 
manually. Each primer pairs are resulting in amplicons of around 60-200 bp in 
length. (Figure 2, Table 9, Section 3.1.2). 
 
 
Figure 2: Scheme of primer design of mt-genome. Primer sets (Table 9) were designed (A) 
generating 108 amplicons spanning the whole mitochondrial genome (B). 
 
3.2.9.2 Singleplex PCR for mt-target enrichment 
Automatic single PCR set-up was performed for enrichment of whole mitochondrial 
genome using the Biomek® FXp workstation (Beckman Coulter, Krefeld, GER). A 
total of 10ng genomic DNA was amplified in each 108 singleplex PCR reactions 
per sample. PCR reactions were performed in total volume of 6µl (Table 22). The 
108 PCRs were conducted in 384-well plate (Figure 3). 




Figure 3: Amplification plate layout. Simultaneous whole mt-genome amplification of two 
samples in a 384-well plate. 
 
Table 22: Singleplex PCR reaction mix and amplification conditions 
A) Singleplex PCR setup 
Component Volume [µl] 
GoTaq® Colorless Master Mix 3 
Forward primer (10µM) 0,75 
Reverse primer (10µM) 0,75 
Genomic DNA (10ng) X 
Nuclease-freewater 1,5-X 
Total 6 
B) Singleplex PCR amplification parameters 
Stage Temperature Time 
Hold 94°C 3 Minutes 
30 Cycles 94°C 30 Seconds 
60°C 4 Minutes 
Extension 72°C 30 Seconds 
 
Then, 2µl of each 108 PCR reactions per sample were pooled and subjected to 
the library construction. 
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3.2.9.3 Library construction of HCC related mt-gene loci 
After singleplex-PCR-based target enrichment, each reaction per sample was 
pooled and amplification products were purified. All purification and size selection 
steps were performed in a 96 well format using Agencourt® AMPure® XP 
magnetic beads and a Biomek® FXp workstation. Each purification and size 
selection step contained two washing steps with 200 µl 80% ethanol. Purification 
step I was done with 1.8-fold reaction volume of magnetic beads. DNA was eluted 
with 25 µl nuclease-free water. Afterward, the quantity and quality of size selected 
and purified amplicons were assessed by Quantifluor (Promega, Heidelberg, GER) 
and Fragment Analyzer (Advanced Analytical Technologies, Heidelberg, GER), 
subsequently, according to the manufacturer´s protocols. Next, 50ng enriched 
targets of each sample were adenylated (Table 23 and 24) and ligated to 
NEXTflex™ DNA barcodes-48 (Bioo Scientific, Austin, USA) (Table 25). 
 
Table 23: End repair reaction mix and conditions 
Component Volume 
DNA (10-200ng) 14.0µl 
End-Repair Buffer, 10x (Core Kit, Qiagen, Hilden, GER) 1.7µl 
End-Repair Enzyme Mix (Core Kit, Qiagen, Hilden, 
GER) 1.3µl 
Total 17.0µl 
Incubation for 30 minutes at 25°C, followed by 20 minutes at 75°C  
 
Table 24: Adenylation reaction mix 
Component Volume 
End-repaired DNA 12.5µl 
A-Addition Buffer, 10x (Core Kit, Qiagen, Hilden, 
GER) 1.5µl 
Klenow Fragment (3’ → 5’ exo-) (Core Kit, Qiagen, 
Hilden, GER) 1.5µl 
Total 15.5µl 
Incubation for 30 minutes at 37°C, followed by 10 minutes at 75°C 
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Table 25: Adaptor ligation reaction mix 
Component Volume 
Adenylated DNA 15.5µl 
Ligation Buffer, 2x (Core Kit, Qiagen, Hilden, GER) 22.5µl 
T4 DNA Ligase (Core Kit, Qiagen, Hilden, GER) 2.0µl 
DNase-free Water 3.0µl 
Adaptor (NEXTflex, 25µM) (Bioo Scientific, Austin, 
USA) 2.0µl 
Total 45.0µl 
Incubation for 10 minutes at 25°C,with cold lid 
 
Further, purification step II was done with 1.8-fold reaction volume of magnetic 
beads. DNA was eluted with 80 µl nuclease-free water. To enrich amplicons with 
library sizes between 200 and 400 bp, size selection was performed with 0.8-fold 
reaction volume of magnetic beads. The DNA was eluted with 24 µl nuclease-free 
water. Amplicon adapter ligated libraries were enriched by a final PCR step (Table 
26) and purified afterwards. 
 
Table26: PCR parameters for the final PCR amplification of adapter ligated DNA libraries 
A) Final PCR setup 
Component Volume 
Adapter-ligated DNA 17.0µl 
HiFi PCR Master Mix, 2x (Amp Kit, Qiagen, Hilden, GER) 25.0µl 
Primer Mix (10µM each) (Amp Kit, Qiagen, Hilden, GER) 1.5µl 
RNase-free Water 6.5µl 
Total 50µl 
B) Final PCR amplification parameters 
Stage Temperature Time 
Denaturation 98°C 2 Minutes 
12 Cycles 
98°C 20 Seconds 
60°C 30 Seconds 
72°C 30 Seconds 
Final extension 72°C 1 Minutes 
Hold 10°C ∞ 
 Materials and Methods 
37 
 
The final purification step III was done with 1.2-fold reaction volume of magnetic 
beads and elution of DNA with 25 µl nuclease-free water. 
 
3.2.10 Quality assessment and quantification of the constructed libraries 
The quality of the enriched libraries was analysed by capillary electrophoresis 
using a High Sensitivity NGS Fragment Analysis Kit on Fragment Analyzer 
(Advanced Analytical, Heidelberg, GER) according to the manufacturer’s 
instructions (Section 3.2.7). Quantitative assessment of amplicon library was 
determined by qPCR using primers covering the Illumina adapter sequences. Five 
5-fold dilutions of PhiX Control V3 (Illumina, San Diego, USA) in a range from 




Figure 4: Amplification curves of the established standard series (0.064pM-40pM) (green) and four 
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The library samples were diluted 1:4,000 and measured in duplicates (Table 27). 
 
Table 27: PCR parameters for quantification of the constructed libraries by qPCR; A) PCR 
components; B) PCR conditions 
A) qPCR setup 
Component Volume [µl] 
Nuclease-free water 7.4 
Forward primer (10µM)*1 0.8 
Reverse primer (10µM)*2 0.8 




DNA library (diluted 1:4,000) 1.0 
Total 20.0 
*
1 5’AAT GAT ACG GCG ACC ACC GAG ATC TAC AC 
*
2 5’CAA GCA GAA GAC GGC ATA CGA GAT 
B) qPCR amplification parameters 
Stage Temperature Time 
Hold 94°C 3 Minutes 
30 Cycles 
94°C 30 Seconds 
60°C 30 Seconds 
72°C 30 Seconds 
 
3.2.11 Illumina sequencing 
Ultra-deep sequencing of HCC related-nuclear and –mitochondrial genes were 
carried out by synthesis technology using MiSeq NGS platform. The samples were 
pooled in an equimolar ratio according to results of the qPCR. 12-15 pM library 
pools including 1%-2.5% PhiX Control V3 library were prepared for sequencing 
according to MiSeq System User Guide (Illumina, San Diego, USA). Finally, 
paired-end sequencing was carried out on a MiSeq instrument (Illumina) using the 
v2 chemistry and 300 cycle cartridges as recommended by the manufacturer. 
 




Figure 5: The flow chart shows an overview of the developed workflow for targeted next 
generation sequencing of HCC samples; *automated process. 
 
3.2.12 Data analysis and software 
3.2.12.1 Data analysis of HCC related hotspot gene loci 
Quality metrics analysis of illumina sequencing output can be assessed by 
Sequencing Analysis Viewer software (SAV) (Illumina, San Diego, USA). FASTQ 
files generated by the MiSeq Reporter Software were analysed with an in-house 
developed bioinformatics pipeline based on our general cancer genome analysis 
tool, which was further optimized for the diagnostic workflow [97]. Before aligning 
raw reads to the reference genome, adaptor sequences were trimmed. The 
resulting data was then aligned to the coordinates of the target amplicons 
according to hg19 reference genome (NCBI build 37) using the Burrows-Wheeler 
alignment tool [98]. Sequencing errors were estimated from known germline 
polymorphisms and each sequenced genomic position was analysed for variants 
that exceed this background rate. Detected variants were finally annotated and 
filtered to remove germline variants by using the databases dbSNP (single 
nucleotide polymorphism database; http://www.ncbi.nlm.nih.gov/SNP/) and the 
exome variant server (http://evs.gs.washington.edu/EVS/).  
Obtained variants with an allelic frequency below 5% and synonymous variants 
were removed. Additional, visual analysis of called variants was performed by 
means of the Integrative Genomic Viewer (IGV, Broad Institute, Cambridge, MA, 
USA). False positive variants, particularly in repetitive or highly homologous 
regions of the genome, variants in high background noise, as well as single strand 
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variants, were either eliminated when they were clearly recognizable as artifacts, 
or were further re-assessed by Sanger sequencing. 
Furthermore, variants were analysed for their functional impact on the protein by 
MutationAssessor (http://mutationassessor.org, release 2) [99] and implementation 
of the ANNOVAR algorithm [100], which combines the bioinformatics tools SIFT 
(sorting tolerant from intolerant) [101], PolyPhen2 (polymorphism phenotyping 2) 
[102] and MutationTaster [103]. 
 
3.2.12.2 Data analysis of HCC related mt-gene loci 
FASTQ files generated by the Illumina platform were analysed by means of the 
Biomedical Genomics Workbench 2.5.1 (QIAGEN Inc. Hilden, GER) 
(www.qiagenbioinformatics.com). In order to determine run performance and off-
target reads, the FASTQ sequences were mapped against the whole human 
reference genome hg19. For variant calling and annotation, the mt-genome 
(Genebank; accession no. NC_012920) served as a reference. Using the workflow 
tool of the Biomedical Genomics Workbench 2.5.1 software in batch mode 
ensured successive and identical analysis of all samples. The minimum read 
depth was set to 30, and the minimum variant frequency to 5%. Furthermore, 
variant calling was restricted to loci with a balanced forward-backward 
performance (<0.2). Polymorphisms were recognized using the MITOMAP 
(http://www.mitomap.org/bin/view.pl/MITO-MAP/HumanMitoSeq), dbSNP-v138 
(http://www.ncbi.nlm.nih.gov/SNP/_id=138) and HAPMAP_phase_3 
http://hapmap.ncbi.nlm.nih.gov/hapmap3r3_B36/) databases. Furthermore, 
sequencing error including sequences in the homopolymer tracts or repeat regions 
were ruled out, and identified variants were subsequently validated by 
conventional Sanger sequencing. 
 
3.2.13 Variant Confirmation 
A subset of variants, including variants with less than 100 reads, was confirmed by 
conventional Sanger sequencing using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Life Technologies, Darmstadt, GER) (Table 28). Variants that 
could not be confirmed were excluded from further analysis. 
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Table 28: PCR reaction mix and conditions for Sanger sequencing; A1 and 2) components and 
conditions for amplification of target regions by PCR I; B1 and 2) components and conditions 
for Sanger sequencing of target regions by PCR II 
A1) PCR setup 
 
B1) Sanger PCR setup 
Component Volume [µl] Component Volume [µl] 
Nuclease-free water 11.5-Y Nuclease-free water 13.5 
Primer forward (10µM) 0.5 Primer forward or reverse (10 µM) 0.5 
Primer reverse (10µM) 0.5 
5x Big Dye sequencing buffer  
(Life Technologies, Darmstadt, 
GER) 
4.5 
Multiplex PCR Master Mix 
(Qiagen, Hilden, GER) 
12.5 
Big Dye® Terminator v3.1 Cycle  
(Life Technologies, Darmstadt, 
GER) 
0.5 
Total 24.0 Total 24.0 
gDNA (10ng) Y DNA amplicons 1.0 
Total 25.0 Total 20.0 
A2) PCR amplification parameters 
 
B2) Sanger PCR amplification parameters 
Stage Temperature Time Stage Temperature Time 
Hold 94°C 15 Minutes Hold 95°C 1 Minutes 
40 Cycles 
94°C 30 Seconds 
34Cycles 
96°C 30 Seconds 
X°C* 90 Seconds X°C* 60 Seconds 
72°C 60 Seconds 60°C 4 Minutes 
Hold 72°C 10 Minutes Hold 60°C 10 Minutes 





In the present study, the nuclear and mitochondrial genomic mutation profiling of HCC 
was successfully performed by multiplex and singleplex PCR target enrichment linked to 
next generation sequencing (NGS). First, nuclear gene panels were defined, targeting 
either HCC relevant mutation hotspots or complete genes that are often mutated in 
HCC. The appropriate primer sets for HCC-specific gene enrichment were designed. 
The designed primer sets were then applied in a deep sequencing study for the 
identification of mutations of different nodules in HCC tumours. 
In order to better understand the complex dynamics of HCC, next I designed a unique 
method based on ultra-deep sequencing of the entire mt-genome as a novel molecular 
tool for characterisation of the tumour clonality. Primer sets for the entire mt-genome 
amplification were designed and used for the singleplex PCR linked to NGS.  
Finally, mt-ultra-deep sequencing technology was tested on FFPE archival material. 
Since DNA of FFPE biopsies is not available in large quantities and it is highly 
fragmented, here a novel multiplex assay was established for target enrichment, 
followed by NGS [104]. 
 
4.1 Characterisation of the genomic landscape of HCC 
One of the four serial tissue sections from cryoconserved specimens was used for dual 
COX/SDH enzyme histochemical staining (see Section 3.2.4). Adjacent non-tumour 
areas and tumour nodules encompassing the HCC, as defined by histology, were then 
subjected to macrodissection from the unstained tissue slides to significantly enrich 






Figure 6: Schematic representation of tumour cell enrichment by macrodissection of a frozen tissue 
sample. Every tumour nodule was macrodissected individually and its DNA was extracted into a separate 
tube. 
 
This material was then applied to comprehensive analysis of HCC relevant genes and 
the mt-genome. 
 
4.1.1 Primer design of specific genomic HCC related regions 
In order to further characterise the genomic landscape, the mutational profile of HCC 
was assessed using two panels of 40 genes covered by 394 amplicons, which were 
chosen according their HCC relevance by searching the literaturesas well as COSMIC 
and other comprehensive databases asdescribed in Material and Methods (see Section 
3.2.8.1). Screening gene loci with HCC relevance resulted in the design of two panels 
(Supplemental Table S1 and S2), which covered the coding sequence of HCC hotspot 
target regions or the entire genes. Both panels were then used in four primer pools, 





Table 29: Overview of the genes covered by the HCC panel 
Gene 
Symbol Gene Description Exons Transcript ID 
n 
Amplicons 
APC Adenomatosis Polyposis Coli 14, 16 NM_000038 10 
ARID1A AT Rich Interactive Domain 1A  Complete (20) NM_006015 75 
ARID2 AT Rich Interactive Domain 2 Complete (21) NM_152641 71 
ASXL1 Additional Sex Combs Like Transcriptional Regulator 1  13 NM_015338 2 
ATM ATM Serine/Threonine Kinase 11, 20, 50, 59, 62 NM_000051 10 
AXIN1 Axin 1 Complete (11) NM_003502 31 
BRAF B-Raf Proto-Oncogene 15 NM_004333 2 
CDH1 Cadherin 1 4 NM_004360 1 
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A Complete (3) NM_058195 11 
CSF1R Colony Stimulating Factor 1 Receptor 7 NM_001288705 1 
CTNNB1 Catenin (Cadherin-Associated Protein) Complete (15) NM_001904 33 
EGFR Epidermal Growth Factor Receptor 20, 28 NM_005228 6 
ERBB2 Erb-b2 Receptor Tyrosine Kinase 2 21 NM_001005862 1 
EZH2 Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit 17 NM_004456 3 
FZD1 Frizzled Class Receptor 1 1 NM_003505 1 
GNAS GNAS Complex Locus 8 NM_080425 2 
HNF1A HNF1 Homeobox A 1, 2, 4 NM_000545 7 
HRAS Harvey Rat Sarcoma Viral Oncogene Homolog 3 NM_176795 1 
IL6ST Interleukin 6 Signal Transducer 6 NM_002184 2 
IRF2 Interferon Regulatory Factor 2  5 NM_002199 2 
JAK2 Janus Kinase 2 8 NM_004972 2 
KDM6A Lysine (K)-specific Demethylase 6A 11, 29 NM_021140 2 
KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog 2, 3 NM_004985 5 
MET MET Proto-Oncogene 17, 19 NM_000245 2 
MLL3 Lysine (K)-specific Methyltransferase 2C 38 NM_170606 3 
MMP9 Matrix Metallopeptidase 9 4 NM_004994 1 
NF1 Neurofibromin 1 26 NM_001042492 2 
NF2 Neurofibromin 2 8 NM_000268 2 
NFE2L2 Nuclear factor, Erythroid 2-like 2 2 NM_006164 3 
NOTCH2 Notch 2 4 NM_024408 1 
NOTCH3 Notch 3 5 NM_000435 1 
NRAS Neuroblastoma RAS Viral (v-ras) Oncogene Homolog 3 NM_002524 2 
PDGFRA Platelet-Derived Growth Factor Receptor 18, 22 NM_006206 3 
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 3, 10, 21 NM_006218 7 
PTEN Phosphatase and Tensin Homolog Complete (9) NM_000314 18 
RB RB1-Inducible Coiled-Coil 1 2, 12 NM_014781 2 
RPS6KA3 Ribosomal Protein S6 Kinase Complete (22) NM_004586 42 
SMAD2 SMAD Family Member 2 10 NM_005901 1 
SMAD4 SMAD Family Member 4 9, 1 NM_005359 4 
TP53 Tumour Protein p53 Complete (12) NM_001126114 19 





4.1.2 Mutational analysis of hotspot regions in HCC nodules 
NGSof 115 samples was conducted in four NGS runs based on a multiplex PCR 
approach for HCC-specific gene enrichment (see Section 3.2.8). In total, a throughput of 
25.14 x 106 reads and an output of 7.03 billion bases (Gb) were generated. The bridge 
amplification of the target regions resulted in a cluster density of 1,334 thousands per 
mm2 (K/mm²) in each run with 90.48% passing the quality filter parameters of the 
instrument. From these reads, 96% had a quality score equal to or greater than Q30. A 
quality score of Q30 means that one base call in 1,000 is predicted to be incorrect 
(Table 30). 
 
Table30: Run parameter of the four sequencing runs 
Parameter Run 1 Run 2 Run 3 Run 4 
Average 





25 25 37 
Amplicons [n] 394 394 394 394 
Cluster Density 
[K/mm²] 1,444 1,261 1,432 1,199 1,334 
Parameter Run 1 Run 2 Run 3 Run 4 Average 
Cluster Passed Filter 88.49% 93.48% 91.36 88.60% 90.48% 
Reads 27.22M 24.38M 27.50M 22.53M 25.14M 
Reads Passed Filter 24.02M 22.79M 25.12M 19,69M 22.91M 
Total Yield 7.3Gb 7.0Gb 7.7Gb 6.1Gb 7.03Gb 
≥ Q30 Score 95.36% 97.10% 96.20% 95.00% 96.00% 
Q30 Score= 0.1% chance of wrong base call; M=million; Gb=gigabases 
 
The HCC patient samples produced a total of 2,580 variants after raw data alignment 
and first (automated) background removal. Exclusion of sequencing artefacts, 
synonymous variants, and polymorphisms led to the determination of 115 significant 
variants with putatively deleterious-, neutral-protein coding variants, or not yet 
determined (ND) (91 missense, 11 splice site, 9 indels (7 insertions, 2deletions), 4 






Figure 7: Filtering the NGS data and annotating the reliable variants from HCC cohorts. NGS output 
data were filtered by removing the allelic frequency below 5%, synonymous variants, and reading error, 
which resulted in 120 final reliable variants (A). The variant count per gene is represented in the bar chart 
(B). 
 
Table31: A comprehensive annotation of non-synonymous variants from 44 HCC samples.FI… 
functional impact; fs… frame shift; ND… not determined; OT… non tumour; TN… tumour nodule 
X1... variants were confirmed by Sanger sequencing. 















OT AXIN1 chr16:347063 missense c.1948G>A p.G650S
1
 98.90% Neutral Tolerated 
H10-
OT AXIN1 chr16:347063 missense c.1948G>A p.G650S
1
 51.50% Neutral Tolerated 
H10-
TN1 AXIN1 chr16:347063 missense c.1948G>A p.G650S
1
 14.90% Neutral Tolerated 
H43-
TN1 AXIN1 chr16:354308 missense c.1250G>A p.R417H
1
 29.40% Neutral Damaging 
H36-
TN1 AXIN1 chr16:354353 missense c.1205C>T p.T402M
1
 58.40% Neutral Damaging 
H36-
OT AXIN1 chr16:354353 missense c.1205C>T p.T402M
1
 77.20% Neutral Damaging 
H11-
TN1 AXIN1 chr16:396193 missense c.833C>T p.P278L
1
 50.70% Neutral Tolerated 
H11-
TN2 AXIN1 chr16:396193 missense c.833C>T p.P278L
1
 50.90% Neutral Tolerated 
H11-
TN3 AXIN1 chr16:396193 missense c.833C>T p.P278L
1
 50.60% Neutral Tolerated 
H11-
OT AXIN1 chr16:396193 missense c.833C>T p.P278L
1
 47.70% Neutral Tolerated 






















TN1 TP53 chr17:7574017 missense c.1010G>T p.R337L 87.80% Deleterious Damaging 
H37-
TN2 TP53 chr17:7574017 missense c.1010G>T p.R337L 81.30% Deleterious Damaging 
H37-
TN3 TP53 chr17:7574017 missense c.1010G>T p.R337L 82.20% Deleterious Damaging 
H33-
TN1 TP53 chr17:7577534 missense c.747G>T p.R249S
1
 53.30% Deleterious Damaging 
H41-
TN1 TP53 chr17:7577534 missense c.747G>T p.R249S
1
 11.90% Deleterious Damaging 
H41-
TN2 TP53 chr17:7577534 missense c.747G>T p.R249S
1
 11.90% Deleterious Damaging 
H41-
TN3 TP53 chr17:7577534 missense c.747G>T p.R249S
1
 22.10% Deleterious Damaging 
H41-
TN5 TP53 chr17:7577534 missense c.747G>T p.R249S
1
 7.40% Deleterious Damaging 
H11-
TN1 TP53 chr17:7577539 missense c.742C>T p.R248W
1
 60.10% Deleterious Damaging 
H11-
TN2 TP53 chr17:7577539 missense c.742C>T p.R248W
1
 56.00% Deleterious Damaging 
H11-
TN3 TP53 chr17:7577539 missense c.742C>T p.R248W
1
 46.30% Deleterious Damaging 
H23-
TN1 TP53  chr17:7578176 splice c.672_splice e6+1 66.10% splice splice 
Huh7 TP53 chr17:7578190 missense c.659A>G p.Y220C1 98.20% Deleterious Damaging 
H07-
TN1 TP53 chr17:7578218 missense c.631A>C p.T211P 31.70% Deleterious Damaging 
H15-
TN1 TP53 chr17:7578493 nonsense c.437G>A p.W146*
1
 16.10% ND ND 
H15-
TN2 TP53 chr17:7578493 nonsense c.437G>A p.W146*
1
 38.20% ND ND 
H42-
OT CDKN2A  chr9:21970916 missense c.442G>A p.A148T 50.60% Neutral Damaging 
H42-
TN1 CDKN2A  chr9:21970916 missense c.442G>A p.A148T 47.90% Neutral Damaging 
H12-
TN1 CDKN2A  chr9:21970916 missense c.442G>A p.A148T 51.60% Neutral Damaging 
H12-
TN2 CDKN2A  chr9:21970916 missense c.442G>A p.A148T 50.00% Neutral Damaging 
H12-
OT CDKN2A  chr9:21970916 missense c.442G>A p.A148T 49.70% Neutral Damaging 
H17-
TN1 CDKN2A  chr9:21970916 missense c.442G>A p.A148T 50.90% Neutral Damaging 
H17-
OT CDKN2A  chr9:21970916 missense c.442G>A p.A148T 51.60% Neutral Damaging 
H04-






43insA 48.50% ND ND 
H04-






43insA 51.80% ND ND 
H04-






43insA 46.50% ND ND 
H04-


































43insA 51.60% ND ND 
H04-






43insA 39.50% ND ND 
H04-






43insA 19.80% ND ND 
H41-
TN1 CTNNB1 chr3:41266097 missense c.94G>T p.D32Y
1
 9.70% Deleterious Damaging 
H41-
TN2 CTNNB1 chr3:41266097 missense c.94G>T p.D32Y
1
 9.70% Deleterious Damaging 
H41-
TN3 CTNNB1 chr3:41266097 missense c.94G>T p.D32Y
1
 17.50% Deleterious Damaging 
H41-
TN5 CTNNB1 chr3:41266097 missense c.94G>T p.D32Y
1
 7.10% Deleterious Damaging 
H34-
TN1 CTNNB1 chr3:41266098 missense c.95A>G p.D32G
1
 17.00% Deleterious Damaging 
H38-
TN1 CTNNB1 chr3:41266098 missense c.95A>G p.D32G
1
 29.20% Deleterious Damaging 
H38-
TN2 CTNNB1 chr3:41266098 missense c.95A>G p.D32G
1
 29.40% Deleterious Damaging 
H38-
TN3 CTNNB1 chr3:41266098 missense c.95A>G p.D32G
1
 32.80% Deleterious Damaging 
H38-
TN4 CTNNB1 chr3:41266098 missense c.95A>G p.D32G
1
 26.80% Deleterious Damaging 
H20-
TN1 CTNNB1  chr3:41266100 missense c.97T>C p.S33P
1
 46.70% Deleterious Damaging 
H25-
TN1 CTNNB1 chr3:41266104 missense c.101G>T p.G34V
1
 36.60% Deleterious Damaging 
H36-
TN1 CTNNB1 chr3:41266104 missense c.101G>T p.G34V
1
 29.30% Deleterious Damaging 
H26-
TN1 CTNNB1 chr3:41266124 missense c.121A>G p.T41A
1
 40.10% Deleterious Damaging 
H18-






delinsP 22.50% Deleterious Damaging 
H40-
TN1 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 36.10% Deleterious Damaging 
H40-
TN2 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 37.20% Deleterious Damaging 
H40-
TN3 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 30.70% Deleterious Damaging 
H40-
TN4 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 22.60% Deleterious Damaging 
H40-
TN5 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 35.50% Deleterious Damaging 
H40-
TN6 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 22.20% Deleterious Damaging 
H22-
TN1 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 29.40% Deleterious Damaging 
H22-
TN2 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 32.90% Deleterious Damaging 
H30-
TN1 CTNNB1  chr3:41266136 missense c.133T>C p.S45P 21.00% Deleterious Damaging 
H33-
TN1 CTNNB1 chr3:41266137 missense c.134C>G p.S45C
1






















TN1 CTNNB1 chr3:41266137 missense c.134C>A p.S45C 
1
 37.60% Deleterious Damaging 
H32-
TN2 CTNNB1 chr3:41266137 missense c.134C>A p.S45C 
1
 37.50% Deleterious Damaging 
H32-
TN3 CTNNB1 chr3:41266137 missense c.134C>A p.S45C 
1
 37.70% Deleterious Damaging 
H29-
TN1 CTNNB1 chr3:41266137 missense c.134C>T p.S45C 
1
 48.40% Deleterious Damaging 
H02-
TN2 CTNNB1  chr3:41280745 missense c.2258T>C p.L753P 5.60% Neutral Tolerated 
H35-
TN1 MMP9 chr20:44639692 splice c.649_splice e4+3 51.40% splice splice 
H26-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 50.30% splice splice 
H21-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 52.90% splice splice 
H21-
TN1 MMP9 chr20:44639692 splice c.649_splice e4+3 28.00% splice splice 
H23-
TN1 MMP9 chr20:44639692 splice c.649_splice e4+3 49.80% splice splice 
H23-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 50.40% splice splice 
H41-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 50.40% splice splice 
H03-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 49.00% splice splice 
H09-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 48.70% splice splice 
H34-
OT MMP9 chr20:44639692 splice c.649_splice e4+3 99.30% splice splice 
H18-
TN1 ARID2 chr12:46244409 nonsense c.2503C>T p.Q835*
1
 22.10% ND ND 
H37-
TN3 PTEN  chr10:89692941 
fs-
deletion c.425delG p.R142fs 37.80% ND ND 
H33-
TN1 PTEN  chr10:89711926 missense c.544T>G p.L182V 5.10% Neutral Tolerated 
H21-
TN1 PTEN  chr10:89711926 missense c.544T>G p.L182V 17.40% Neutral Tolerated 
H42-
OT PTEN  chr10:89711926 missense c.544T>G p.L182V 5.10% Neutral Tolerated 
H24-
TN1 PTEN  chr10:89711926 missense c.544T>G p.L182V 5.90% Neutral Tolerated 
H31-
TN1 PTEN  chr10:89711926 missense c.544T>G p.L182V 7.10% Neutral Tolerated 
H17-
OT PTEN  chr10:89711926 missense c.544T>G p.L182V 5.50% Neutral Tolerated 
H24-
TN1 PTEN chr10:89711938 missense c.556C>G p.L186V
1
 8.00% Neutral Tolerated 
H43-
TN1 ATM  
chr11:10812259
2 missense c.1636C>G p.L546V
1
 41.50% Neutral Damaging 
H06-
OT APC chr5:112175122 missense c.3831A>T p.L1277F 9.20% Deleterious Damaging 
H11-






















TN1 APC chr5:112175122 missense c.3831A>T p.L1277F 5.20% Deleterious Damaging 
H27-
OT APC chr5:112175240 missense c.3949G>C p.E1317Q
1
 45.60% Neutral Tolerated 
H08-
TN1 APC chr5:112175240 missense c.3949G>C p.E1317Q 
1
 43.30% Neutral Tolerated 
H08-
OT APC chr5:112175240 missense c.3949G>C p.E1317Q 
1
 45.30% Neutral Tolerated 
H33-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1
 9.90% Deleterious Damaging 
H21-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1
 11.40% Deleterious Damaging 
H30-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1
 7.80% Deleterious Damaging 
H42-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1
 7.80% Deleterious Damaging 
H24-
OT MET chr7:116423405 missense c.3734G>A p.R1245K
1
 10.00% Deleterious Damaging 
H24-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1
 11.20% Deleterious Damaging 
H31-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1
 10.70% Deleterious Damaging 
H43-
TN1 MET chr7:116423405 missense c.3734G>A p.R1245K
1




1 missense c.838A>G p.K280E
1




0 missense c.847A>G p.M283V
1
 38.70% Neutral Damaging 
H27-
TN1 BRAF chr7:140453149 missense c.1786G>C p.G596R
1
 41.10% Deleterious Damaging 
H42-
TN1 PIK3CA  chr3:178936029 missense c.1571G>A p.R524K 20.00% Neutral Tolerated 
H33-
TN1 PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 6.70% Deleterious Damaging 
H21-
TN1 PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 5.60% Deleterious Damaging 
H30-
TN1 PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 13.90% Deleterious Damaging 
H42-
TN1 PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 5.90% Deleterious Damaging 
H24-
OT PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 8.20% Deleterious Damaging 
H24-
TN1 PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 7.00% Deleterious Damaging 
H31-
TN1 PIK3CA  chr3:178936092 missense c.1634A>C p.E545A 9.50% Deleterious Damaging 
FI… functional impact; fs… frame shift; ND… not determined; OT… non tumour; TN… tumour nodule 





4.1.3 Variant validation by Sanger sequencing 
The significant variants were validated using conventional Sanger sequencing (56\115), 
and the rest were confirmed somatic mutations in tumour samples with pathogenic 
impact by COSMIC databases, or high confidence somatic mutations called by NGS 
(Figure 8 and Table 31). Furthermore, obtained variants were analysed for their 
functional impact on the protein using Mutation Assessor (http://mutationassessor.org/; 




Figure 8: Evaluation of annotated variants.The significant 115 variants were selected based on Sanger 
sequencing (A), reliable somatic mutations called by NGS were visually identified in the Integrative 
Genomic Viewer (IGV, Broad Institute) (B), and somatic mutations were confirmed in tumour samples 
with pathogenic impact according to COSMIC database (C),  
 
4.1.4 Significantly mutated genes in HCC 
The highest frequencies of mutated genes were observed in the CTNNB1, TP53, and 





Figure 9: Global annotated genomic variants in HCC nodules of different grades and in Hep3B and Huh7 
hepatoma cell lines.The highest frequencies of potential pathogenic mutations were observed in the β-
catenin, TP53 and AXIN1 genes. 
 
The Wnt/β-catenin pathway was the most frequently altered, either due to activating 
mutations in the CTNNB1 gene with a frequency of 25.2% (29/115) or inactivating 
mutations in AXIN1 (11/115, 9.5%) or APC (6/115, 5.2%). 
Most CTNNB1 mutations strongly predicted the impairment of the function of the 
corresponding encoded proteins, and were predominantly detected in the N-terminus of 
β-catenin (amino acids 32 to 45), which responsible for β-catenin phosphorylation 
(Figure 10). 
β-catenin mutations were detected in 25% of HCCs; most of these were considered to 





Figure10: Sites of identified mutations in the CTNNB1 gene. Arm: Armadillo/beta-catenin-like repeats 
(224-264/ 350-390/ 431-473/ 583-623). 
 
Notably, CTNNB1 mutations were only identified in the tumour sample,and were absent 
in corresponding non-tumour tissue. In contrast, AXIN1 and APC mutations occurred in 
both the tumour and matched normal samples. Furthermore, point mutations in the 
AXIN1 gene, e.g. at p.G650S and p.T402M, showed a higher frequency in the non-
tumour sample (51.5% and 77.2%, respectively) than in thetumour sample (14.9% and 
58.4%, respectively). This indicates the loss of heterozygosity (LOH) in the tumour 
samples, suggesting a tumour suppressor function of this gene. 
Four missense mutations of the AXIN1 gene, p.G650S, p.R417H, p.T402M, and 
p.P278L, occurred in 10 samples, and one nonsense mutation p.R146* was detected in 
the Hep3B cell line (9.5%) (Figure 11). 
 
 
Figure 11: AXIN1 variants and their detected locations. RGS: Regulator of G protein signalling domain 




Somatic changes of the APC gene were two missense mutations, p.E1317Q and 
p.L1277F, in six samples (5%). 
The second most frequently altered pathway in HCC was the TP53 pathway. This 
resulted from either TP53 inactivating mutations (16/115, 14%), or mutations in the 
CDKN2A gene (7/115, 6%), which is the downstream cellular outcome of TP53 and is 
important for the tumour suppressive ability of wild-type TP53. All except one TP53 
mutation occurred in the DNA-binding domain of the tumour suppressor and were 
identified to disrupt the TP53 DNA-binding function (Figure 12). 
 
 
Figure12: Somatic mutations in the TP53 gene. P53_TAD pfama: P53 transactivation motif (5-29); P53 
pfama: P53 DNA-binding domain (95-289); P53_tetramer pfama: P53 tetramerisation motif (318-359). 
 
Most of TP53 mutations were missense mutations (p.T211P, p.Y220C, p.R248W, 
p.R249S, and p.R337L) and were predicted to cause a dysfunctional protein (Table 31). 
Furthermore, one missense mutation was detected inPICK3A (p.E545A), MET 
(p.R1245K), BRAF (p.G596R), and HNF1A (p.K280E) each; these were determined to 
be functionally damaging mutations. Other mutations exhibited non-functional impact, 
and were demonstrated in both tumour and non-tumour tissue. This indicates a 
polymorphic variant, or these tumours exhibiting loss of heterozygosity. 






4.2 Evolution analysis of HCC by ultra-deep sequencing of the mt-genome 
Tumour tracking and evolution analysis are of particular interest for identifying the intra-
tumour clonal structure and heterogeneity, affecting overall survival rates and 
therapeutic outcomes of many cancer types. Since HCCs manifest by a nodule-in-
nodule development, in molecular pathology it is an important issue to identify whether 
the secondary tumour is a recurrent tumour or a new primary tumour that has a more 
favourable prognosis and overall survival rate. In the present study, a novel approach 
was designed for analysing the clonal characteristics of the HCC nodules by screening 
variations of the mt-genome[104]. 
 
4.2.1 Characterisation of HCC nodules by histoenzymatic stains (COX/SDH) 
In order to assess the clonal architecture of HCC nodules, first histoenzymatic stains 
were performed. Cytochrome C oxidase/succinate dehydrogenase (COX/SDH) double-
labelling histochemistry stains are considered to be the histologic marker of the 
mitochondrial disorders. COX activity reflects the activity of complex IV of the 
mitochondrial respiratory chain and is mainly encoded by mtDNA, whereas SDH 
represents the activity of complex II and is encoded exclusively by nuclear DNA 
(nDNA). Sequential staining for COX followed by SDH was performed in this study. 
Deficient COX activity resulted in a reduction of nitro-blue tetrazolium chloride (NBT) 
due to SDH function, and to the formation of black or blue formazan (COX─). Brown 
insoluble compound resulted at the site of the COX activity (COX+) due to the use of 
3,3' di-amino benzidine (DAB). Partial deficient COX activity resulted in brown and blue 






Figure 13: COX/SDH staining in HCC lesions showing three different nodule types. Use of DAB 
resulted in a brown insoluble compound at the site of COX activity, indicating that this nodule is COX 
positive (COX+) (A). Deficient COX activity resulted in the reduction of NBT and in the formation of dark 
blue formazan, demonstrating that this nodule is COX deficient (COX-) (C). Furthermore, intermediate 
activity of COX resulted in phenotypically mixed nodule (COX +) (E). (B, D, F) represent the 
corresponding haematoxylin and eosin staining. 
 
4.2.2 Establishment of the mt-primer design 
For molecular tumour tracking, a PCR-based NGS of the entire mt-genome was 
established. In order to generate amplicons of low size (around 60-200bp), 108 primer 
sets, spanning the entire mtDNA (see Section 3.2.9.1), were designed according to the 
mt-sequence of accession no. NC_012920 or taken from previously published primer 
sets (Figure 2, Table 9 of primer seq.). 
The designed mitochondrial primers were tested on hepatoma cell lines Huh7 and 
Hep3B, as well as on HCC samples by qPCR and microfluidic analysis, showing an 






Figure 14: Efficient PCR amplification of mt-regions by designed mt-primers. The average Ct value 
obtained during the amplification was18 (A), and the PCR products resolved by microfluidic-based 
electrophoresis showed asingle sharp band in the range of the molecular weight, estimated from the 
respective primer sets (B). 
 
4.2.3 Data analysis revealed an extensive and ultra-deep analysis, targeting the 
entire mt-genome 
Forty-eight HCC nodules from 10 samples were studied for nodule heterogeneity. 
FASTQ files generated by the entire mitochondrial sequence of 48 samples were 
applied to bioinformatics analysis. The sequences where mapped against the entire 
human reference genome hg19 to exclude the possibility that nuclear pseudogenes, 
which have a high homology to the parts of the mt-genome, were recognised. For 
variant calling and annotation, a workflow was used. As a threshold for variant calling, a 
minimum read depth was set to 30, and the minimum variant frequency to 5%. 
Polymorphisms were recognised using the MITOMAP (www.mitomap.org), dbSNP-v138 
(www.ncbi.nlm.nih.gov/SNP), and HAPMAP_phase_3 (hapmap.ncbi.nlm.nih.gov) 
databases. 
The data analysis output generated an average of 199 x 104 reads per sample. A total of 
194 x 104 reads were mapped to the mtDNA reference sequence, demonstrating ca. 




regions, mainly affecting chromosome 1 (1.6%), thus indicating the efficiency of the 
designed primer sets and a good run performance for the analysis of the entire mt-
genome. 
 
4.2.4 Data filtering and accurate mt-gene annotation 
In total, the 48 HCC patient samples and three liver specimens of the control produced 
a total of 2,089 variants. Seven variants (263A, 311C-315C, 750A, 1438A, 4769A, 
8860A, and 15326A) were excluded, as they are considered to be polymorphisms 
according to the MITOMAP database. Furthermore, the *3107delvariant, announced by 
'N' annotating the wobble nucleotide in the reference, and 18 additional variants 
16296C, 16294C, 16163A, 15928G, 10916T, 8995G, 295C, 235A, 207G, 204T, 200A, 
199T, 195T, 189A, 186C, 182C, 93A, and 73A, recognised by the HAPMAP_phase_3 
and dbSNP_v138 databases, were removed. Next, sequencing errors, mostly occurring 
in homopolymer tracts, sequence repeats, and at the amplicon ends, were excluded 
from the data, resulting in 469 confident variants (Figure 15, Supplemental Table S3). 
The most relevant variants (430/469, 92%) were validated using Sanger sequencing. 
 
 
Figure 15: Workflow of NGS data interpretation and mt-variant frequencies.  After deletion of the 
reading errors and dbSNP variants as described in MITOMAP, dbSNP-v138, and HAPMAP_phase_3 
databases from total sequencing variant output, 469 reliable variants remain (A). The most frequent mt-
variants are located in the genes of respiratory chain, and at the D-LOOP regulatory site for replication 




4.2.5 High frequency of mt-mutation located in D-LOOP and respiratory chain 
subunits 
NGS analysis revealed a wide spectrum of mt-alterations. In agreement with previous 
reports[44, 45, 105], most of the mutations detected in the present study were 
homoplasmic, and the highest frequency was observed in the genes of respiratory chain 
complexes (144/469, 31%), and in the D-LOOP regulatory site for replication and 
expression of mtDNA (143/469, 30.5%).These mutations could lead to an abnormal 
metabolism, as well as to altered apoptosis. Furthermore, most of the samples 
contained a T>C transition at nucleotide 16519 (Figure 16). The defined mutations are 
listed in the Supplemental Table S3. 
 
Figure 16: Global annotated mt-variants in the HCC cohort and control liver. Ahigh frequency of mt-
mutation was observed in the D-LOOP region and in the genes of respiratory chain complexes. The 






4.2.6 Accumulation of mt-mutations in non-tumour areas, reflecting the pre-
tumour machinery of mtDNA 
Interestingly, highly frequent mt-mutations were observed in both tumour and non-
tumour liver specimens, compared to the control liver. The mtDNA sequence obtained 
from HCC nodules (e.g. Sample-H41) showed accumulated mt-mutations compared to 
non-tumour lesions of individual patients, and to the control liver, as depicted in Figure 




Figure 17: Annotated mt-mutations in HCC sample and in control liver. Numerous mt-mutations 
were detected in HCC nodules, here shown exemplary in the HCC sample H41 (26 variants) (A), and 
some of these mutations were apparent in the corresponding non-tumour, but cirrhoticliver specimen of 
the same patient (11 variants) (B). Only three variants were observed in the liver specimen of a control 
tissue derived from the non-tumorous part of CRC metastasized liver (C). 
 
In addition, there were differences in the overall frequency of alteration between 




observed in non-cirrhotic, non-tumour liver lesions. However, in cirrhotic liver disease, 
mt-mutation frequencies were markedly increased after HCC development (Figure 18).  
 
Figure 18: The high rate of mt-mutation in HCC nodules is not based on advanced fibrosis or 
cirrhosis. Quantitative analysis of the number of mt-mutations [N] in cirrhotic and non-cirrhotic pre-
tumorous tissue showed a high mt-mutant accumulation in non-cirrhotic, non-tumour lesions, and 
occurred in nearly equal frequency in the HCC nodules. 
 
When comparing the mt-mutations present in tumour and non-tumour lesions of 
individual patients, some mt-mutations were found to exhibit a homoplasmic conversion 
in tumour nodules, while the heteroplasmic mutations present in non-tumour lesions 
became homoplasmic mutations in tumour nodules. These observations support the 
suggestions made in previous studies [106, 107]. Furthermore, some mt-mutations were 
detected only in tumour nodules and their frequencies correlated with tumour 
dedifferentiation, suggesting that the accumulation of mtDNA mutations in HCC tissue 







Figure 19: Frequency of mt-mutations in HCC nodules with different tumour grades. The heat map 
shows the increasing frequency of mt-mutations linked to advanced tumour grades. (TN: tumour nodule; 
NT: non-tumour; T+NT*: sample obtained at tumour border with mixed tumour and normal liver tissue). 
 
4.2.7 Analysis of HCC clonality by mt-genome 
Screenings of mt-mutations are well-established clonal markers for cell lineage tracing. 
The present results show that the HCC nodules and non-tumour lesions harboured 




Figure 20: Venn diagrams illustrating common mt-variants (intersection area) among the HCC nodules 




4.3 Establishment of entire mt-genome deep-sequencing for tumour-tracking 
and clonality analysis of FFPE material 
In order to use mt-genome analysis for tumour clonality analysis and evaluation of 
tumour history on a wide panel of samples which are mostly available as FFPE material, 
the technology of ultra-deep sequencing was adapted to the low DNA quantity and 
quality of FFPE biopsy material.  
First, mt-genome target enrichment was established by multiplex PCR instead of 




Figure 21: Scheme of primer design and the multiplex PCR-based approach of mt-genome 
enrichment. Designed primer sets generating 108 amplicons spanning the whole mitochondrial genome 
(A), were pooled in four primer pools (each 27 primer sets) for multiplex PCR (B), in order to ensure that 





Next, the method was tested on tumour DNA from FFPE material. Notably, the 
coverage of the mt-genome was 98 % and the out-off target sequencing was only 2 % 
as described by Amer et al. [104]. The method was then primarily used on various 
lesions of non-small-cell lung cancer (NSCLC). The well histologically classified, 
heterogeneous NSLCC lesions were studied for their tumour history by ultra-deep 
sequencing of the mt-genome. Application of this novel technology was successfully 






HCC is an aggressive cancer of the liver with poor prognosis, and there is no 
effective treatment against it in spite of aggressive conventional therapy [108]. 
Genetic alterations in HCC have been identified previously using whole genome or 
whole exome sequencing [18, 94,95]. In the present study, the genetic alterations 
in different nodules of HCC, using a nuclear and mt-genome analysis by ultra-
deep sequencing were addressed. The genomic HCC assay was first applied on 
115 matched HCC tumour and non-tumour tissue areas of a total of 44 HCC 
patients, using newly designed HCC-relevant target panels. Furthermore, a novel 
approach of whole mtDNA analysis was used as a molecular tool for tumour cell 
tracking. Interestingly, the data from the mt-genome analysis revealed that the mt-
genome alterations precede hepatocellular oncogenic transformation and might be 
used as an early marker of hepatocarcinogenesis. 
 
5.1 Massive sequencing of HCC-relevant nuclear gene targets 
In the present study, a novel HCC-relevant panel of genomic targets was first 
designed for ultra-deep sequencing using the information about HCC-relevant 
genomic alterations from previous whole exome data analyses [18, 94-96], as well 
as updated data documented in the COSMIC database. Next, the primer sets were 
configured in order to enrich the coding exomes of potential HCC-relevant genes 
by multiplex PCR assays. 
In previous studies, whole genome (WGS) and whole exome sequencing (WES) 
were applied to identify the causative variations that might be critical in the 
development of HCC. Although these approaches provided information about HCC 
typical genomic alterations and might be used as a primary screening method, 
they do not present ultra-deep sequence data, which are needed to find rare 
variants and to evaluate tumours of early dedifferentiation. 
Another benefit of target sequencing is that it enables simultaneous testing for a 
broad spectrum of point mutations and indels with high accuracy and sensitivity 
[109]. Furthermore, many variants detected by previous approaches are prone to 
high rates of false positives and false negatives. The false positives are due to 




misalignment [110], whereas most false negatives result from low coverage, or 
aggressive data filtering obtained from WGS [111]. 
The targeted gene panels that were designed for this thesis encompassed 
hotspots and commonly mutated regions in HCC, to detect the genomic changes 
resulting in oncogene activation and tumour suppressor gene inactivation, which 
are essential for maintenance of the malignant phenotype. Gene panel sequencing 
provides efficient target enrichment, analysis of several genes in one 
comprehensive test, high coverage in targeted regions, and sequences with high 
uniformity. Therefore, efficient strategies for selectively sequencing targeted gene 
panels would be preferable over whole exome sequencing for determining 
disease-causative mutations [112]. Notably, the genomic data generated from 
gene panel sequencing can help in the development of novel targeted therapies, 
and can assist in the selection of currently available treatments likely to be most 
effective.  
By using the current protocol in this study, the simultaneous testing of 394 
disease-specific targets was possible. Optimal sequencing depth of targeted 
regions is sufficient to detect low frequent mutation at every single nucleotide of a 
genomic region [113]. 
 
5.1.1 β-Catenin and TP53 mutations in HCC 
After a good NGS run performance, the data analysis revealed that the β-catenin 
gene (CTNNB1) was most frequently mutated. These data confirm previous 
studies that demonstrate that the Wnt\β-catenin pathway is the main and early 
events in hepatocarcinogenesis [18, 24,114]. Since the Wnt\β-catenin pathway is 
implicated in cell proliferation, migration, and invasiveness of cancer cells, 
activation of this pathway is associated with an aggressive HCC phenotype [114, 
115]. In HCC the Wnt\β-catenin pathway is mainly activated by CTNNB1 exon 3 
mutations [18, 116].  
In the present study, CTNNB1 mutations were detected in 25% of HCCs, and were 
mostly considered to cause amino acid substitutions, while one mutation was an 
interstitial deletion. Most of the β-catenin mutations were located in the exon 3 




four presumptive GSK3b phosphorylation sites, and is responsible for β-catenin 
phosphorylation. These data confirm previous work [18, 116], demonstrating that 
the N-terminus is highly mutated, in this way affecting β-catenin phosphorylation, 
and thereby phosphorylated β-catenin is rapidly degraded by the ubiquitin-
proteasome pathway [117]. β-catenin mutations were detected exclusively in low- 
and high-grade tumour samples but were absent in the corresponding non-tumour 
tissue, indicating β-catenin’s contribution in HCC initiation and development [22, 
116]. Importantly, β-catenin was not related to a certain risk factor, such as 
intoxication or viral infection. However, other studies have demonstrated that the 
Wnt\β-catenin pathway is frequently dysregulated in HCV- and HBV-related HCC 
[118, 119]. Furthermore, Cieply et al. demonstrate that β-catenin mutations are 
more often observed in HCCs that are not based on cirrhosis. The data obtained in 
the present study show that β-catenin mutations occurred in some HCC lesions in 
the absence of cirrhosis. This indicates that β-catenin mutations themselves might 
be the tumour driving force, independent to the cirrhotic features [115]. Effective 
targeting of the Wnt signalling pathway is considered as a potential target for 
pharmacological therapy that is eagerly awaited. 
Furthermore, the dysregulated signalling cascade of the Wnt/β-catenin pathway 
resulted from mutations in genes that regulate β-catenin signalling. Thus 
inactivated mutations were found in 9.5% of AXIN1 and 5.2% of APC. 
Interestingly, novel AXIN1 variants T402M and G650S were found that occur in 
the non-tumour tissue with a higher frequency (77% and 51%, respectively) than in 
tumour samples (58% and 15%, respectively), suggesting a germline 
polymorphisms of the AXIN1 gene. The lower frequency in the tumour lesion 
indicates that one allele of the tumour suppressor AXIN1 gene is lost in the tumour 
as a hallmark of heptocarcinogenesis [120]. AXIN1 is a master scaffolding protein 
critical for β-catenin degradation [121]. It acts as a tumour suppressor by 
negatively controlling the Wnt pathway and as a positive regulator of JNK, TGFβ, 
and Tp53 signalling in the liver [122, 123]. Targeting of the AXIN1 gene is 
suggested to be an effective therapeutic molecule for tumour growth suppression 
in HCC [124]. 
Two APC gene mutations were detected in tumour and non-tumour samples. The 




database this mutation is documented as a somatic mutation in various types of 
cancer. However, the average of 45% frequency in all nodules suggests that, in 
this respective case, the p.E1317Q is a germline variant that might have caused 
an increased individual risk of cancer. Furthermore, the p.L1277F mutation was 
predicted to have a functional impact on the APC protein, and its occurrences in 
pre-neoplastic cirrhotic lesions, suggesting its role in hepatocarcinogenesis.   
In concordance with previous studies, the β-catenin gene was the most frequently 
mutated oncogene and theTP53 was the most frequently mutated tumour 
suppressor gene (14% frequency). More than 50% of all human cancers exhibit 
mutations in the TP53 gene [125, 126]. The vast majority of TP53 mutations are 
missense mutations, single base-pair substitutions resulting in an exchange of the 
encoding amino acid. The majority of these missense mutations is located within 
the DNA-binding domain, the most conserved region of TP53[127]. These 
mutations generate mutant TP53 proteins with novel activities or gain-of-function 
activities that actively promote tumour growth by dominant-negative effects of the 
respective allelic TP53 wild type protein [128-130]. Interestingly, inactivated 
missense mutations in TP53 were detected in patients with advanced-stage HCC. 
The TP53 mutations have been reported to be associated with a high recurrence 
rate of HCC, suggesting that the mutant TP53 gene is correlated with tumour 
aggressiveness and metastatic potential [131]. Furthermore, the TP53 hotspot 
mutation, R248W, is associated with a significantly poorer prognosis compared to 
other missense mutations [132]. In addition, the R249S mutation, a hotspot 
residue linked to aflatoxin B exposure, was observed in patients known to be 
infected with HCV and HBV, suggesting that aflatoxin B exposure could be a 
second risk factor for HCC development [9]. Villar et al. found that the R249S 
mutation occurs independent of cirrhosis in a context of HBV chronic infection 
[133]. One missense mutation was observed outside the DNA-binding domain in 
the TP53 tetramerisation domain, amino acid 337 arginine to leucine. This 
mutation was detected previously by others using yeast assay, which the colonies 
with R337L mutation exhibit a resistance to temperature, perhaps due to 
destabilisation of the tetramer [134, 135]. 
In accordance with previous studies, TP53 mutations mainly occurred in HCC of a 




TP53 occurring late in tumourigenesis has already been shown in other tumours 
such as prostate cancer [139, 140], bladder cancer [141], pancreatic cancer [142], 
and breast cancer [132]. 
In addition, altered TP53 signalling pathway may be caused by CDKN2A 
mutations. The CDKN2A encodes the p16 cell cycle regulating protein, 
downstream acting to TP53. One CDKN2A variant (p.A148T) was detected; it was 
a common germline mutant associated with familial cancer predisposition, e.g. 
melanoma, glioblastoma, and pancreatic cancer [143, 144]. However, this mutant 
was also previously described as a common polymorphism without a major impact 
on p16 function [145, 146]. In spite of these controversial reports, recent studies 
have also considered CDKN2A p.A148T to be a melanoma susceptibility variant 
[147, 148]; however, the influence of the p.A148T CDKN2A variant in HCC is not 
yet known. Nevertheless, it is assumed that it will be also be associated with cell 
cycle dysregulation and promotion of the hepatocarcinogenesis risk. 
In 7% of HCC lesions, a p.R1245K of the MET gene occurred. The proto-
oncogene MET is a protein coding gene that encodes for the receptor tyrosine 
kinase (RTK), MET, or the hepatocyte growth factor receptor (HGFR). The MET 
receptor is expressed on the surface of epithelial and endothelial cells. It is a multi-
domain receptor that after binding of the HGF ligand, leads to receptor 
phosphorylation and activation of different downstream signalling pathways, 
including activation of mitogen-activated protein kinase (MAPK) cascade and the 
phosphatidylinositol 3 kinase (PI3K)-AKT signal transduction [149, 150]. HGF/MET 
signalling mediates an increase in cell proliferation and motility, resulting in 
enhanced tumour invasion and angiogenesis but inhibited apoptosis [151, 152]. 
MET overexpression was demonstrated in HCC and associated with poor 
prognosis and an aggressive phenotype [153].  
One BRAF mutation (p.G596R) was detected in a single NASH-related HCC 
sample. The three RAF genes code for cytoplasmic serine/threonine kinases that 
are regulated by RAS binding and driving an uncontrolled process of cell division. 
This mutation occurs within the kinase domain, and has functional impact on the 
BRAF protein. According to the COSMIC database, mutations within the BRAF 
gene are extremely rare in HCC. Furthermore, p.G596R point mutation in BRAF 




cancers [156], and this is the first time that it has been detected in HCC. 
Sorafenib, the BRAF inhibitor, was the first clinically useful agent for the treatment 
of advanced unresectable HCC [83]. 
Somatic mutations in PIK3CA were found to carry the activating point mutation 
p.E545A in exon 9. This hotspot mutation occurs within the highly conserved 
helical domain, and has been previously reported in HCC [157-160] and several 
other cancers [161-164]. The functional impact of this mutation is linked to 
increased oncogenic potential by an increased catalytic activity resulting in 
enhanced downstream signalling [165]. HCC patients with the hotspot PIK3CA 
mutation (p.E545A) can benefit from inhibitors effective against the kinase activity 
of this mutant [166]. 
The coding sequence mutations of the PTEN gene were found in patients with 
advanced-stage HCC. These mutations have non-functional impact and were 
detected in two non-tumour samples, suggesting the importance of these 
mutations in tumourigenesis. The PTEN gene is a negative regulator of the 
PI3K\AKT\mTOR pathway by dephosphorylating of the lipid products of PI3K 
[167]. The PI3K counteracts activity of PTEN, resulting in inhibition of cell cycle 
progression, induction of cell death, modulation of the arrest signal, and 
stimulation of angiogenesis [168]. This result is consistent with that of a previous 
study that demonstrated that the decreased PTEN expression was correlated with 
tumour progression and poor HCC prognosis [169]. 
A putative splice site mutation was detected in the MMP9 gene in tumour and non-
tumour lesions with equal frequency, suggesting that this mutation may be a 
polymorphic variant. The MMP9 gene mutation may lead to protein alteration and 
to an increase in the MMP9 expression. The MMP9 gene plays a key role in 
cancer invasion and metastasis by degrading the extracellular matrix. The MMP9 
was observed to have significant expression in HCC with capsular infiltration, 
suggesting a role of MMP9 mutation in tumour invasion and metastatic potential 
[170, 171].  
Two HNF1A missense mutations were observed in the same HCCs sample: one 
functional and one non-functional mutation were located in the DNA-binding 




well-differentiated HCC. The inactivation of both HNF1A alleles is required, 
indicating the tumour suppressor activity of the HNF1A gene [172]. 
Additionally, ARID1A and ARID2 are genes that encode chromatin remodelling 
complex components. They have recently been shown to be inactivated in several 
tumour types [173, 174] and also in HCC [94, 96,175]. They are important tumour 
suppressor genes and a promising therapeutic target for HCC [96, 175,176]. 
Decreased expression of ARID1A has previously been observed in HCC, and has 
been associated with tumour progression, metastasis, and reduced overall 
survival. In the present study, frame-shifting insertions were found in tumour 
suppressors ARID1A located in exon 1. Furthermore, there was a nonsense 
mutation of the chromatin remodelling gene ARID2, located in proline-and 
glutamine-rich region (GLN) in one case. Mutations within subunits of SWI/SNF 
chromatin remodelling complex are predicted to truncate the ARID1A and 
ARID2proteins, leading to their inactivation. 
 
5.2 Ultra-deep sequencing of the entire mt-genome 
In the light of previous reports on accumulated mutations of the mtDNA in different 
types of cancer [48, 49, 51, 52]and in HCC [47, 55, 56, 177], an aim of this study 
was to determine the mtDNA mutations in different HCC grades and its correlation 
with tumour dedifferentiation. Therefore, the entire mtDNA was screened for the 
mutations in a cohort of 48 HCCs and the corresponding non-tumour tissues. 
Since the mt-genome is a small circular DNAof approximately 16.6 Kb, 108 primer 
sets were designed to span the entire mt-genome. Conversely, others have 
focused on the analysis of the control region (D-LOOP), which encompasses a 
hotspot region but only covers 7% of the total mt-genome [47, 48, 52].  
The primer design generated 108 amplicons of 160-bp in average, guaranteeing 
that these primers were applicable on FFPE material of the pathology routine 
processing[104], which is characterised by a high degree of DNA fragmentation 
[178]. Previous NGS-based approaches of mtDNA analysis have used long-range 
PCR amplicons, which only works on native material [107, 179]. To amplify the 
entire mt-genome per sample, first 108 singleplex PCRs were successfully 




of contamination and error-prone pipetting; in addition, the process is time-
consuming. Therefore, an automatic singleplex PCR processing was established 
in 384 well-layouts. Next, singleplex PCR-based ultra-deep sequencing was 
conducted. 
Notably, the eukaryotic nuclear genome harbours pseudogenes with more than 
60% homology to the mt-genome, the so-called nuclear mitochondrial DNA (Numt) 
as documented in the MITOMAP database. However, the possibility of accidental 
amplification of these sequences in reactions directed to mtDNA amplification is 
unlikely when sufficient mtDNA is present in a sample, due to the presence of 
many copies of mtDNA per cell [180]. Intriguingly, after mapping the sequencing 
reads against the entire human reference genome hg19, the generated data 
showed that the out-target annotation was in total only 2.5%, mainly affecting 
chromosome 1 (1.6%)[104]. These findings indicate the specificity and efficiency 
of the designed primer for mtDNA target enrichment. A high quality andoutput of 
data generated from 48 paired tumour/non-tumour samples demonstrated that the 
majority of mtDNA were homoplasmic or highly heteroplasmic, as has already 
been reported in previous studies [44, 105]. In addition, mt-mutations may acquire 
a selective replicative advantage during cellular development and become 
dominant, developing a homoplasmic mutant in the clonal cell population [44, 
45,181]. 
 
5.2.1 The mt-genome alteration as an early marker of HCC development 
In agreement with previous reports, a majority of the mutations were homoplasmic, 
and most were T-C or G-A transitions [44, 45,105]. The highest frequency was 
observed in the D-LOOP region and in genes of respiratory chain complexes. This 
might lead to an impairment of replication and transcription of mtDNA, 
mitochondrial respiration, and Oxidative phosphorylation (OXPHOS) function, 
which might ultimately result in enhanced reactive oxygen species (ROS) 
production. Furthermore, a high number of mtDNA mutations were detected in 
tumour and corresponding non-tumour lesions, and were markedly greater than 
those in control liver tissue, which is consistent with a previous report [55]. This 
can be explained by the fact that during chronic liver injury, the parenchymal tissue 




mtDNA alteration and subsequent mitochondrial respiratory dysfunction. 
Furthermore, a decline in mitochondrial respiratory function and oxidative 
phosphorylation led to an increase in mitochondrial production of ROS, which in 
turn led to further mtDNA damage. Repetitive oxidative damage and oxidative 
stress as a result of additional mitochondrial dysfunction may extend to oxidative 
damage of nuclear DNA (nDNA), contributing to the mutagenic transformation of 
hepatocytes [182-185]. Thus, concurrent accumulation of mtDNA mutations in pre-
neoplastic lesions may possess a critical role in pre-tumour machinery and may 
contribute to hepatocarcinogenesis (Figure 22). 
 
 
Figure 22: Mechanism of mtDNA mutation and its contribution to tumourigenesis. (A) 
Schematic representation of repetitive mtDNA damage by ROS leading to mtDNA mutations (c.f. 
main text). (B) Hypothetical model whereby mtDNA damage accumulates within the cell during the 
life [A] and confers a growth/survival advantage likely to become intra- and intercellular dominant. 
[B] Accumulation of mutant mtDNA causes further oxidative stress and an increase in ROS 
generation; this may in turn trigger nDNA alterations, which promote the tumour machinery 
[C](Figure 1B adapted from Salk et al. [186], with modification). 
 
Some homoplasmic mutations were restricted to the tumour lesions, whereas 
others exhibited a homoplasmic conversion in the tumour nodules. Here, the 
homoplasmic conversion in tumour lesions means that the heteroplasmic mutation 
presents in non-tumour lesion become homoplasmic in tumour nodules. The 
homoplasmic conversions have been reported by others [44, 106, 107], and it has 




selective growth advantage during tumour evolution, allowing it to become 
dominant at the intracellular and intercellular levels [44]. Furthermore, the present 
study detected some heteroplasmic mutations with a different mutation load in the 
HCC lesions and the corresponding non-tumour samples. The heteroplasmic 
mutations can occur as a result of de novo mutations, which are not yet 
homoplasmic or which were intolerant homoplastic mutations that underwent shift 
segregation [187]. In addition, heteroplasmic mutations are considered to be 
pathogenic mutations when the level of mutant mtDNA is higher in clinically 
abnormal tissues than in normal tissues [187]. Since most mtDNA point mutations 
are homoplasmic, it can be difficult to prove the pathogenicity of these mutations; 
therefore the application of parallel genomic nuclear analysis may be helpful. In 
the present study, nuclear and mitochondrial data aggregation revealed that mt-
alterations precede nuclear alterations: e.g in sample21743, mt-mutations of 
respiratory chain subunits were observed with high frequency in non-tumour 
lesions, but the nuclear alterations of TP53 (p.R249S) and CTNNB1 (p.D32S) 
were undetected in non-tumour lesions, and increased in frequency with tumour 
initiation and progression (Figure 23). 
 
 
Figure 23: mt-alterations precede nuclear alterations in HCC. Nuclear genes (TP53 and 
CTNNB1) were not evident in non-tumour lesions, whereas the homoplasmic mtDNA mutations 





Taken together, our findings illustrate that the mtDNA is susceptible at the earliest 
stage of hepatocarcinogenesis, and that it has a critical role as an early marker of 
HCC development. Many studies support this result that somatic mt-mutations are 
specific biomarkers for cancer diagnostics due to; homoplasmic nature of mt-
mutations, combined with the presence of hundreds of copies of mtDNA within 
each cell,500-1000 fold more numerous in the cell than nDNA[105, 188, 189]. In a 
study by He et al., the tumour specificity of mutant mtDNA was determined; mt-
mutations have been detected in the plasma of colorectal cancer patients after 
surgical removal of the cancer, while nDNA mutations were not evident. 
Additionally, the plasma concentration of mutant mtDNA was lower after surgery 
than before it [107].  
Interestingly, in the present study a higher number of mt-mutations were observed 
in non-cirrhotic non-tumour lesions compared to in cirrhotic non-tumour lesions. 
This suggests that the exposure to strong carcinogens can induce genetic 
alterations, particularly in mtDNA, through alterations in cell cycle regulation, 
oxidative stress, and activated mitogenic signalling pathways that promote the 
development of HCC without underlying cirrhosis [190, 191]. However, in cirrhotic 
liver disease, mt-mutation frequencies are markedly increased after HCC 
development. 
 
5.2.2 The mt-genome alterations as tools for tumour tracking analysis of 
HCC 
The mt-genome is a useful molecular tool with which to assess precise cell 
lineages and to track tumour history [47-49, 52]. The present study addressed the 
evolution of tumours by screening the mt-mutations in tumour/non-tumour nodules 
of an individual patient with multi-focal HCC. Previous studies have already 
alluded to the monoclonal nature of HCCs based on methylation patterns of the X 
chromosome genes [192-194]. However, these studies often ignore the distribution 
of X chromosome-inactivated cells. Because X-inactivation occurs relatively early 
in embryogenesis, the progeny of a single X-inactivated embryonic cell may be 
clustered together, forming a patch and sharing a common X-inactivation pattern. 
HCC nodules arising in the middle of a patch could be mono-phenotypic for an X-




Furthermore, the polyclonality can be demonstrated only at the border of a patch; 
therefore the patch size is crucial in determining the chance of demonstrating 
polyclonality, which has rarely been mentioned in previous studies. Another 
limitation of these studies is that CpG methylation changes over time, especially in 
cancer, which is often associated with an increase or a decrease of the DNA-
methylation pattern. Therefore, these studies might be not informative. 
Using the mtDNA mutation pattern as a diagnostic tool, it was found in the present 
study that all HCC samples were monoclonal, because all HCC nodules and case-
matching non-tumour lesions harboured identical mt-mutations, suggesting their 
single cell origin. Monoclonality of cirrhotic regenerative nodules of human liver 
have been characterized in the past [195]. Since the cirrhotic regenerative nodules 
represent pre-neoplastic stages of HCC development, it is likely that HCC lesions 
are also monoclonal. 
Remarkably, mtDNA constantly undergoes mutation, with the loss or expansion of 
mutated mtDNA copies over several generations [45, 106]. Dominant mt-mutation 
during tumour development leads to the evolution of a homoplasmic status in 
clonal cell population [44, 45,181]. Clonal homoplasmic expansion develops, as 
previously shown, by crypt fission, forming large tumour patches with identical mt-
mutations [62, 196]. The present data demonstrate that tumour nodules arise 





Figure 24: Clonal mt-mutation expansion of HCC development. A stochastic mt-mutation (open 
arrows) arises at the germline or somatic level (A) and confers a cellular growth advantage. It is 
likely to become dominant, leading to clonal patch formation (dashed boundaries) (B). Monoclonal 
tumour nodules, arising from a single patch, carry an identical mt-mutation pattern of homoplasmic 
and heteroplasmic mutations (red mitochondria) (C). Tumour nodules, which arise from different 
clonal patches, contain a distinct pattern of homoplasmic and heteroplasmic mt-mutations (blue 
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7.1 Primer sequences of HCC gene panel 











chr1 ARID1A-1F GTCTCAGCAGTCCCAGCAAA 27058041 27058167 
 ARID1A-1R GTTCTCATGACACTAACCCCCAAG   
chr1 ARID1A-2F AGAGATATTAGTGAGTTGCTAGTGAGT 27089404 27089577 
 ARID1A-2R GCTGTCCATGCATTTGACCTC   
chr1 ARID1A-3F CGCCTCCTCGTCGTCTT 27023668 27023796 
 ARID1A-3R GACGTGAGCAGTTGGTTGAG   
chr1 ARID1A-4F CAGACTCCCCAGTCAACCAG 27099017 27099188 
 ARID1A-4R AAGGAGTTCCCATGCACTTATCTT   
chr1 ARID1A-5F GGCCTTATGGCCCTAACATGG 27089641 27089808 
 ARID1A-5R CACTGACACCCTCTCTGCTT   
chr1 ARID1A-6F GACATCTTTGCAGCTGCTGATTC 27097757 27097926 
 ARID1A-6R ACAGATCCTTGGCATATCCTGTT   
chr1 ARID1A-7F ACATTCCAGAAGCGGAATTCCA 27099355 27099512 
 ARID1A-7R GAGCACAAGTTCAAATAGCAATCAGAT   
chr1 ARID1A-8F GTGCCATTGCAGTGCAGAAG 27106937 27107087 
 ARID1A-8R CGCCGCATCATGTCCACA   
chr1 ARID1A-9F GCTGTTGGACATCTCGGTATCA 27107160 27107310 
 ARID1A-9R AGTCAGTTTCTAAGTTCTCCACACAC   
chr1 ARID1A-10F GCCCCCTCCATCTAACTACCA 27101416 27101567 
 ARID1A-10R CTGCCTTCTGCATTTTCATCCC   
chr1 ARID1A-11F AGGGTTGCTAGAGCTCCTTGTA 27105519 27105662 
 ARID1A-11R GGAGCTGGACTAGACACCTTG   
chr1 ARID1A-12F ATGCTCCGGGAAAACACCTT 27106552 27106682 
 ARID1A-12R TCAGCTGAAGGGCAAACTG   
chr1 ARID1A-13F AACCAGGCGGGAGATATACCT 27097564 27097725 
 ARID1A-13R CATTCAAAGGCATAGAGACACTGGATA   
chr1 ARID1A-14F GGTCTTGGAAACCCTCAGCAA 27106740 27106872 
 ARID1A-14R CGGGTTCTTTCGGTCACTGA   
chr1 ARID1A-15F GAATTCCCAGGCTTAGCCATGATA 27087823 27087953 
 ARID1A-15R GCAATGCTTGATTGGTTCATGGAAG   
chr1 ARID1A-16F CACTGAGCATATCCAGACCCA 27105942 27106070 
 ARID1A-16R TGGTCTGTTGTCCCTGGTGTA   
chr1 ARID1A-17F CCCAGGATAAGGATGGAGAGCAT 27088569 27088739 
 ARID1A-17R GTGTGTATCTGTCCTCCGGAAG   
chr1 ARID1A-18F CTCATCATCAGTGCATAGCTTCTCA 27057553 27057724 
 ARID1A-18R GGTGAGGACTTTGCTGGTTGTA   
chr1 ARID1A-19F CTCAACCACCACAGCTCCA 27057809 27057981 
 ARID1A-19R CTGCTGCTGGTAAGGAGACT   
chr1 ARID1A-20F GCAGAGAGCACATGGGCATTA 27102118 27102244 
 ARID1A-20R AGAAGATCCCAAACCCTCTCAATCT   
chr1 ARID1A-21F CCCCCTCAATGACCTCCAGT 27059207 27059348 
 ARID1A-21R CTAACTAGTTTGCATTGGTTTCCTCTCT   
chr1 ARID1A-22F GGGCTAGGAAATGTGGCGAT 27099920 27100051 
 ARID1A-22R CAGATTGAGCCCACTATAGCTTCAG   
chr1 ARID1A-23F CCGCTGGGAAAGGAGCTG 27023096 27023254 
 ARID1A-23R CGGCTCCGTGAGGTTATTGTT   
chr1 ARID1A-24F TGGTTGTAGCCATCTTGGCAT 27100737 27100911 














chr1 ARID1A-25F GGCGCCTCCTCACTCAG 27023293 27023427 
 ARID1A-25R CTTTGTTGTCCGCCATGTTGT   
chr1 ARID1A-26F CCTTCCCCTCAGCAAGATGTAT 27100979 27101109 
 ARID1A-26R ACACGGTCTCGGCCAAAC   
chr1 ARID1A-27F CATACAGGCATCAGCTGAGGTT 27101170 27101332 
 ARID1A-27R CCTCTGATCTGTGTGCAGCATT   
chr1 ARID1A-28F ACCTTCCAGAAATCCAGTTCTTCTACT 27094272 27094446 
 ARID1A-28R AGAGGTCCAGAGGTTTCCTACC   
chr1 ARID1A-29F GGGATGTAAAGTTAACTCCAGCCA 27092981 27093135 
 ARID1A-29R ACTCTCTTTTCTTTTTCCTTCCTATCAC   
chr1 ARID1A-30F TGGTTCAATAGATGACCTCCCCAT 27087355 27087485 
 ARID1A-30R GGGAGGTATGAGGAGAGAAAGG   
chr1 ARID1A-31F CTTGACCGAGGATGGAGCTAA 27106152 27106305 
 ARID1A-31R GTCCAGAAGGGTACACAGTGG   
chr1 ARID1A-32F GTCCAATACCATTCGAAGCCTGT 27106341 27106514 
 ARID1A-32R CTCACCCCTTGGTCCTGTTC   
chr1 ARID1A-33F TGATGGGAACTGGACCTCCT 27092747 27092899 
 ARID1A-33R TGACTCTTGAAGAAATCCCTAGTGAGAA   
chr1 ARID1A-34F ATTCGGCGGGATATCACCTTC 27101621 27101775 
 ARID1A-34R GAGGGAACAATGGACAAGATGGAAA   
chr1 ARID1A-35F GCCCCAGCAGAACTCTCA 27023485 27023612 
 ARID1A-35R CCGGAGTGCCACCTCTC   
chr1 ARID1A-36F GAGGCCATCAAAGCTCAGGTT 27056097 27056257 
 ARID1A-36R GGGTACCCATGTCCTTGCTG   
chr1 ARID1A-37F AAGAGGAAGTAGTTGAAAATGATGAGGA 27105722 27105892 
 ARID1A-37R GCACACGCCCAAGCTTATCT   
chr1 ARID1A-38F ATGCCTTCCAACCCAGACTC 27100132 27100302 
 ARID1A-38R GGAATCATGTCTATAGGAGGCAAAGAAA   
chr1 ARID1A-39F CCTGAAGCTATAGTGGGCTCAA 27100026 27100176 
 ARID1A-39R GTAGCGGCTAGGAGAATACATCC   
chr1 ARID1A-40F CCCCAGAGTAAGAAGCTTTAACACT 27094173 27094324 
 ARID1A-40R AACTTGGTGATCTTCTCATTGGTTGT   
chr1 ARID1A-41F GACTCCTGCGTGTCCTTTGTTA 27099229 27099398 
 ARID1A-41R TGATACCCAGGGTTTGGAGTCA   
chr1 ARID1A-42F GCTGGAGGCATAAACCCCAT 27089529 27089684 
 ARID1A-42R CCCAACCTGAGGTGGCATATTG   
chr1 ARID1A-43F CCCACCCTTTGAGCCAACTA 27107049 27107206 
 ARID1A-43R GTGAAACCAATGAGTTCATCAACGG   
chr1 ARID1A-44F CAAGTCTCCATTCCTGCACTCT 27101524 27101661 
 ARID1A-44R GCTTCAACAGAGCCAGGTG   
chr1 ARID1A-45F ACTCTGCCTCTCCCAACTGATA 27105402 27105565 
 ARID1A-45R CAATCAGGCATCGTCGGAAATATTC   
chr1 ARID1A-46F GCACCACTAACTTATGAAAAGGAGGAG 27106468 27106594 
 ARID1A-46R CCGAGATGTTGGCGAGTGTAA   
chr1 ARID1A-47F CTGGACGGACTCCTACACTG 27106642 27106782 
 ARID1A-47R ATTGTTGTCCTGGATGCTGAGT   
chr1 ARID1A-48F GCCAGCTCCTTGAAAAAGCAGTA 27097676 27097800 
 ARID1A-48R ATCTTGGGCTGGGACTTCTTG   
chr1 ARID1A-49F TTGTATAGCACTATGGTGCGCTT 27106828 27106978 
 ARID1A-49R CCAGGAGGTTGCCGATACTG   
chr1 ARID1A-50F AAGAATGATCCATTTGTGGTGGACT 27105844 27105984 
 ARID1A-50R CAGCTCTGTCTTGCTCTCGAA   
chr1 ARID1A-51F AGTCGGACAGCATCATGCATC 27087908 27088051 














chr1 ARID1A-52F CAGCCTTATCTCCGCGTCA 27088697 27088850 
 ARID1A-52R CTCTCACCCGTATCTACTCCTAACT   
chr1 ARID1A-53F TCAACAGGGCCAGACTCCATAT 27057681 27057849 
 ARID1A-53R GGAGTATGGAGGCTGAGAGGAC   
chr1 ARID1A-54F GTGGATAGACGACATGGAGGTT 27102038 27102165 
 ARID1A-54R ATCATACAGCAGGATGTTGATGGTATC   
chr1 ARID1A-55F CCCCCTACTCACAGCCACA 27057938 27058084 
 ARID1A-55R GGAAGCGCTGCTGGGAATA   
chr1 ARID1A-56F CATGACAAATCTGCCTGCTGTG 27094403 27094559 
 ARID1A-56R AGCCAGTGAGTACCTAGAAAGG   
chr1 ARID1A-57F GAGAGACAGTCCCATAACCCTTTC 27059076 27059250 
 ARID1A-57R GTTCATATCTTCTTGCCCTCCCTT   
chr1 ARID1A-58F TGTTCACCGCTTGCCTTTCTA 27099809 27099966 
 ARID1A-58R CCATAGGGATAGTGCTGTCGTG   
chr1 ARID1A-59F GCCTTAGGAAGAACTTTCCCAAAGAG 27098883 27099057 
 ARID1A-59R CCTCCTTCTGCCATGGAACTG   
chr1 ARID1A-60F CAACAGGGACCTCCGTCAG 27056214 27056388 
 ARID1A-60R AACAAGGGTCAAGGTAATCACAATCA   
chr1 ARID1A-61F CACTGCCCACCCTAATCCT 27100253 27100427 
 ARID1A-61R AACCTGCATGCCAGTCCAT   
chr1 ARID1A-62F CAGGTAAGTGCTAGTCATTCTCACT 27092855 27093029 
 ARID1A-62R CCATCTGCCTTGTTGTTCATTTTGG   
chr1 ARID1A-63F CCGGACCTGAAGAACTCGAA 27023186 27023352 
 ARID1A-63R GGTTGCCCGAAGCCGTA   
chr1 ARID1A-64F GGCGTGAACCGAACAGATGA 27101291 27101464 
 ARID1A-64R AATGTGATTCTGCATGCTTGGTG   
chr1 ARID1A-65F GGAGATGTACAGCGTGCCA 27100876 27101021 
 ARID1A-65R AGGCATTGCCATACTGGTTGT   
chr1 ARID1A-66F CCTACGCGCTGAGCTCC 27023577 27023701 
 ARID1A-66R CTGCTGAGCGAAGGACGAA   
chr1 ARID1A-67F GCCCCCAGAACCAATTTCCATT 27101067 27101211 
 ARID1A-67R CACATGGTGCCTTGCTGAG   
chr1 ARID1A-68F TGTGTGATGTATTTGCTCTTGGTTGT 27087229 27087403 
 ARID1A-68R AGGACTCAGAGCTCCTTCTGTC   
chr1 ARID1A-69F AGCAGAGTAATCCAGCTCAGTCT 27087441 27087613 
 ARID1A-69R CCCTAAAGCCCAGCACTTGA   
chr1 ARID1A-70F CTACTGGATCCTGGGAGGTTCA 27105619 27105772 
 ARID1A-70R TGTCCTTGCCTGAAAAGGCTATC   
chr1 ARID1A-71F GGAAGCATGTGACAACAGCAGA 27106025 27106195 
 ARID1A-71R TCTCCTTGATGGCCTCTGAACT   
chr1 ARID1A-72F CGAACCCCACAGTAAGGATGAGA 27106260 27106385 
 ARID1A-72R AAGTCATTGCCTGGCACAAATG   
chr1 ARID1A-73F ACAGCACTATTTGGCTCCAGTT 27092631 27092794 
 ARID1A-73R CAGCCATACTATTAATCCCTTGTCCATA   
chr1 ARID1A-74F GCCGTCTTCCACCAACAACAT 27023393 27023542 
 ARID1A-74R GTAGTAGGAGTTGTACTGGTGGTTG   
chr1 ARID1A-75F CCCGGACCCCTCAGGTA 27024018 27024154 
 ARID1A-75R GCAGCTCCCCAGCAGTG   
chr12 ARID2-1F CAGCAACTGAACATGGAGGAAAAG 46285598 46285762 
 ARID2-1R ACGTCAAAATCTTTAATGCAGTCAAATGA   
chr12 ARID2-2F CAACTCTGGAAGAAGCATAGCTCA 46231055 46231217 
 ARID2-2R CTTCAGTGAAAACTCACCTCTCATCTTT   
chr12 ARID2-3F ACGTATGCACTCTCCTATCAAATGAAAG 46211567 46211691 














chr12 ARID2-4F ACAGTCGCAGGAATTCCAAATAAAGTA 46246482 46246638 
 ARID2-4R GCTTTTGCTGAACAGCACTTTCTATTG   
chr12 ARID2-5F AAATGGGAGAAAGTACAGTGACTCAAG 46245788 46245952 
 ARID2-5R ATATCTTGCATGTCTATTTGTTCTGAGTT   
chr12 ARID2-6F CATCCGACTAACAGCTGCCTTAATAT 46287442 46287611 
 ARID2-6R TTGATGAGAAAAACAATGAAGAAAATACAGTTA   
chr12 ARID2-7F CCAAATCATACAGTGAAGAGAGTGGA 46243373 46243545 
 ARID2-7R GCAGGAGATACATCAGGAACAGAAT   
chr12 ARID2-8F AATGAGAAAACCTGGACAGAACTTCA 46254682 46254807 
 ARID2-8R GATGACAGAAACTTAAATATAAAAGCATTCCAA   
chr12 ARID2-9F GAAAAGGAAAACAAATATGTGGTGAGAG 46205115 46205289 
 ARID2-9R CAATAGGAAGCTGTGGCTTTGG   
chr12 ARID2-10F TTAAAGCTGTGTTCTGTATTCAAGGG 46211367 46211538 
 ARID2-10R TCCAGATAACAGTGAAAGCACCAATTTA   
chr12 ARID2-11F AAGTTCGTGACCTCATTTCTGACA 46230400 46230569 
 ARID2-11R GGTGGATGAAATAAAGACTCCCAA   
chr12 ARID2-12F AGTGTCATGTCACAAACTCTGCAT 46254544 46254669 
 ARID2-12R TGACTGGATCCACTGAATGGAGAA   
chr12 ARID2-13F AGCTTTAGGATCCTTTTCCACTGTATTTG 46215201 46215331 
 ARID2-13R TCTATTGTTGGCTTAGCTGCATGTAA   
chr12 ARID2-14F TTCTTTAGCTTCCAGAGCAGTTGTAG 46240631 46240772 
 ARID2-14R CTTTGCTTTACTCCTCCCAAGGATAA   
chr12 ARID2-15F TTTGCAAAGCAGAAGATAATGGTGTTTT 46231302 46231429 
 ARID2-15R GTATAGCACCTCGAGTGTTGAGATTAC   
chr12 ARID2-16F GGAGATGTTGCTTGCACAAAAATTG 46231445 46231617 
 ARID2-16R CCTGAGGAGGTAATGACTCTTCAAAATA   
chr12 ARID2-17F GGTTCTCATTTAAGCAAAAACATTCCA 46246011 46246184 
 ARID2-17R TGAACCACCCAAAGTTAATACAGGTC   
chr12 ARID2-18F GGTACTTCAGATTGCAGTGATTTTGAGA 46230606 46230780 
 ARID2-18R GCTTACCTCAGCTGCAATATTTCC   
chr12 ARID2-19F TTCCTACTTGGGATTTTCAGTCATTTCAT 46243758 46243926 
 ARID2-19R CACCTTGTACAGGAAAAGACATTTGTG   
chr12 ARID2-20F ATTTGCTTAATGGACCTCTAGCTTCAA 46246243 46246412 
 ARID2-20R GTCAGATGATAGGGCAGGAGAATG   
chr12 ARID2-21F CACTGATCTCAAATAGCCCAGCA 46245367 46245527 
 ARID2-21R CTGCGTTCCGCTCATGGTA   
chr12 ARID2-22F TCCTCTACCCCTCAATCACAGG 46244877 46245047 
 ARID2-22R TGCATTCGACTGTTGAGGTTGA   
chr12 ARID2-23F AATGCTCCAGTGACTGTCATTCAA 46243995 46244166 
 ARID2-23R CAGGTTGTGGCCCTGTACTATG   
chr12 ARID2-24F CTGATGCACTAGCTGCGGTA 46233157 46233322 
 ARID2-24R ACACTCGTAACCACACTGAAAAAGAA   
chr12 ARID2-25F CTACTCCCCCATTCAAAGGTGAT 46245604 46245739 
 ARID2-25R GTGTTTGTGGCTCCTCGTC   
chr12 ARID2-26F TGTTTCTCGAGCAGAAATGTATTCTGA 46242655 46242808 
 ARID2-26R AAGAGATGTTGTAAGTGACGTAAATGGA   
chr12 ARID2-27F GGTCCCGGCTGACAAGT 46123787 46123914 
 ARID2-27R GAATCCGCCTAAAGTAGTGACTCTG   
chr12 ARID2-28F CTTCAACACCAGGTGGTAAGCTTAT 46245115 46245288 
 ARID2-28R GAACATTTTGCTGCCCAACCAA   
chr12 ARID2-29F TCATAGCACCCCCACAGTATGT 46244446 46244582 
 ARID2-29R CCCTACCCTTGAGGCTTGTG   
chr12 ARID2-30F GGCGCTTTTAAAACACCGATCT 46123567 46123711 














chr12 ARID2-31F TTCTTAGATTGTTCACGTTCAGACAACT 46124954 46125100 
 ARID2-31R CACCGCAAGTAATACTGTTTTAAAGCAA   
chr12 ARID2-32F CCATCTGTAATTCCACAGCAGTCTC 46244202 46244375 
 ARID2-32R GGTGATTAACTGTTGACCCTGTGAA   
chr12 ARID2-33F CAACCCAACAAAGCGTAGTGATT 46244668 46244821 
 ARID2-33R GAAGATGGAGTTATGTTAGGTTGTCCAG   
chr12 ARID2-34F AGTGCTAGCCATTAGTAACATGGAAG 46298747 46298912 
 ARID2-34R TGTGAAATGTGGCTGACTTTGAGT   
chr12 ARID2-35F CTCTTCCTCAAAAAGGATAAGCACTGT 46285779 46285950 
 ARID2-35R CGTTTCATTTTCTTGTGTTTTGCCTAGT   
chr12 ARID2-36F CAAGCTCAACTCCTAGAGCACAA 46287223 46287360 
 ARID2-36R ACTTTTACAGATAAGGGTTTCAAGGCAT   
chr12 ARID2-37F ATATTAAGATGTAGTTTTGTTGTTTTTCCAAGC 46215097 46215253 
 ARID2-37R CAGTCTTCTCTTTCCATTCTTCTCCAAA   
chr12 ARID2-38F CCATGGACTTTAATTCGCCAAATGATT 46211480 46211619 
 ARID2-38R TTTTTCAAGTTGCATGACGTGCT   
chr12 ARID2-39F GGCCAGCCTAACAGTTCTCA 46254623 46254750 
 ARID2-39R AATAAAATTGCCATTTACTTTTTACAAGACTGC   
chr12 ARID2-40F GAGAATGGAGCATCTGGGAAACA 46245900 46246072 
 ARID2-40R TCACCATTTCCTACATGATTGGAAGTTT   
chr12 ARID2-41F CAGATCCAAGCACTGTAGCTAAAGTAG 46246585 46246720 
 ARID2-41R CAGAAATTTCATAAGAGAAATGTGATCATGGAA   
chr12 ARID2-42F GTCATGGAGAACCCGTCCTG 46245699 46245838 
 ARID2-42R TTCCCTGAGTTTGAAGGAGGTAGA   
chr12 ARID2-43F AAGCATGCCTTGAAACCCTTATCT 46287329 46287503 
 ARID2-43R TGCGACCACATTCTGAATATTTACCAAT   
chr12 ARID2-44F CTGGTTCATACATAAGCAACAGTAAACA 46243252 46243421 
 ARID2-44R CCTGCCCATTGCTACTGGAATC   
chr12 ARID2-45F CAGTTTCTACTTCTGTTGTTCGTGTTG 46243494 46243668 
 ARID2-45R GCTACTGGAGACACAAAAGTTATACAT   
chr12 ARID2-46F GCTTTTACTGGACCCTGTTGATTTC 46231103 46231229 
 ARID2-46R AGAAAGTAAATACTTCAGTGAAAACTCACCTC   
chr12 ARID2-47F TGTGTTCACCAGTGATGGCAT 46233042 46233201 
 ARID2-47R TGGAACTTGGGTGTTCAATGAGTTT   
chr12 ARID2-48F AGAAGTTGTTCTAACGCTGCCT 46125051 46125197 
 ARID2-48R AACTGTTTGGTGTGCAAGGTTT   
chr12 ARID2-49F ACCTAGCCTGTGTGTGACTATTTCT 46230291 46230458 
 ARID2-49R TTTTGCTTTCACTAACTTACCATGAGACT   
chr12 ARID2-50F GATGAGGTACCACCAGGCAAT 46205247 46205371 
 ARID2-50R GCGGACATATATCCTGTTAATTTGCAGT   
chr12 ARID2-51F GCCAAAGGTGATCAACTAGAAAGAATTT 46246125 46246293 
 ARID2-51R GCTGAGGCACATCTGAATTCAAAC   
chr12 ARID2-52F CCCGACTCAGGATCAAAAGTATCC 46246365 46246537 
 ARID2-52R GGGTCACTGATTGTAACAATTCTAACTC   
chr12 ARID2-53F GGTATTCATTGTGTTAATGGGTTCAATATCC 46240538 46240687 
 ARID2-53R ACTATTCCTGGAGGTGGAGCAA   
chr12 ARID2-54F TGTAGAAGGTACATCAGGAGAATGGAT 46230519 46230657 
 ARID2-54R ATTGCCCTCCTCAAAGGAAAGATT   
chr12 ARID2-55F TCATCTCACTTTACCTGATGTGCTG 46231375 46231501 
 ARID2-55R TCCAGTCTTACCTATGCTCTTTTCTACT   
chr12 ARID2-56F AGGCAATTAGGCCTTGACACATTA 46230733 46230860 
 ARID2-56R GGCAACTATAAAATGCCACATCCTAAAA   
chr12 ARID2-57F CAAACTCCAGCTCAGCAGCTA 46245246 46245412 














chr12 ARID2-58F GCTGGTCAGACAGTTCAGCTAA 46244772 46244920 
 ARID2-58R TGACTGACAGTAGGAGGTGGTC   
chr12 ARID2-59F CAACCAATCTTCAAATCTGACTGCAA 46243874 46244044 
 ARID2-59R ACTTCACAAGGAATTGGAGCTTTACT   
chr12 ARID2-60F GCTCATTGCTCCAGCAGGAAT 46245488 46245654 
 ARID2-60R CTTCCTCCTCCTTTTGGCAAATTATTTT   
chr12 ARID2-61F CCCCAACAAGTACAGATGCAAGT 46245003 46245160 
 ARID2-61R GGAATCTGTGGAGCTGGGAGA   
chr12 ARID2-62F GAACATACCAGCATGTACTTCTACAGT 46244324 46244495 
 ARID2-62R TGAGACAATATTGGATGCAGAAGTTGTT   
chr12 ARID2-63F CATTGCCTCCACATGGCTTTAG 46242534 46242708 
 ARID2-63R GCTAATTTACTGCAAGTCGAGAGGTAT   
chr12 ARID2-64F GGGAAGGAGCTGGATCTTCAC 46123858 46123985 
 ARID2-64R GGGTCAAAGGAGACTTTTTGGA   
chr12 ARID2-65F CTCCACAGAGTTCTGTTGTTCAGAAT 46244119 46244250 
 ARID2-65R GTCCTGGTACCACTGTGTGTAATG   
chr12 ARID2-66F GACTCGCTTTCCTGGACGA 46123666 46123812 
 ARID2-66R AAGCCCCGCACTTGTCA   
chr12 ARID2-67F TTACTATTGCTGGTGTCCCAAGTC 46244539 46244710 
 ARID2-67R TGTTGAGCTGGCTGGCTTAC   
chr12 ARID2-68F CTGTGACCTTGGAGACTGACA 46298673 46298803 
 ARID2-68R TCATAAAGGCATTTGGCAAGGGT   
chr12 ARID2-69F GTTGGCAGGGTGGTCATAGTT 46287122 46287267 
 ARID2-69R TGGGATGATTCACAATGGCCTT   
chr12 ARID2-70F TGTGAGCCTTTTCAGCGACA 46285654 46285827 
 ARID2-70R CTGCAAGTAGGGCATCCTTTGA   
chr12 ARID2-71F TACTTGAATACATCCAAGTGTCTACTACTTTTA 46285520 46285646 
 ARID2-71R CAAAGACACTGCCCTGGATATACAT   
chr16 AXIN1-1F CCGCTCCTCCAGCTTCTC 354322 354467 
 AXIN1-1R GTGCCTCACAGTCCTGTCC   
chr16 AXIN1-2F CCTGACTTGGGTACGTGCTT 347944 348106 
 AXIN1-2R CTGAGAGCATCCTGGACGAG   
chr16 AXIN1-3F GCGGGAAGTGGTGCCAA 348161 348292 
 AXIN1-3R GCTGGTGCTGAGAGGTGATG   
chr16 AXIN1-4F CGGCTCTACGATGGGACCT 341112 341241 
 AXIN1-4R CGGTGCTGCACGTGGTA   
chr16 AXIN1-5F TCCGTGAGGGACTGGGTATC 364508 364667 
 AXIN1-5R GAGCCAGTCAACCCCTATTATGTC   
chr16 AXIN1-6F CCGTTTTTCCCCTGAAGACCT 343387 343540 
 AXIN1-6R CGACGTCTGGAGGAGGAAGAA   
chr16 AXIN1-7F GGTGGTACACCCAACACTGTT 338005 338156 
 AXIN1-7R AGAAGATCATCGGCAAAGTGGAG   
chr16 AXIN1-8F GTCTTGGATGAAGAGGTGGGA 343598 343751 
 AXIN1-8R CCACAGTCACAACTTGTTCTCTTG   
chr16 AXIN1-9F CATGTCCTGGTCACACTTCCA 396267 396436 
 AXIN1-9R CCTATCCCTCCTTCCTTAAGTCTGATAT   
chr16 AXIN1-10F CTGATCTCCTTTTCCCCCTCA 347080 347253 
 AXIN1-10R GGCGACTCGCAGCTCTT   
chr16 AXIN1-11F GGCTTATCCCATCTTGGTCATCC 396725 396898 
 AXIN1-11R GTTTCTGCTCCGGGAAAGGT   
chr16 AXIN1-12F GCAGCGCCAACACTCTCT 347752 347905 
 AXIN1-12R ACGTCCACCACCACGTC   
chr16 AXIN1-13F CAGGATCGATCAGCTGCTTCA 396488 396638 














chr16 AXIN1-14F GAAACTTGCTCCGAGGTCCAA 396978 397118 
 AXIN1-14R TGGTTTCAACAGGACAGATTGATTCA   
chr16 AXIN1-15F CGTTGGGCACCCACATACTC 339385 339559 
 AXIN1-15R CAGCATCGTTGTGGCGTACTA   
chr16 AXIN1-16F AGGACATCCGGTGTGGGTTA 396041 396180 
 AXIN1-16R CAGTAGACGGTACAGCGAAGG   
chr16 AXIN1-17F ACCAGCCTATCAGTCCACCTT 338113 338277 
 AXIN1-17R TCACTGCCCTCCTCACCT   
chr16 AXIN1-18F GTCCTCAGCACACGCTGTA 348064 348206 
 AXIN1-18R CCGTGTCACAAGCTGCCT   
chr16 AXIN1-19F GCACGTACTCTGTCTCGGA 341182 341322 
 AXIN1-19R ACCTTTGACGCGGGTTGTT   
chr16 AXIN1-20F TGAGGAGGTTCTGGCCTTCT 347648 347788 
 AXIN1-20R CAAGGTCCCGAGGCTACTC   
chr16 AXIN1-21F AGGGCATAGCCGGCATT 364627 364752 
 AXIN1-21R GAAAATGTGAAATAAAATGAGAGGCTGTT   
chr16 AXIN1-22F GCTCGGCTGGCTCTCTT 343503 343646 
 AXIN1-22R CCCTCAGCTCCGGACCT   
chr16 AXIN1-23F TCGGACTCACCTGAACTCTCT 396138 396312 
 AXIN1-23R GCCGACCTTAAATGAAGATGAGGAA   
chr16 AXIN1-24F GATGGCTCTCGCCAGCTT 396594 396767 
 AXIN1-24R GAGTCACTGCATTCCCTGCT   
chr16 AXIN1-25F ACTCGCCACACACACTGAAG 346958 347125 
 AXIN1-25R ACCAGAAAATCATGCAGTGGATCAT   
chr16 AXIN1-26F CCGGGCATCCCCATGAA 354211 354384 
 AXIN1-26R CTCATCCACCGCCTGGAG   
chr16 AXIN1-27F GAGCCTGTCCTCGTATATTCCAAATAA 396382 396530 
 AXIN1-27R AGCTTCATAAAGGGCTGCATCA   
chr16 AXIN1-28F TCGAAGTCTCACCTTTAATGCCAA 396854 397025 
 AXIN1-28R ATGAATATCCAAGAGCAGGGTTTCC   
chr16 AXIN1-29F GCCTCCACCTGCTCCTT 347851 348014 
 AXIN1-29R CACGTGGCCAAGATGCC   
chr16 AXIN1-30F ATGGGTTCCCCGCAGAAG 339521 339650 
 AXIN1-30R CTCAGTCCAAAACCAGGTACCA   
chr16 AXIN1-31F GAGGACGATGGGCTGAGG 359935 360102 
 AXIN1-31R CTGAGTTAACGGCTGCCTCTT   
chr9 CDKN2A-1F ACCAGCGTGTCCAGGAAG 21971074 21971239 
 CDKN2A-1R CCTGGCTCTGACCATTCTGTT   
chr9 CDKN2A-2F CCTGTAGGACCTTCGGTGACT 21968162 21968300 
 CDKN2A-2R TGTGCCACACATCTTTGACCT   
chr9 CDKN2A-3F CCTTCTGAAAACTCCCCAGGAA 21974543 21974708 
 CDKN2A-3R CACCGAATAGTTACGGTCGGA   
chr9 CDKN2A-4F GCGGGATGTGAACCACGA 21994246 21994395 
 CDKN2A-4R GCTCACCTCTGGTGCCAAA   
chr9 CDKN2A-5F TTTGGAAGCTCTCAGGGTACAA 21970856 21971023 
 CDKN2A-5R GTCTGCCCGTGGACCTG   
chr9 CDKN2A-6F GTCAGCCGAAGGCTCCAT 21974785 21974952 
 CDKN2A-6R GGCTCTTCCGCCAGCAC   
chr9 CDKN2A-7F GACCCTCTACCCACCTGGAT 21974663 21974810 
 CDKN2A-7R GGAGCAGCATGGAGCCTT   
chr9 CDKN2A-8F CGGACTTTTCGAGGGCCTT 21994113 21994280 
 CDKN2A-8R GCCGCGAGTGAGGGTTT   
chr9 CDKN2A-9F CCAGCCAGCTTGCGATAAC 21968655 21968814 














chr9 CDKN2A-10F CCCCTTCAGATCTTCTCAGCA 21974427 21974592 
 CDKN2A-10R GCTTCGATTCTCCGGAAAAAGG   
chr9 CDKN2A-11F GATGGCCCAGCTCCTCAG 21970988 21971139 
 CDKN2A-11R CGACCCCGCCACTCTCA   
chr3 CTNNB1-1F AAAACTACTGTGGACCACAAGCA 41268764 41268888 
 CTNNB1-1R CTGCAGATGCTATACACAAGACTCA   
chr3 CTNNB1-2F CCCAGAATGCAGTTCGCCTT 41275276 41275419 
 CTNNB1-2R CAGCTAGAGATGCTTCATTTTCAATTC   
chr3 CTNNB1-3F GTACCGGAGCCCTTCACATC 41277249 41277375 
 CTNNB1-3R TTTATGGACATAAAACCTAGAACACTTCACTT   
chr3 CTNNB1-4F GTCCTCTGTGAACTTGCTCAGG 41277885 41278027 
 CTNNB1-4R ACACATCTGCTAAAGGCTTTGGTT   
chr3 CTNNB1-5F TCTAGGTGGAATGCAAGCTTTAGG 41274827 41274963 
 CTNNB1-5R CCATGGCACCAGTTTACTCAGAA   
chr3 CTNNB1-6F GTGACATTTAACAGGTATCCCAGTGA 41265426 41265578 
 CTNNB1-6R ACAAACCTTGAGTAGCCATTGTCC   
chr3 CTNNB1-7F TCAGAATGTCTACCCAATACCAGTACTT 41266761 41266927 
 CTNNB1-7R GTACAATAGCAGACACCATCTGAGG   
chr3 CTNNB1-8F GGTTGCCTTGCTCAACAAAACAAA 41267262 41267392 
 CTNNB1-8R CAATGCTCCATGAAAACCACATAAAGAA   
chr3 CTNNB1-9F CTTGTTCAGCTTCTGGGTTCAGAT 41275047 41275220 
 CTNNB1-9R CTCAGTGATGTCTTCCCTGTCA   
chr3 CTNNB1-10F CGACATATGCAGCTGCTGTTT 41278079 41278248 
 CTNNB1-10R ACCTGCTCTAGGAAACTACCAGATAAAT   
chr3 CTNNB1-11F TGCTGAACTTTGGATGCCCTAA 41280517 41280683 
 CTNNB1-11R GTCCATACCCAAGGCATCCTG   
chr3 CTNNB1-12F GGTGCCATTCCACGACTAGTTC 41275696 41275833 
 CTNNB1-12R GCATTCCTTTTAGATAGCCAGGTATCAC   
chr3 CTNNB1-13F CTCATGGATGGGCTGCCT 41280771 41280920 
 CTNNB1-13R CCAACCAAGTCTTTCTGAAGTTCTGTA   
chr3 CTNNB1-14F GTGAGGGCTTACTGGCCATC 41267003 41267171 
 CTNNB1-14R AACACAGAATCCACTGGTGAACT   
chr3 CTNNB1-15F GTATGCAATGACTCGAGCTCAGA 41266458 41266620 
 CTNNB1-15R CAAGTTTACAACTGCATGTTTCAGCA   
chr3 CTNNB1-16F CCTTCTCTGAGTGGTAAAGGCAATC 41266133 41266285 
 CTNNB1-16R ATTCTGACTTTCAGTAAGGCAATGAA   
chr3 CTNNB1-17F ATTTCAATGGGTCATATCACAGATTCTT 41265928 41266093 
 CTNNB1-17R GTAAGACTGTTGCTGCCAGTG   
chr3 CTNNB1-18F CCTCAAACTTTACAGAGGAGAATGCC 41277160 41277290 
 CTNNB1-18R GGTTGTGAACATCCCGAGCTA   
chr3 CTNNB1-19F AATTGGGAATGTTTGCACCACAG 41277755 41277929 
 CTNNB1-19R AATAGCTTCTGCAGCTTCCTTGT   
chr3 CTNNB1-20F AGACAGAAAAGCGGCTGTTAGT 41266051 41266181 
 CTNNB1-20R AGGTATCCACATCCTCTTCCTCAG   
chr3 CTNNB1-21F CATACAACTGTTTTGAAAATCCAGCGT 41265528 41265681 
 CTNNB1-21R CCTGACAAGTAAGCAGGGAGAGA   
chr3 CTNNB1-22F TTTGCTTTCTATTCTTCCTTGCTTTGTG 41279466 41279640 
 CTNNB1-22R AACCGGCTCTTCTGATAAAAGTTTTAGA   
chr3 CTNNB1-23F AGACACGCTATCATGCGTTCT 41266882 41267045 
 CTNNB1-23R GCAGGAATGCCTCCAGACTTAAA   
chr3 CTNNB1-24F CGTTCTTTTCACTCTGGTGGATATGG 41280636 41280810 
 CTNNB1-24R CCAGCTGATTGCTGTCACCT   
chr3 CTNNB1-25F GCTGCAACTAAACAGGTAAATTCTGAGT 41274921 41275095 














chr3 CTNNB1-26F TTGTGGTGAAGAAAAGAGAGTAATAGCA 41266334 41266501 
 CTNNB1-26R GGAACATAGCAGCTCGTACCC   
chr3 CTNNB1-27F GTTGTATGCCAGTTCTTCCTTCTGT 41275598 41275738 
 CTNNB1-27R GATGTGCACGAACAAGCAACT   
chr3 CTNNB1-28F TGTGCGTACTGTCCTTCGG 41275175 41275322 
 CTNNB1-28R CTTAACCACAACTGGTAGTCCATAGTG   
chr3 CTNNB1-29F CGTTTGGCTGAACCATCACAGA 41266573 41266731 
 CTNNB1-29R GCAGACTAAAAAGCTAGCTATGTCATTG   
chr3 CTNNB1-30F CCCTGGTGAAAATGCTTGGGTAA 41267045 41267200 
 CTNNB1-30R GGTTGTGGAGAGTTGTAATGGCATA   
chr3 CTNNB1-31F ACTCTAGGAATGAAGGTGTGGGT 41277970 41278122 
 CTNNB1-31R CTTGTCCTCAGACATTCGGAACA   
chr3 CTNNB1-32F CTTAGGTGAAAGGAAGTAAACTCTGGAA 41274707 41274873 
 CTNNB1-32R GACTTGGATCTGTCAGGTGAAGT   
chr3 CTNNB1-33F GGCTCTTCTCAGACATGTGATCAA 41268635 41268808 
 CTNNB1-33R ACAGATAGCACCTTCAGCACTC   
chr10 PTEN-1F ATTTTCTTTCTCTAGGTGAAGCTGTACTTC 89725029 89725175 
 PTEN-1R ATCAGAGTCAGTGGTGTCAGAATATCTA   
chr10 PTEN-2F GCCATCTCTCTCCTCCTTTTTCTT 89624184 89624346 
 PTEN-2R GTGACAGAAAGGTAAAGAGGAGCA   
chr10 PTEN-3F TTGACTTTTTGCAAATGTTTAACATAGGT 89720535 89720708 
 PTEN-3R AGGTTTCCTCTGGTCCTGGTAT   
chr10 PTEN-4F CTACGACCCAGTTACCATAGCAATTTA 89711785 89711923 
 PTEN-4R GGTAGCTATAATAATACACATAGCGCCTC   
chr10 PTEN-5F GACAGTTAAAGGCATTTCCTGTGA 89717556 89717717 
 PTEN-5R GTAACGGCTGAGGGAACTCAAA   
chr10 PTEN-6F AACTTTTCTTTTAGTTGTGCTGAAAGACATT 89690789 89690943 
 PTEN-6R TCACTCGATAATCTGGATGACTCATT   
chr10 PTEN-7F TAACCCACCACAGCTAGAACTTATC 89692795 89692946 
 PTEN-7R TGCCCCGATGTAATAAATATGCACAT   
chr10 PTEN-8F TCCAAACATTATTGCTATGGGATTTCCT 89653789 89653959 
 PTEN-8R ATCTTTTTCTGTGGCTTAGAAATCTTTTC   
chr10 PTEN-9F AAGAAATCGATAGCATTTGCAGTATAGA 89720742 89720866 
 PTEN-9R TGGAGAAAAGTATCGGTTGGCTTT   
chr10 PTEN-10F AGTATTCTTTTAGTTTGATTGCTGCATATTTCA 89653719 89653843 
 PTEN-10R CCTGTATACGCCTTCAAGTCTTTCT   
chr10 PTEN-11F TTACAGTGCTTAAAAATTAATATGTTCATCTGC 89724916 89725085 
 PTEN-11R ATTTGACGGCTCCTCTACTGTTTT   
chr10 PTEN-11F GTTAGCTCATTTTTGTTAATGGTGGCT 89685218 89685388 
 PTEN-11R ACAAGCAGATAACTTTCACTTAATAGTTGTT   
chr10 PTEN-12F TCACTTTTGGGTAAATACATTCTTCATACCA 89720662 89720794 
 PTEN-12R ATATTCCTTGTCATTATCTGCACGC   
chr10 PTEN-13F GAAAGGGACGAACTGGTGTAATGAT 89692896 89693061 
 PTEN-13R ATAAATTCTCAGATCCAGGAAGAGGAAAG   
chr10 PTEN-14F GCAGTTCAACTTCTGTAACACCAG 89725096 89725268 
 PTEN-14R TATTTTCATGGTGTTTTATCCCTCTTGA   
chr10 PTEN-15F CGACGGGAAGACAAGTTCATGTA 89717672 89717821 
 PTEN-15R TGTCCTTATTTTGGATATTTCTCCCAATG   
chr10 PTEN-16F TGCAACATTTCTAAAGTTACCTACTTGT 89692686 89692845 
 PTEN-16R TGGTCAAGATCTTCACAAAAGGGTTT   
chr10 PTEN-17F CCAGGGAGTAACTATTCCCAGTCA 89711871 89712045 
 PTEN-17R ATGGAAGGATGAGAATTTCAAGCA   
chrX RPS6KA3-1F CTCCTCCTCTCCCATAGGTTCAT 20252891 20253065 














chrX RPS6KA3-2F AACTGGTAGTATTTCTTCTCACTATGGA 20179685 20179859 
 RPS6KA3-2R GTCCTGATGATACACCAGAGGAAA   
chrX RPS6KA3-3F GCTTTAGTTCAAACAGGATGCATGTAA 20212250 20212399 
 RPS6KA3-3R TTTCTTCATTCAGCTTTTCAAACTGAAGG   
chrX RPS6KA3-4F GCAGGTTTAAATGGCGGATGAATT 20194430 20194560 
 RPS6KA3-4R GACTGGAATGTAAGTATAGAATGAAAACTTGC   
chrX RPS6KA3-5F AGCTTACACCATGGTACCAAATATCTC 20173477 20173651 
 RPS6KA3-5R TTCCTTTGTTCAGGGTGCCA   
chrX RPS6KA3-6F GCCTGGCCCTAATACAAGTTTTTAAT 20206486 20206640 
 RPS6KA3-6R TGAAGAAGGTCACATCAAGTTAACAGG   
chrX RPS6KA3-7F AAAAGCACACACTCATGACTTACCT 20227383 20227554 
 RPS6KA3-7R CCTGTTTGCTCCTCTTACGTTTATCTC   
chrX RPS6KA3-8F AGTCTGGAAAAGATTTTCTGATGAAACA 20194287 20194424 
 RPS6KA3-8R GCAGGCCTGAAGATACATTCTATTTTGA   
chrX RPS6KA3-9F TGAACAAATGCTTAGGTGCTTAGAACA 20181039 20181172 
 RPS6KA3-9R TGCACTTTTTCTAGGTTTTAAAAAGACAAGG   
chrX RPS6KA3-10F TTTCTATCTAATTCTAGCTCAAACATAAAGGAA 20185632 20185758 
 RPS6KA3-10R TGCTGTCCTGTTCACTATAACTAAAACC   
chrX RPS6KA3-11F TGGCCTCTCGTTCAGAGAAAAATT 20185760 20185924 
 RPS6KA3-11R TTCGTTTTGGGCACATATAGTTTCA   
chrX RPS6KA3-12F TTTAACATTCACTGCTGATCCTCACTTA 20205875 20206046 
 RPS6KA3-12R CATATTCTTTTTGTGGAACTGTGGAGT   
chrX RPS6KA3-13F ATCCTTTAGAGTGATAATGTTTGGATGCT 20187520 20187693 
 RPS6KA3-13R AATACCCAAGGTCTGTAGCTATAAACAA   
chrX RPS6KA3-14F ACTAATACTGCAAGCAAACTCTCTCAC 20182984 20183139 
 RPS6KA3-14R GTGGATGAATCTGGTAATCCGGAAT   
chrX RPS6KA3-15F GGGAGTTTCATGAAGCCACTTGAT 20211519 20211682 
 RPS6KA3-15R CTACTTGGCTGAACTTGCACTTG   
chrX RPS6KA3-16F ACCTCTACCAAGATATCACGTTCCA 20213215 20213346 
 RPS6KA3-16R TTAACATGGGCACCAAAAAGAATTTGT   
chrX RPS6KA3-17F ACATCCACTCACCTGAACAATTGA 20193270 20193399 
 RPS6KA3-17R TGGCATTCCACCTAGTGCTAATG   
chrX RPS6KA3-18F GTGTGGCCTTCTTCAATACCTTCA 20222146 20222293 
 RPS6KA3-18R GCAGGGTCTTATTTTAACAAGGATATAGTTTAT   
chrX RPS6KA3-19F GAGGACCTGTGGAAAACAGTGA 20174187 20174359 
 RPS6KA3-19R GTCAAAGATGCTTCATGTAGACCCT   
chrX RPS6KA3-20F AACAAATATCTACTCCCCGCTAAAAACA 20195040 20195201 
 RPS6KA3-20R GCCAAACTTGGAATGCCACA   
chrX RPS6KA3-21F CTTCACTGCAAACTCCATGTTTGT 20190864 20191029 
 RPS6KA3-21R GGCATTATGGGACTCTTCACCAATTTAT   
chrX RPS6KA3-22F ATCAGAACGGGCCGAGTG 20284585 20284730 
 RPS6KA3-22R GGACCCGTGGCAGAAGATG   
chrX RPS6KA3-23F AGGGATGAGGTCAAGGGATGAT 20213139 20213277 
 RPS6KA3-23R ACAATCTTTTATAGTTCGAGACCGAGTTC   
chrX RPS6KA3-24F GCCCAGCCTGAAGCATTTATTTTAA 20204352 20204519 
 RPS6KA3-24R TGACTAACACTTCTGATTATTTTGCCTTTCT   
chrX RPS6KA3-25F GACGATTAACTACTTCTGGAGCCATAT 20205993 20206120 
 RPS6KA3-25R ATGTAGGATATTTATGATATTTGTTTTGGCAGA   
chrX RPS6KA3-26F CCAGTCTATCGTTGAGAAAAATGAATGTC 20194555 20194694 
 RPS6KA3-26R CAAGTATTGAAAACAAAGGCTGAGCAA   
chrX RPS6KA3-27F AGTAGCATGATTCCTTACTTTTCTGGTTTT 20211587 20211711 
 RPS6KA3-27R GTGATGTTCACAGAAGAAGATGTCAAAT   
chrX RPS6KA3-28F TGCAAAGCCAAAATCACAAATTCGAATA 20183086 20183257 














chrX RPS6KA3-29F ACTCCATATATCACAAGCAGCATCATAG 20181114 20181242 
 RPS6KA3-29R TTGGAATATATAATTCAACTCATAGCCTTACAA   
chrX RPS6KA3-30F CTTACCCCTTGTGCGTGAAGATATT 20185702 20185826 
 RPS6KA3-30R CTTATGAAAGGAGGTGAATTGCTGGATA   
chrX RPS6KA3-31F CTCCGCTGAGCAAGAGTAGAG 20173550 20173705 
 RPS6KA3-31R TTTTGTATTTGTGTACGTGTGACTATCCA   
chrX RPS6KA3-32F GCTGGTAACAGGAACCTATTCAG 20222022 20222196 
 RPS6KA3-32R GCTCTGATGCTAGGCAGCTTTATG   
chrX RPS6KA3-33F TGATGAGTTCTTTGTCTACCACATGAT 20187420 20187571 
 RPS6KA3-33R TGAAATTCTTCTTCGTTATGGACAGCA   
chrX RPS6KA3-34F CCGCTACCTATTCGTGCCAAT 20179814 20179957 
 RPS6KA3-34R CTGAATTAGAGTACTTTTGAGATTACCAACCA   
chrX RPS6KA3-35F TTGCTCACTTGAAGTCAGTAGAAAAAGA 20193188 20193317 
 RPS6KA3-35R GCTATGCAGACAGTTGGTGTACAT   
chrX RPS6KA3-36F CCCCCGAAAAAGCTGATGTG 20193357 20193489 
 RPS6KA3-36R AGTGAAAAAGGTCATAGTGTCAACAGTT   
chrX RPS6KA3-37F ACATTTTCTCCTTACCTTTGGGAGTT 20194353 20194479 
 RPS6KA3-37R CCCCTCCAGAAACTGTATAGAAGAGA   
chrX RPS6KA3-38F GAGCAGCAGTCAGTCTCTGATG 20174313 20174468 
 RPS6KA3-38R CAGTATCACAGAAGCTAAGGAAGAATGT   
chrX RPS6KA3-39F AACAGAAAACATTGCTGGTAGGAAGA 20227284 20227432 
 RPS6KA3-39R GTATTAGGGCAGGGATCATTTGGAA   
chrX RPS6KA3-40F ACCTGTTAACTTGATGTGACCTTCTTC 20206613 20206743 
 RPS6KA3-40R TGGTGATCTGATGCTTAAGGATGTAATTT   
chrX RPS6KA3-41F GGGAGTGTAATTTTTAACTGGTACTGA 20190786 20190924 
 RPS6KA3-41R CTCCTACTCTGTTTGCAAGAGATGTATA   
chrX RPS6KA3-42F TGTAAAATGATTACTCTGCTCAGCTGAA 20252784 20252941 
 RPS6KA3-42R TTTTCACAGAATGGACAGCAAATTATGG   
chr17 TP53-1F CTCTGGCATTCTGGGAGCTT 7579483 7579618 
 TP53-1R TCTGACTGCTCTTTTCACCCATC   
chr17 TP53-2F GCCACTGACAACCACCCTTAA 7578121 7578258 
 TP53-2R GGAAGGAAATTTGCGTGTGGAGTA   
chr17 TP53-3F GGGCCAGACCTAAGAGCAATC 7578281 7578453 
 TP53-3R CATGGCCATCTACAAGCAGTCA   
chr17 TP53-4F GGGCCTGCCCTTCCAAT 7579810 7579941 
 TP53-4R GCAGCCAGACTGCCTTCC   
chr17 TP53-5F GTGCTTCTGACGCACACCTA 7572811 7572957 
 TP53-5R GTTCAAGACAGAAGGGCCTGA   
chr17 TP53-6F GGGATGTGATGAGAGGTGGAT 7577372 7577532 
 TP53-6R CCATCCTCACCATCATCACACTG   
chr17 TP53-7F TCAGGCAAAGTCATAGAACCATTTTCA 7576590 7576714 
 TP53-7R TGGTTGTAGCTAACTAACTTCAGAACAC   
chr17 TP53-8F CATGAAGGCAGGATGAGAATGGAA 7573839 7573988 
 TP53-8R GCCTTGGAACTCAAGGATGCC   
chr17 TP53-9F GGATACGGCCAGGCATTGAAG 7579258 7579407 
 TP53-9R TCATCTTCTGTCCCTTCCCAGA   
chr17 TP53-10F AAGAGGCAAGGAAAGGTGATAAAAG 7576933 7577087 
 TP53-10R CAGAGGAAGAGAATCTCCGCAAG   
chr17 TP53-11F CAAGAAGTGGAGAATGTCAGTCTGAG 7572911 7573063 
 TP53-11R CAGACCCTCTCACTCATGTGATG   
chr17 TP53-12F GGCTCCTGACCTGGAGTCTT 7577489 7577636 
 TP53-12R CTCATCTTGGGCCTGTGTTATCT   
chr17 TP53-13F CTGGAGTGAGCCCTGCT 7573927 7574060 














chr17 TP53-14F GTCGAAAAGTGTTTCTGTCATCCAAA 7578209 7578382 
 TP53-14R CAGATAGCGATGGTGAGCAG   
chr17 TP53-15F GGGACTGTAGATGGGTGAAAAGA 7579587 7579750 
 TP53-15R GGGACTGACTTTCTGCTCTTG   
chr17 TP53-16F CGTAGCTGCCCTGGTAGGTTT 7579365 7579523 
 TP53-16R CTGAAGACCCAGGTCCAGATG   
chr17 TP53-17F ACAACCTCCGTCATGTGCTG 7578412 7578585 
 TP53-17R TTTCAACTCTGTCTCCTTCCTCTT   
chr17 TP53-18F GTGGTGAGGCTCCCCTTT 7577047 7577186 
 TP53-18R CCTCTTGCTTCTCTTTTCCTATCCT   
chr17 TP53-19F TGGAAACTTTCCACTTGATAAGAGG 7576812 7576978 
  TP53-19R TGCAGTTATGCCTCAGATTCACTTTTAT     
 








chr5 APC-ex14F AGGTTATTGCGAGTGTTTTGAGGAA 112164551 112164675 
 APC-ex14R AGGTACCTTTTTAACTTCTAAAGCACAT   
chr5 APC-ex14F TTGTCTTGGCGAGCAGATGT 112164577 112164750 
 APC-ex14R AAATCTCATGGCTAAAAGAAGGCA   
chr5 APC-ex16F GCAAATCCTAAGAGAGAACAACTGTCT 112173250 112173422 
 APC-ex16R TGAGGTTCTTGAGCATGCTAACTG   
chr5 APC-ex16F AAAGATTGGAACTAGGTCAGCTGAAG 112175218 112175362 
 APC-ex16R TCCTGAAGAAAATTCAACAGCTTTGTG   
chr5 APC-ex16F TCATTATCATCTTTGTCATCAGCTGAA 112175117 112175264 
 APC-ex16R CTGGAACTTCGCTCACAGGAT   
chr5 APC-ex16F GTGGTGCTCAGACACCCAAAA 112175382 112175550 
 APC-ex16R GGGCTTATAATGCCACTTACCAT   
chr5 APC-ex16F TACTCCAGATGGATTTTCTTGTTCATC 112175776 112175917 
 APC-ex16R AGGCTGCTCTGATTCTGTTTCATT   
chr5 APC-ex16F CCAGTTCAGGAAAATGACAATGGG 112175870 112176043 
 APC-ex16R TGGCATGGCAGAAATAATACATTCTTCT   
chr5 APC-ex16F AGCAGCCTAAAGAATCAAATGAAAACC 112175910 112176084 
 APC-ex16R GCAGTCTGGGCTGGCTTTTT   
chr20 ASXL1-ex13F GGAAGCAGCCCCAGTTCTTTA 31024005 31024178 
 ASXL1-ex13R TGTAATGGGATTTGTCACTGGATGG   
chr11 ATM-ex11F GCCAGGCACTGTCCTGATAGA 108122485 108122616 
 ATM-ex11R TTCCTGGAACTATACTGGTGGTCA   
chr11 ATM-ex11F CAGTATGCTGTTTGACTTTGGCA 108122569 108122734 
 ATM-ex11R GTGCTATTTTCTAAGTCACCCTCTAACT   
chr11 ATM-ex20F ATGTTCTTGAACTTCTGAAACCACTAT 108141846 108142017 
 ATM-ex20R ACAAACATCTTGGTCACGACGA   
chr11 ATM-ex20F CCACAGCAATGTGTGTTCTTTGTA 108141972 108142127 
 ATM-ex20R GCTCCAATTACTGTAAGAAACTGTCCTT   
chr11 ATM-ex50F TCATTAAATGTTGTATATCATGTGTGATTTTGT 108200855 108200990 
 ATM-ex50R GCAGGGCTAATTCATCCAACTC   
chr11 ATM-ex50F ATACACAGTAAAGGTTCAGCGAGAG 108200941 108201083 
 ATM-ex50R CCCACATATCATGTTCTTCTCCACTTA   











 ATM-ex59R AGTTCTGCTGACTGCTCATTTATCAA   
chr11 ATM-ex59F GGACTTGGTGATAGACATGTACAGAAT 108218020 108218159 
 ATM-ex59R GCAAACAACATTCCATGATGACCAAATA   
chr11 ATM-ex62F CATCAACTACCATGTGACTGGCTTA 108235700 108235841 
 ATM-ex62R GGTCCAGTCAAAGAGTGGATCATATAG   
chr11 ATM-ex62F TTTAATACATATGTTCTCTCTGTTTAGGTCCTT 108235782 108235911 
 ATM-ex62R TCAGAGTAGGGTGAAGCTCAGTTT   
chr7 BRAF-ex15F AAATAGCCTCAATTCTTACCATCCACAA 140453056 140453221 
 BRAF-ex15R CTGTTTTCCTTTACTTACTACACCTCAGA   
chr16 CDH1-ex4F CCTGAAGTATCCGTCTTGAATTGTCTTA 68842271 68842444 
 CDH1-ex4R CTTTTTCATTTTCTGGGCAGCTGA   
chr5 CSF1R-ex7F GGGTAGGCCTCCACCATGA 149452960 149453134 
 CSF1R-ex7R TGGGTGGATGACAAAATGGACAAATAA   
chr7 EGFR-ex20F GGTCTTTTGCAGGCACAGCTTT 55248838 55249000 
 EGFR-ex20R CATCACGTAGGCTTCCTGGAG   
chr7 EGFR-ex20F CCACACTGACGTGCCTCTC 55248956 55249123 
 EGFR-ex20R GTCTTTGTGTTCCCGGACATAGT   
chr7 EGFR-ex20F ACGCAGCTCATGCCCTT 55249070 55249237 
 EGFR-ex20R GCGCAGACCGCATGTGA   
chr7 EGFR-ex28F CCGAGTATCTCAACACTGTCCA 55273084 55273210 
 EGFR-ex28R GGAAAGAAGTCCTGCTGGTAGTC   
chr7 EGFR-ex28F GCTCTGTGCAGAATCCTGTCTA 55272985 55273130 
 EGFR-ex28R GAATGTGCTGTTGACACAGGT   
chr17 ERBB2-ex21F TCGGAACGTGCTGGTCAAG 37881352 37881525 
 ERBB2-ex21R TCAGAGTTCTCCCATGGGCTA   
chr7 EZH2-ex17F CCCAGCTCTGAAACATACCATTGT 148507407 148507558 
 EZH2-ex17R AGGCTTGATCACCTTTATCCAAAAGAAT   
chr7 EZH2-ex17F CCCCCATGCCTCTAAGGAGAT 148507294 148507453 
 EZH2-ex17R GTGCAGCTTTCTGTTCAACTTGA   
chr7 FZD1-ex1F CTGCTGCTGCTGCTTTGG 90894358 90894532 
 FZD1-ex1R GGTCCGGGACGGAGATG   
chr20 GNAS-ex8F CCAGACCTTTGCTTTAGATTGGCA 57484325 57484499 
 GNAS-ex8R AAAAGGTAACAGTTGGCTTACTGGAA   
chr12 HNF1A-ex1F GCAGCCGAGCCATGGTT 121416561 121416721 
 HNF1A-ex1R GCAGGACTCCCCCTTGTC   
chr12 HNF1A-ex1F CTACCTCCTGGCTGGAGAAG 121416676 121416817 
 HNF1A-ex1R CGTGAAGTCTTCCCCATCGT   
chr12 HNF1A-ex2F CCTGGGCTCCATAACTGCTTT 121426502 121426670 
 HNF1A-ex2R ACTTGACCATCTTCGCCACAC   
chr12 HNF1A-ex2F GTCGATACCACTGGCCTCAA 121426709 121426874 
 HNF1A-ex2R GCCCTCCCAGGGAAGATG   
chr12 HNF1A-ex2F CTGAGCAGATCCCGTCCTTG 121426605 121426774 
 HNF1A-ex2R CTTCATGGGAGTGCCCTTGTT   
chr12 HNF1A-ex4F CTGAGCCTGGCCTGGAG 121431926 121432092 
 HNF1A-ex4R TTGTGCCGGAAGGCTTCTT   
chr12 HNF1A-ex4F GCTATTTCTGCAGGGCGGAAT 121431954 121432119 
 HNF1A-ex4R GGCCCGCTGTACGTGTC   
chr11 HRAS-ex3F CTTGGTGTTGTTGATGGCAAACA 533792 533966 
 HRAS-ex3R CCTGAGCCCTGTCCTCCT   
chr5 IL6ST-ex6F AAACGACTACAGTGTCAAATAAACTCT 55259926 55260095 











chr5 IL6ST-ex6F CCCAGACTTCAATGTTGACAAAATACAC 55260040 55260185 
 IL6ST-ex6R TCAGATGTGTTTTTAATGACTGATTCTTCAATT   
chr4 IRF2-ex5F CCTGTGACTCATCTTTACAAGGCA 185339237 185339409 
 IRF2-ex5R CCCTTCGTGAATTAATCCAAAACTACAT   
chr9 JAK2-ex8F AATGGCTCTGTAAATTCTACCCGTTT 5055617 5055756 
 JAK2-ex8R CAACTCGGCTTTCATTTGAACCC   
chr9 JAK2-ex8F TGTCAGTATTAAGCAAGCAAACCAAGA 5055707 5055847 
 JAK2-ex8R AATACACATTTCTGAGAACTATAAAATGAAACC   
chrX KDM6A-ex29F TTTTATGTTGCATAGCAGGCTGTTG 44970493 44970661 
 KDM6A-ex29R CAATATCAAGATGAGGCGGATGGTAA   
chrX KDM6A-ex29F CCTTACTTTTATTTTCAGGCTCCTCCA 44970609 44970748 
 KDM6A-ex29R GCCTTACGAGATAGCTACAAAAACCA   
chr12 KRAS-ex2F AAAGAATGGTCCTGCACCAGTAA 25398161 25398331 
 KRAS-ex2R AGGCCTGCTGAAAATGACTGAATATAA   
chr12 KRAS-ex2F CCAGCTCCAACTACCACAAGT 25398284 25398410 
 KRAS-ex2R CTGGTGGAGTATTTGATAGTGTATTAACCTT   
chr12 KRAS-ex3F TTCAATTTAAACCCACCTATAATGGTGA 25380152 25380286 
 KRAS-ex3R ACAGCAGGTCAAGAGGAGTACA   
chr12 KRAS-ex3F ATGTACTGGTCCCTCATTGCAC 25380243 25380372 
 KRAS-ex3R TCCAGACTGTGTTTCTCCCTTCT   
chr7 MET-ex17F GCCTGCGAAGTGAAGGGT 116418926 116419098 
 MET-ex17R TTTTTAAAGACTCAGAGCAGGCCTATTT   
chr7 MET-ex19F GTTGCTGATTTTGGTCTTGCCA 116423383 116423557 
 MET-ex19R AAGAGGAGAAACTCAGAGATAACCA   
chr7 MLL3-ex38F GAACCAGAGTTTTGTTTTCTTGTTCCTT 151874122 151874249 
 MLL3-ex38R ACTTGACATGGGAGATAAGAAAAGCAT   
chr7 MLL3-ex38F AGTTTCACATTTGGATTCCACCTTAGA 151874021 151874179 
 MLL3-ex38R AATCAGTGTGTATCTGTTGAACCAAAAA   
chr20 MMP9-ex4F GGGTATCCCTTCGACGGGAA 44639572 44639746 
 MMP9-ex4R GGTGATGAGTGGGAGAGAATGAAG   
chr17 NF1-ex26F CCATTCACACCATGCACATATGATT 29559619 29559786 
 NF1-ex26R CCTGTTTGCGCACTTTCATCTTC   
chr17 NF1-ex26F CCTTTTGAATGACTGCAGTGAAGTT 29559739 29559884 
 NF1-ex26R GACCACTGTCTACGTTGGCATT   
chr2 NF2-ex8F GACTGCTTCTTTCTGCCTGAGA 30057087 30057231 
 NF2-ex8R CTGGCTACTGCTACTTGGCAT   
chr2 NF2-ex8F AGGTTTTGTGGGCTTGACACA 30057190 30057317 
 NF2-ex8R GTACTTCCCCTAGAATTTTCTGCCT   
chr2 NFE2L2-ex2F TTAAACCTGCCATAACTTTCCCAAGA 178098691 178098827 
 NFE2L2-ex2R AGTTACAACTAGATGAAGAGACAGGTGA   
chr2 NFE2L2-ex2F CTCTTTCCGTCGCTGACTGA 178098910 178099040 
 NFE2L2-ex2R AAACATGAGCTCTCTCCTTCCTTTTT   
chr2 NFE2L2-ex2F GGCTGGCTGAATTGGGAGAAAT 178098778 178098917 
 NFE2L2-ex2R GGAAAGAGTATGAGCTGGAAAAACAGAA   
chr1 NOTCH2-ex4F AGGTGCCTCCATTGACACAA 120539665 120539839 
 NOTCH2-ex4R AAATGTGAGACTGATGTCAATGAGTGT   
chr19 NOTCH3-ex15F ACACAGATGCAGCAGTCCA 15302476 15302640 
 NOTCH3-ex15R TGTCCAGGACACCGATGTCT   
chr4 NRAS-ex3F GACAGAAAACTAGGTCAATAGGTCTTGG 115256475 115256619 
 NRAS-ex3R CAGGCTAGAAGAAAGGCAGATACAAG   











 NRAS-ex3R CCTACACAATGCCAGATTCTAGAAAACA   
chr4 PDGFRA-ex18F GAAGGCCAGCCCTTTATATCCAG 55151881 55152009 
 PDGFRA-ex18R CACTGCATGGAAAAGGAAGAAATGA   
chr4 PDGFRA-ex18F GCTACAGATGGCTTGATCCTGAG 55151962 55152135 
 PDGFRA-ex18R CGTACACTGCCTTTCGACACATAG   
chr4 PDGFRA-ex22F AATGCATACATTGGTGTCACCTACA 55156555 55156727 
 PDGFRA-ex22R AGCTACCTGTGTCTGTTCCTCT   
chr3 PIK3CA-ex10F GAGTAACAGACTAGCTAGAGACAATGA 178935997 178936129 
 PIK3CA-ex10R CACTTACCTGTGACTCCATAGAAAATCT   
chr3 PIK3CA-ex10F CGAGATCCTCTCTCTGAAATCACTGA 178936067 178936202 
 PIK3CA-ex10R ACATGCTGAGATCAGCCAAATT   
chr3 PIK3CA-ex21F TCGACAGCATGCCAATCTCTT 178951918 178952091 
 PIK3CA-ex21R CCATGATGTGCATCATTCATTTGTTTCA   
chr3 PIK3CA-ex21F ATCATGGTGGCTGGACAACAA 178952085 178952218 
 PIK3CA-ex21R CTGCTGAGAGTTATTAACAGTGCAGT   
chr3 PIK3CA-ex21F TGGAATGCCAGAACTACAATCTTTTGA 178951969 178952129 
 PIK3CA-ex21R TTGTGTGGAAGATCCAATCCATTT   
chr3 PIK3CA-ex3F ATTGTGATCTTCCAAATCTACAGAGTTC 178917376 178917540 
 PIK3CA-ex3R AGTCCTGTACTTCTGGATCTTTAACCAT   
chr3 PIK3CA-ex3F GCATGCCAGTGTGTGAATTTGAT 178917490 178917614 
 PIK3CA-ex3R TGCTCTACTATGAGGTGAATTGAGGT   
chr10 PTEN-ex2F AGTATTCTTTTAGTTTGATTGCTGCATATTTCA 89653719 89653843 
 PTEN-ex2R CCTGTATACGCCTTCAAGTCTTTCT   
chr10 PTEN-ex2F TCCAAACATTATTGCTATGGGATTTCCT 89653789 89653959 
 PTEN-ex2R ATCTTTTTCTGTGGCTTAGAAATCTTTTC   
chr10 PTEN-ex4F AACTTTTCTTTTAGTTGTGCTGAAAGACATT 89690789 89690943 
 PTEN-ex4R TCACTCGATAATCTGGATGACTCATT   
chr10 PTEN-ex5F GAAAGGGACGAACTGGTGTAATGAT 89692896 89693061 
 PTEN-ex5R ATAAATTCTCAGATCCAGGAAGAGGAAAG   
chr10 PTEN-ex5F GCACAATATCCTTTTGAAGACCATAAC 89692772 89692946 
 PTEN-ex5R TGCCCCGATGTAATAAATATGCACAT   
chr10 PTEN-ex7F CTGTGTGTGGTGATATCAAAGTAGAGT 89717718 89717892 
 PTEN-ex7R ACACCTGCAGATCTAATAGAAAACAAATT   
chr10 PTEN-ex7F ATTTAACCATGCAGATCCTCAGTTT 89717596 89717769 
 PTEN-ex7R AGCATCTTGTTCTGTTTGTGGAAGA   
chr10 PTEN-ex8F AAGAAATCGATAGCATTTGCAGTATAGA 89720742 89720866 
 PTEN-ex8R TGGAGAAAAGTATCGGTTGGCTTT   
chr10 PTEN-ex8F TCACTTTTGGGTAAATACATTCTTCATACCA 89720662 89720794 
 PTEN-ex8R ATATTCCTTGTCATTATCTGCACGC   
chr13 RB-ex12F TTTCTCCCTTCATTGCTTAACACATTTTC 48947493 48947619 
 RB-ex12R GGAAATCAGATTTTCTGAAGGTTGATCAC   
chr13 RB-ex2F TCATTTGGTAGGCTTGAGTTTGAAGAAA 48881405 48881565 
 RB-ex2R AAACGTTTTAAGAAAATCCTTACCAATACTC   
chr18 SMAD2-ex10F ACTCCAGAATATGCAAGAATGCAATGA 45371636 45371809 
 SMAD2-ex10R GGCTCAGTCTGTTAATCAGGGT   
chr18 SMAD4-ex10F TCAATATTAAGCATGCTATACAATCTGAACTAA 48593301 48593445 
 SMAD2-ex10R ACCCAAACATCACCTTCACCTTTAC   
chr18 SMAD4-ex10F GCAAAGGTGTGCAGTTGGAAT 48593400 48593535 
 SMAD2-ex10R ATCTTATGAACAGCATCTCCAGGTG   
chr18 SMAD4-ex9F GTTTTGGGTGCATTACATTTCCATCT 48591661 48591830 











chr18 SMAD4-ex9F CCCATTTATTTCCTATAGCTCCTGAGTA 48591775 48591948 
  SMAD4-ex9R GGACATTGGAGAGTTGACCCA     
 
7.2 Sequencing data 
Table S3: A comprehensive data of mt-genome sequencing. X 1 : represents the variants 
which validated by Sanger sequencing 
Sample 
ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H41-




 C T Heterozygous 95.2 
H41-




 C T Homozygous 100.0 
H04-




 C T Homozygous 100.0 
H41-




 C T Heterozygous 93.3 
H41-




 C T Homozygous 100.0 
H41-




 C T Homozygous 100.0 
H41-




 C T Homozygous 100.0 
H04-




 T C Homozygous 100.0 
H41-




 T C Homozygous 100.0 
H41-




 T C Homozygous 100.0 
H41-




 T C Homozygous 97.7 
H41-




 T C Homozygous 100.0 
H02-
T+OT Toxic - RNR1 709 
1
 G A Homozygous 98.6 
H02-
TN1 Toxic - RNR1 709 
1
 G A Homozygous 98.7 
H02-
TN2 Toxic - RNR1 709 
1
 G A Homozygous 99.1 
H02-
TN3 Toxic - RNR1 709 
1
 G A Homozygous 99.4 
H03-OT n.d - RNR1 709 1 G A Homozygous 100.0 
H03-
TN1 n.d - RNR1 709 
1
 G A Homozygous 100.0 
H03-
TN2 n.d - RNR1 709 
1
 G A Homozygous 98.3 
H03-
TN3 n.d - RNR1 709 
1
 G A Heterozygous 94.1 
H11-OT HCV + RNR1 709 1 G A Heterozygous 17.0 
H28-OT SH - RNR1 709 1 G A Homozygous 99.2 
H28-
TN1 SH - RNR1 709 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H28-
TN2 SH - RNR1 709 
1
 G A Homozygous 99.3 
H28-
TN3 SH - RNR1 709 
1
 G A Homozygous 99.1 
H03-OT n.d - RNR1 930 1 G A Homozygous 100.0 
H03-
TN1 n.d - RNR1 930 
1
 G A Homozygous 100.0 
H03-
TN3 n.d - RNR1 930 
1
 G A Homozygous 100.0 
H28-
TN3 SH - RNR1 930 
1
 G A Homozygous 99.3 
H28-
TN1 SH - TV 1611 
1
 G A Heterozygous 50.3 
H28-
TN2 SH - TV 1611 
1
 G A Heterozygous 5.3 
H02-
T+OT Toxic - RNR2 1888 
1
 G A Homozygous 97.2 
H02-
TN1 Toxic - RNR2 1888 
1
 G A Homozygous 98.0 
H02-
TN2 Toxic - RNR2 1888 
1
 G A Homozygous 98.5 
H02-
TN3 Toxic - RNR2 1888 
1
 G A Homozygous 98.9 
H28-OT SH - RNR2 1888 1 G A Homozygous 99.1 
H28-
TN1 SH - RNR2 1888 
1
 G A Homozygous 98.7 
H28-
TN2 SH - RNR2 1888 
1
 G A Homozygous 97.5 
H28-
TN3 SH - RNR2 1888 
1
 G A Homozygous 98.8 
H41-
TN1 HBV - RNR2 2158 
1
 T C Heterozygous 90.0 
H41-
TN2 HBV - RNR2 2158 
1
 T C Homozygous 100.0 
H41-
TN3 HBV - RNR2 2158 
1
 T C Homozygous 100.0 
H41-
TN5 HBV - RNR2 2158 
1
 T C Homozygous 100.0 
C10661 Control - RNR2 2706 1 A G Heterozygous 74.0 
H03-
TN2 n.d - RNR2 2706 
1
 A G Homozygous 97.1 
H03-
TN3 n.d - RNR2 2706 
1
 A G Heterozygous 92.3 
H04-
TN3 HCV + RNR2 2706 
1
 A G Homozygous 100.0 
H40-
TN3 Toxic - RNR2 2706 
1
 A G Homozygous 100.0 
H41-
TN1 HBV - RNR2 2706 
1
 A G Homozygous 100.0 
H41-
TN2 HBV - RNR2 2706 
1
 A G Homozygous 100.0 
H41-
TN3 HBV - RNR2 2706 
1
 A G Heterozygous 93.2 
H41-
TN4 HBV - RNR2 2706 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H41-
TN5 HBV - RNR2 2706 
1
 A G Homozygous 100.0 
C10661 Control - RNR2 3010 1 G A Heterozygous 34.0 
H04-OT HCV + RNR2 3010 1 G A Homozygous 100.0 
H04-
TN2 HCV + RNR2 3010 
1
 G A Homozygous 99.0 
H04-
TN3 HCV + RNR2 3010 
1
 G A Homozygous 99.0 
H04-
TN4 HCV + RNR2 3010 
1
 G A Heterozygous 95.2 
H04-
TN5 HCV + RNR2 3010 
1
 G A Homozygous 100.0 
H04-
TN6 HCV + RNR2 3010 
1
 G A Heterozygous 96.6 
H32-OT HCV + RNR2 3010 1 G A Homozygous 97.4 
H32-
TN1 HCV + RNR2 3010 
1
 G A Homozygous 99.2 
H32-
TN2 HCV + RNR2 3010 
1
 G A Homozygous 98.1 
H32-
TN3 HCV + RNR2 3010 
1
 G A Homozygous 98.5 
H37-OT n.d - RNR2 3010 1 G A Heterozygous 28.0 
H38-OT n.d - RNR2 3010 1 G A Heterozygous 58.0 
H38-
TN1 n.d - RNR2 3010 
1
 G A Homozygous 98.6 
H38-
TN2 n.d - RNR2 3010 
1
 G A Homozygous 97.9 
H38-
TN3 n.d + RNR2 3010 
1
 G A Heterozygous 96.9 
H38-
TN4 n.d - RNR2 3010 
1
 G A Homozygous 98.5 
H40-OT Toxic - RNR2 3010 1 G A Homozygous 99.2 
H41-OT HBV - RNR2 3010 1 G A Homozygous 100.0 
H41-
TN1 HBV - RNR2 3010 
1
 G A Homozygous 99.1 
H41-
TN2 HBV - RNR2 3010 
1
 G A Homozygous 97.2 
H41-
TN3 HBV - RNR2 3010 
1
 G A Homozygous 100.0 
H41-
TN5 HBV - RNR2 3010 
1
 G A Homozygous 97.1 
H02-
T+OT Toxic - ND1 4216 
1
 T C Homozygous 98.8 
H02-
TN1 Toxic - ND1 4216 
1
 T C Homozygous 99.5 
H02-
TN2 Toxic - ND1 4216 
1
 T C Homozygous 99.6 
H02-
TN3 Toxic - ND1 4216 
1
 T C Homozygous 99.9 
H04-
TN3 HCV + ND1 4216 
1
 T C Homozygous 100.0 





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H28-
TN1 SH - ND1 4216 
1
 T C Homozygous 99.7 
H28-
TN2 SH - ND1 4216 
1
 T C Homozygous 98.3 
H28-
TN3 SH - ND1 4216 
1
 T C Homozygous 99.0 
H41-
TN1 HBV - ND1 4216 
1
 T C Homozygous 100.0 
H41-
TN3 HBV - ND1 4216 
1
 T C Homozygous 100.0 
H11-
TN1 HCV + ND1 4261 T C Heterozygous 38.5 
H11-
TN2 HCV + ND1 4261 T C Heterozygous 48.0 
H11-
TN3 HCV + ND1 4261 T C Heterozygous 46.1 
H03-OT n.d - ND2 4823 1 T C Homozygous 100.0 
H03-
TN1 n.d - ND2 4823 
1
 T C Homozygous 100.0 
H03-
TN2 n.d - ND2 4823 
1
 T C Homozygous 100.0 
H02-
T+OT Toxic - ND2 4917 
1
 A G Homozygous 98.1 
H02-
TN1 Toxic - ND2 4917 
1
 A G Homozygous 98.5 
H02-
TN2 Toxic - ND2 4917 
1
 A G Homozygous 99.0 
H02-
TN3 Toxic + ND2 4917 
1
 A G Homozygous 99.4 
H03-OT n.d - ND2 4917 1 A G Homozygous 100.0 
H03-
TN1 n.d - ND2 4917 
1
 A G Homozygous 100.0 
H03-
TN2 n.d - ND2 4917 
1
 A G Homozygous 98.0 
H03-
TN3 n.d - ND2 4917 
1
 A G Homozygous 100.0 
H28-OT STE - ND2 4917 1 A G Homozygous 98.2 
H28-
TN1 SH - ND2 4917 
1
 A G Homozygous 99.1 
H28-
TN2 SH - ND2 4917 
1
 A G Homozygous 97.1 
H28-
TN3 SH - ND2 4917 
1
 A G Homozygous 99.4 
H02-
T+OT Toxic - ND2 5120 
1
 A G Heterozygous 22.7 
H02-
TN2 Toxic - ND2 5120 
1
 A G Heterozygous 41.2 
H02-
TN3 Toxic - ND2 5120 
1
 A G Heterozygous 37.0 
H04-
TN3 HCV + ND2 5460 
1
 G A Homozygous 98.4 
H41-OT HBV - ND2 5460 1 G A Homozygous 97.6 
H41-
TN2 HBV - ND2 5460 
1
 G A Homozygous 97.6 
H41-
TN3 HBV - ND2 5460 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H41-
TN5 HBV - ND2 5460 
1
 G A Homozygous 98.2 
C633 Control - CO1 6776 1 T C Homozygous 99.5 
H37-OT n.d - CO1 6776 1 T C Heterozygous 78.3 
H37-
TN1 n.d - CO1 6776 
1
 T C Homozygous 97.9 
H37-
TN2 n.d - CO1 6776 
1
 T C Homozygous 98.9 
H37-
TN3 n.d - CO1 6776 
1
 T C Homozygous 98.7 
H38-OT n.d - CO1 6776 1 T C Heterozygous 49.4 
C10661 Control - CO1 7028 1 C T Heterozygous 71.5 
H02-
T+OT Toxic - CO1 7028 
1
 C T Homozygous 97.7 
H02-
TN1 Toxic - CO1 7028 
1
 C T Homozygous 98.1 
H02-
TN2 Toxic - CO1 7028 
1
 C T Homozygous 98.3 
H02-
TN3 Toxic - CO1 7028 
1
 C T Homozygous 99.1 
H04-
TN3 HCV + CO1 7028 
1
 C T Homozygous 99.1 
H28-OT STE - CO1 7028 1 C T Homozygous 98.2 
H28-
TN1 SH - CO1 7028 
1
 C T Homozygous 98.5 
H28-
TN2 SH - CO1 7028 
1
 C T Homozygous 98.0 
H28-
TN3 SH - CO1 7028 
1
 C T Homozygous 98.6 
H40-
TN1 Toxic - CO1 7028 
1
 C T Heterozygous 93.3 
H40-
TN2 Toxic - CO1 7028 
1
 C T Homozygous 97.3 
H40-
TN3 Toxic - CO1 7028 
1
 C T Homozygous 99.2 
H40-
TN4 Toxic - CO1 7028 
1
 C T Homozygous 98.2 
H40-
TN5 Toxic - CO1 7028 
1
 C T Homozygous 99.4 
H40-
TN6 Toxic - CO1 7028 
1
 C T Homozygous 97.3 
H41-OT HBV - CO1 7028 1 C T Homozygous 98.1 
H41-
TN1 HBV - CO1 7028 
1
 C T Homozygous 99.3 
H41-
TN2 HBV - CO1 7028 
1
 C T Homozygous 97.1 
H41-
TN3 HBV - CO1 7028 
1
 C T Homozygous 99.0 
H41-
TN4 HBV - CO1 7028 
1
 C T Homozygous 98.9 
H41-
TN5 HBV - CO1 7028 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H37-OT n.d - CO1 7153 1 T C Heterozygous 9.1 
H37-
TN2 n.d - CO1 7153 
1
 T C Heterozygous 15.0 
H37-
TN3 n.d - CO1 7153 
1
 T C Heterozygous 10.7 
H38-OT n.d - CO1 7153 1 T C Heterozygous 6.8 
H02-
T+OT Toxic - ATP6 8697 
1
 G A Homozygous 98.2 
H02-
TN1 Toxic - ATP6 8697 
1
 G A Homozygous 98.9 
H02-
TN2 Toxic - ATP6 8697 
1
 G A Homozygous 98.8 
H02-
TN3 Toxic - ATP6 8697 
1
 G A Homozygous 99.3 
H03-OT n.d - ATP6 8697 1 G A Homozygous 100.0 
H03-
TN1 n.d - ATP6 8697 
1
 G A Homozygous 100.0 
H03-
TN2 n.d - ATP6 8697 
1
 G A Homozygous 99.0 
H03-
TN3 n.d - ATP6 8697 
1
 G A Homozygous 100.0 
H28-OT STE - ATP6 8697 1 G A Homozygous 98.5 
H28-
TN1 SH - ATP6 8697 
1
 G A Homozygous 99.2 
H28-
TN2 SH - ATP6 8697 
1
 G A Homozygous 98.8 
H28-
TN3 SH - ATP6 8697 
1
 G A Homozygous 98.8 
H04-
TN3 HCV + ATP6 8752 
1
 A G Homozygous 97.4 
H41-OT HBV - ATP6 8752 1 A G Homozygous 100.0 
H41-
TN1 HBV - ATP6 8752 
1
 A G Homozygous 97.8 
H41-
TN2 HBV - ATP6 8752 
1
 A G Homozygous 98.2 
H41-
TN3 HBV - ATP6 8752 
1
 A G Homozygous 98.1 
H41-
TN5 HBV - ATP6 8752 
1
 A G Homozygous 98.2 
H28-OT STE - CO3 9843 1 A G Homozygous 98.8 
H28-
TN1 SH - CO3 9843 
1
 A G Homozygous 98.9 
H28-
TN2 SH - CO3 9843 
1
 A G Homozygous 97.7 
H28-
TN3 SH - CO3 9843 
1
 A G Homozygous 98.7 
H02-
T+OT Toxic - TR 10463 
1
 T C Heterozygous 96.2 
H02-
TN1 Toxic - TR 10463 
1
 T C Homozygous 100.0 
H02-
TN2 Toxic - TR 10463 
1
 T C Homozygous 98.5 
H02-
TN3 Toxic - TR 10463 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H03-
TN2 n.d - TR 10463 
1
 T C Homozygous 100.0 
H28-OT SH - TR 10463 1 T C Homozygous 100.0 
H28-
TN1 SH - TR 10463 
1
 T C Homozygous 100.0 
H28-
TN2 SH - TR 10463 
1
 T C Homozygous 100.0 
H28-
TN3 SH - TR 10463 
1
 T C Homozygous 99.4 
H02-
T+OT Toxic - ND4 11165 
1
 T C Heterozygous 28.7 
H02-
TN1 Toxic - ND4 11165 
1
 T C Heterozygous 39.0 
H02-
TN2 Toxic - ND4 11165 
1
 T C Heterozygous 41.3 
H02-
TN3 Toxic - ND4 11165 
1
 T C Heterozygous 56.2 
H02-
T+OT Toxic - ND4 11251 
1
 A G Homozygous 98.7 
H02-
TN1 Toxic - ND4 11251 
1
 A G Homozygous 99.2 
H02-
TN2 Toxic - ND4 11251 
1
 A G Homozygous 98.8 
H02-
TN3 Toxic - ND4 11251 
1
 A G Homozygous 99.4 
H03-OT n.d - ND4 11251 1 A G Homozygous 100.0 
H03-
TN1 n.d - ND4 11251 
1
 A G Heterozygous 94.1 
H03-
TN2 n.d - ND4 11251 
1
 A G Homozygous 100.0 
H03-
TN3 n.d - ND4 11251 
1
 A G Homozygous 100.0 
H04-
TN3 HCV + ND4 11251 
1
 A G Homozygous 99.2 
H28-OT STE - ND4 11251 1 A G Homozygous 99.0 
H28-
TN1 SH - ND4 11251 
1
 A G Homozygous 99.2 
H28-
TN2 SH - ND4 11251 
1
 A G Homozygous 98.1 
H28-
TN3 SH - ND4 11251 
1
 A G Homozygous 99.1 
H41-OT HBV - ND4 11251 1 A G Heterozygous 93.3 
H41-
TN1 HBV - ND4 11251 
1
 A G Homozygous 100.0 
H41-
TN2 HBV - ND4 11251 
1
 A G Homozygous 100.0 
H41-
TN3 HBV - ND4 11251 
1
 A G Homozygous 98.8 
H41-
TN5 HBV - ND4 11251 
1
 A G Heterozygous 96.2 
H41-
TN3 HBV - ND4 11253 
1
 T C Heterozygous 13.7 
H41-
TN5 HBV - ND4 11253 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
C10661 Control - ND4 11719 1 G A Heterozygous 64.3 
H02-
TN1 Toxic - ND4 11719 
1
 G A Homozygous 99.0 
H02-
TN2 Toxic - ND4 11719 
1
 G A Homozygous 99.0 
H02-
TN3 Toxic - ND4 11719 
1
 G A Homozygous 99.5 
H03-OT n.d - ND4 11719 1 G A Homozygous 98.4 
H03-
TN1 n.d - ND4 11719 
1
 G A Homozygous 98.3 
H03-
TN3 n.d - ND4 11719 
1
 G A Homozygous 100.0 
H04-
TN3 HCV + ND4 11719 
1
 G A Homozygous 97.1 
H28-
TN1 SH - ND4 11719 
1
 G A Homozygous 99.4 
H28-
TN3 SH - ND4 11719 
1
 G A Homozygous 98.8 
H41-OT HBV - ND4 11719 1 G A Homozygous 100.0 
H41-
TN1 HBV - ND4 11719 
1
 G A Homozygous 97.1 
H41-
TN2 HBV - ND4 11719 
1
 G A Homozygous 100.0 
H41-
TN3 HBV - ND4 11719 
1
 G A Homozygous 98.1 
H41-
TN5 HBV - ND4 11719 
1
 G A Homozygous 98.1 
H02-
T+OT Toxic - ND4 11812 
1
 A G Homozygous 98.3 
H02-
TN1 Toxic - ND4 11812 
1
 A G Homozygous 99.1 
H02-
TN2 Toxic - ND4 11812 
1
 A G Homozygous 98.6 
H02-
TN3 Toxic - ND4 11812 
1
 A G Homozygous 98.7 
H03-
TN2 n.d - ND4 11812 
1
 A G Homozygous 100.0 
H28-OT SH - ND4 11812 1 A G Homozygous 98.0 
H28-
TN1 SH - ND4 11812 
1
 A G Homozygous 98.3 
H28-
TN2 SH - ND4 11812 
1
 A G Homozygous 98.7 
H28-
TN3 SH - ND4 11812 
1
 A G Homozygous 98.2 
H04-
TN3 HCV + ND4 12007 G A Homozygous 97.2 
H41-
TN1 HBV - ND4 12007 G A Homozygous 98.0 
H41-
TN2 HBV - ND4 12007 G A Homozygous 97.6 
H41-
TN3 HBV - ND4 12007 G A Homozygous 99.1 
H41-
TN5 HBV - ND4 12007 G A Homozygous 98.0 
H28-
TN1 SH - ND5 13231 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H28-
TN2 SH - ND5 13231 
1
 A - Heterozygous 43.3 
H28-
TN3 SH - ND5 13231 
1
 A - Heterozygous 8.4 
H02-
T+OT Toxic - ND5 13268 
1
 G A Heterozygous 21.8 
H02-
TN1 Toxic - ND5 13268 
1
 G A Heterozygous 53.2 
H02-
TN2 Toxic - ND5 13268 
1
 G A Heterozygous 50.8 
H02-
TN3 Toxic - ND5 13268 
1
 G A Heterozygous 37.0 
H02-
T+OT Toxic - ND5 13368 
1
 G A Homozygous 99.3 
H02-
TN1 Toxic - ND5 13368 
1
 G A Homozygous 98.9 
H02-
TN2 Toxic - ND5 13368 
1
 G A Homozygous 99.7 
H02-
TN3 Toxic - ND5 13368 
1
 G A Homozygous 99.7 
H03-OT n.d - ND5 13368 1 G A Homozygous 100.0 
H03-
TN1 n.d - ND5 13368 
1
 G A Heterozygous 90.0 
H03-
TN2 n.d - ND5 13368 
1
 G A Homozygous 98.9 
H03-
TN3 n.d - ND5 13368 
1
 G A Homozygous 100.0 
H28-OT SH - ND5 13368 1 G A Homozygous 99.5 
H28-
TN1 SH - ND5 13368 
1
 G A Homozygous 99.6 
H28-
TN2 SH - ND5 13368 
1
 G A Homozygous 99.5 
H28-
TN3 SH - ND5 13368 
1
 G A Homozygous 99.4 
H04-
TN3 HCV + ND5 13605 
1
 C T Homozygous 100.0 
H41-OT HBV - ND5 13605 1 C T Homozygous 100.0 
H41-
TN1 HBV - ND5 13605 
1
 C T Homozygous 100.0 
H41-
TN2 HBV - ND5 13605 
1
 C T Heterozygous 96.4 
H41-
TN3 HBV - ND5 13605 
1
 C T Homozygous 100.0 
H41-
TN5 HBV - ND5 13605 
1
 C T Homozygous 100.0 
H04-
TN3 HCV + ND5 13708 
1
 G A Homozygous 100.0 
H11-OT HCV + ND5 13708 1 G A Homozygous 97.7 
H11-
TN1 HCV + ND5 13708 
1
 G A Homozygous 99.4 
H11-
TN2 HCV + ND5 13708 
1
 G A Homozygous 99.4 
H11-
TN3 HCV + ND5 13708 
1
 G A Homozygous 99.2 





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H41-
TN1 HBV - ND5 13708 
1
 G A Homozygous 97.0 
H41-
TN2 HBV - ND5 13708 
1
 G A Homozygous 100.0 
H41-
TN3 HBV - ND5 13708 
1
 G A Homozygous 99.1 
H41-
TN5 HBV - ND5 13708 
1
 G A Homozygous 100.0 
H41-
TN1 HBV - ND5 13879 T C Homozygous 100.0 
H41-
TN2 HBV - ND5 13879 T C Homozygous 100.0 
H02-
T+OT Toxic - ND6 14233 
1
 A G Homozygous 97.4 
H02-
TN1 Toxic - ND6 14233 
1
 A G Homozygous 98.1 
H02-
TN2 Toxic - ND6 14233 
1
 A G Homozygous 98.8 
H02-
TN3 Toxic - ND6 14233 
1
 A G Homozygous 99.2 
H03-
TN2 n.d - ND6 14233 
1
 A G Homozygous 100.0 
H28-OT SH - ND6 14233 1 A G Homozygous 99.0 
H28-
TN1 SH - ND6 14233 
1
 A G Homozygous 99.2 
H28-
TN2 SH - ND6 14233 
1
 A G Homozygous 98.1 
H28-
TN3 SH - ND6 14233 
1
 A G Homozygous 97.2 
H11-OT HCV + ND6 14364 1 G A Homozygous 97.6 
H11-
TN1 HCV + ND6 14364 
1
 G A Homozygous 97.3 
H11-
TN2 HCV + ND6 14364 
1
 G A Homozygous 97.6 
H11-
TN3 HCV + ND6 14364 
1
 G A Homozygous 98.1 
H37-
TN3 n.d - ND6 14364 
1
 G A Heterozygous 25.0 
C10661 Control - CYB 14766 1 C T Heterozygous 83.6 
H02-
T+OT Toxic - CYB 14766 
1
 C T Homozygous 98.0 
H02-
TN1 Toxic - CYB 14766 
1
 C T Homozygous 98.6 
H02-
TN2 Toxic - CYB 14766 
1
 C T Homozygous 98.7 
H02-
TN3 Toxic - CYB 14766 
1
 C T Homozygous 99.2 
H03-OT n.d - CYB 14766 1 C T Homozygous 100.0 
H03-
TN1 n.d - CYB 14766 
1
 C T Homozygous 100.0 
H03-
TN2 n.d - CYB 14766 
1
 C T Homozygous 98.4 
H03-
TN3 n.d - CYB 14766 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H04-
TN3 HCV + CYB 14766 
1
 C T Homozygous 100.0 
H28-OT SH - CYB 14766 1 C T Homozygous 99.2 
H28-
TN1 SH - CYB 14766 
1
 C T Homozygous 99.1 
H28-
TN2 SH - CYB 14766 
1
 C T Homozygous 98.9 
H28-
TN3 SH - CYB 14766 
1
 C T Homozygous 98.8 
H41-OT HBV - CYB 14766 1 C T Homozygous 100.0 
H41-
TN1 HBV - CYB 14766 
1
 C T Heterozygous 93.2 
H41-
TN2 HBV - CYB 14766 
1
 C T Homozygous 100.0 
H41-
TN3 HBV - CYB 14766 
1
 C T Heterozygous 96.8 
H41-
TN5 HBV - CYB 14766 
1
 C T Homozygous 98.9 
H02-
T+OT Toxic - CYB 15452 
1
 C A Homozygous 98.7 
H02-
TN1 Toxic - CYB 15452 
1
 C A Homozygous 98.0 
H02-
TN2 Toxic - CYB 15452 
1
 C A Homozygous 98.6 
H02-
TN3 Toxic - CYB 15452 
1
 C A Homozygous 97.5 
H03-OT n.d - CYB 15452 1 C A Heterozygous 96.2 
H03-
TN1 n.d - CYB 15452 
1
 C A Homozygous 100.0 
H03-
TN2 n.d - CYB 15452 
1
 C A Homozygous 100.0 
H03-
TN3 n.d - CYB 15452 
1
 C A Homozygous 100.0 
H04-
TN3 HCV + CYB 15452 
1
 C A Homozygous 98.4 
H28-OT SH - CYB 15452 1 C A Homozygous 98.4 
H28-
TN1 SH - CYB 15452 
1
 C A Homozygous 98.6 
H28-
TN2 SH - CYB 15452 
1
 C A Homozygous 98.4 
H28-
TN3 SH - CYB 15452 
1
 C A Homozygous 98.6 
H32-
TN1 HCV + CYB 15452 
1
 C A Heterozygous 37.5 
H32-
TN2 HCV + CYB 15452 
1
 C A Heterozygous 46.7 
H41-OT HBV - CYB 15452 1 C A Homozygous 100.0 
H41-
TN1 HBV - CYB 15452 
1
 C A Heterozygous 92.9 
H41-
TN2 HBV - CYB 15452 
1
 C A Homozygous 97.1 
H41-
TN3 HBV - CYB 15452 
1
 C A Homozygous 97.2 
H41-
TN5 HBV - CYB 15452 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H02-
T+OT Toxic - CYB 15607 
1
 A G Homozygous 98.5 
H02-
TN1 Toxic - CYB 15607 
1
 A G Homozygous 98.8 
H02-
TN2 Toxic - CYB 15607 
1
 A G Homozygous 99.0 
H02-
TN3 Toxic - CYB 15607 
1
 A G Homozygous 99.5 
H03-OT n.d - CYB 15607 1 A G Homozygous 99.5 
H03-
TN1 n.d - CYB 15607 
1
 A G Homozygous 99.4 
H03-
TN2 n.d - CYB 15607 
1
 A G Homozygous 99.4 
H03-
TN3 n.d - CYB 15607 
1
 A G Homozygous 98.9 
H28-OT SH - CYB 15607 1 A G Homozygous 99.3 
H28-
TN1 SH - CYB 15607 
1
 A G Homozygous 99.3 
H28-
TN2 SH - CYB 15607 
1
 A G Homozygous 98.0 
H28-
TN3 SH - CYB 15607 
1
 A G Homozygous 99.1 
H04-
TN3 HCV + 
D-
LOOP 16069 C T Homozygous 100.0 
H41-
TN1 HBV - 
D-
LOOP 16069 C T Homozygous 100.0 
H41-
TN2 HBV - 
D-
LOOP 16069 C T Homozygous 97.3 
H41-
TN3 HBV - 
D-
LOOP 16069 C T Homozygous 100.0 
H41-
TN5 HBV - 
D-
LOOP 16069 C T Homozygous 100.0 
H02-




 T C Heterozygous 96.3 
H02-




 T C Homozygous 98.3 
H02-




 T C Homozygous 98.7 
H02-




 T C Homozygous 99.0 
H03-OT n.d - D-LOOP 16126 
1
 T C Homozygous 100.0 
H03-




 T C Homozygous 100.0 
H03-




 T C Homozygous 99.1 
H03-




 T C Homozygous 97.1 
H04-




 T C Homozygous 98.4 
H28-OT SH - D-LOOP 16126 
1
 T C Homozygous 97.8 
H28-




 T C Homozygous 98.8 
H28-









ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H28-




 T C Homozygous 98.1 
H41-




 T C Homozygous 100.0 
H41-




 T C Homozygous 100.0 
H41-




 T C Homozygous 100.0 
H41-




 T C Homozygous 100.0 
H04-
TN3 HCV + 
D-
LOOP 16145 G A Heterozygous 96.8 
H41-
TN1 HBV - 
D-
LOOP 16145 G A Homozygous 100.0 
H41-
TN2 HBV - 
D-
LOOP 16145 G A Homozygous 100.0 
H41-
TN3 HBV - 
D-
LOOP 16145 G A Homozygous 98.8 
H41-
TN5 HBV - 
D-
LOOP 16145 G A Homozygous 100.0 
H32-OT HCV + D-LOOP 16162 
1
 A G Homozygous 97.5 
H32-




 A G Homozygous 99.0 
H32-




 A G Homozygous 97.7 
H32-




 A G Homozygous 97.7 
H37-OT n.d - D-LOOP 16162 
1
 A G Heterozygous 25.9 
H38-OT n.d - D-LOOP 16162 
1
 A G Heterozygous 47.6 
H38-




 A G Homozygous 97.9 
H38-




 A G Homozygous 97.6 
H38-




 A G Homozygous 98.2 
H38-




 A G Homozygous 98.7 
H04-
TN3 HCV + 
D-
LOOP 16172 T C Heterozygous 95.2 
H41-
TN1 HBV - 
D-
LOOP 16172 T C Homozygous 100.0 
H41-
TN2 HBV - 
D-
LOOP 16172 T C Heterozygous 96.2 
H41-
TN3 HBV - 
D-
LOOP 16172 T C Homozygous 97.6 
H41-
TN5 HBV - 
D-
LOOP 16172 T C Homozygous 100.0 
H04-




 C T Homozygous 99.4 
H41-OT HBV - D-LOOP 16261 
1
 C T Homozygous 98.5 
H41-









ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H41-




 C T Homozygous 98.3 
H41-




 C T Homozygous 98.6 
H41-




 C T Homozygous 97.8 
H40-
TN1 Toxic - 
D-
LOOP 16298 T C Homozygous 97.3 
H40-
TN2 Toxic - 
D-
LOOP 16298 T C Heterozygous 96.8 
H40-
TN3 Toxic - 
D-
LOOP 16298 T C Homozygous 97.2 
H40-
TN4 Toxic - 
D-
LOOP 16298 T C Homozygous 97.8 
H40-
TN5 Toxic - 
D-
LOOP 16298 T C Heterozygous 94.0 
H40-
TN6 Toxic - 
D-
LOOP 16298 T C Heterozygous 86.9 
H41-
TN4 HBV - 
D-
LOOP 16298 T C Homozygous 97.9 
H02-




 T C Homozygous 98.3 
H02-




 T C Homozygous 98.9 
H02-




 T C Homozygous 98.6 
H02-




 T C Homozygous 99.2 
H03-OT n.d - D-LOOP 16304 
1
 T C Homozygous 99.5 
H03-




 T C Homozygous 99.0 
H03-




 T C Homozygous 98.0 
H03-




 T C Homozygous 97.5 
H28-OT SH - D-LOOP 16304 
1
 T C Homozygous 98.9 
H28-




 T C Homozygous 99.1 
H28-




 T C Homozygous 98.4 
H28-




 T C Homozygous 98.8 
C10661 Control - D-LOOP 16311 
1
 T C Heterozygous 52.6 
H32-OT HCV + D-LOOP 16311 
1
 T C Homozygous 97.3 
H32-




 T C Homozygous 99.1 
H32-




 T C Homozygous 98.7 
H32-




 T C Homozygous 98.4 
H37-OT n.d - D-LOOP 16311 
1





ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H38-OT n.d - D-LOOP 16311 
1
 T C Heterozygous 22.6 
C10661 Control - D-LOOP 16519 
1
 T C Heterozygous 63.4 
C5764 Control - D-LOOP 16519 
1
 T C Homozygous 99.7 
C633 Control - D-LOOP 16519 
1
 T C Homozygous 99.7 
H02-




 T C Homozygous 99.8 
H02-




 T C Homozygous 99.8 
H02-




 T C Homozygous 99.9 
H02-




 T C Homozygous 99.9 
H03-OT n.d - D-LOOP 16519 
1
 T C Homozygous 100.0 
H03-




 T C Homozygous 100.0 
H03-




 T C Homozygous 98.5 
H03-




 T C Homozygous 100.0 
H04-OT HCV + D-LOOP 16519 
1
 T C Homozygous 97.0 
H04-




 T C Homozygous 100.0 
H04-




 T C Homozygous 100.0 
H04-




 T C Homozygous 100.0 
H11-OT HCV + D-LOOP 16519 
1
 T C Homozygous 99.0 
H11-




 T C Homozygous 99.8 
H11-




 T C Homozygous 99.3 
H11-




 T C Homozygous 99.8 
H28-OT Toxic - D-LOOP 16519 
1
 T C Homozygous 100.0 
H28-




 T C Homozygous 99.8 
H28-




 T C Homozygous 99.2 
H28-




 T C Homozygous 99.6 
H32-OT HCV + D-LOOP 16519 
1
 T C Homozygous 100.0 
H32-




 T C Homozygous 99.6 
H32-




 T C Homozygous 100.0 
H32-









ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H37-OT n.d - D-LOOP 16519 
1
 T C Homozygous 99.9 
H37-




 T C Homozygous 100.0 
H37-




 T C Homozygous 100.0 
H37-




 T C Homozygous 99.9 
H38-OT n.d - D-LOOP 16519 
1
 T C Homozygous 99.8 
H38-




 T C Homozygous 99.7 
H38-




 T C Homozygous 100.0 
H38-




 T C Homozygous 99.6 
H38-




 T C Homozygous 100.0 
H40-OT Toxic - D-LOOP 16519 
1
 T C Homozygous 100.0 
H11-
TN1 HCV + ND5 
12384^1
2385 - C Heterozygous 37.7 
H11-
TN2 HCV + ND5 
12384^1
2385 - C Heterozygous 36.2 
H11-
TN3 HCV + ND5 
12384^1
2385 - C Heterozygous 37.5 
H41-
TN1 HBV - RNR2 
2777..2
778 GT - Heterozygous 62.5 
H41-
TN2 HBV - RNR2 
2777..2
778 GT - Heterozygous 66.7 
H41-
TN3 HBV - RNR2 
2777..2
778 GT - Heterozygous 69.0 
H41-
TN5 HBV - RNR2 
2777..2
778 GT - Heterozygous 47.4 




- C Heterozygous 17.5 




- CC Heterozygous 7.8 




- C Heterozygous 78.2 




- CC Heterozygous 5.4 




- C Heterozygous 79.2 
H02-






- C Homozygous 97.2 
H02-






- C Heterozygous 95.5 
H02-






- C Heterozygous 95.1 




- C Heterozygous 6.9 




- CC Heterozygous 47.4 
H37-











ID Aetiology Cirrhosis 
Gene 
Cards Region Reference Allele Zygosity Frequency 
H37-






- CC Heterozygous 90.4 
H37-






- CC Heterozygous 90.3 




- C Heterozygous 5.5 




- CC Heterozygous 29.8 




- CA Heterozygous 67.5 
H37-






- CA Homozygous 100.0 
H37-






- CA Heterozygous 96.0 
H37-






- CA Heterozygous 93.1 




- CA Heterozygous 44.7 







Gene names are written italic 
Abbreviation Explanation 
°C degrees celsius 
µg microgram 
µl  microliter 
µM micromolar 
AFP alpha-fetoprotein  
Al Alcohol intake 
APC Adenomatous Polyposis Coli 
ARID1A AT-Rich Interactive Domain-containing protein 1A 
ARID2 AT-Rich Interactive Domain-containing protein 2 
ASXL1 Additional Sex Combs Like Transcriptional Regulator 1 
ATM Ataxia Telangiectasia Mutated 
ATP Adenosine triphosphate 
AXIN1 Axin 1 
BAD BCL-2 associated death promoter  
BCL-2  B-Cell CLL/Lymphoma 2 
BCLC Barcelona Clinic Liver Cancer  
bp  basepairs 
BRAF  v-Raf murine sarcoma viral oncogene homolog B 
CDH1 Cadherin-1  
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A 
cDNA complementary DNA 
COSMIC Catalogue Of Somatic Mutations in Cancer 
COX Cytochrome C 
CSF1R Colony Stimulating Factor 1 Receptor 
CTNNB1  Catenin (Cadherin-Associated Protein), Beta 1 
DAAs Direct-Acting Antivirals  
DAB 3,3′-diaminobenzidine tetrahydrochloride  
dbSNP Single Nucleotide Polymorphism database 
DMEM Dulbecco's modified Eagles medium  
DMSO dimethyl sulfoxide 
DNA  DeoxyriboNucleic Acid 
DNMT DNA methyltransferase  
dsDNA double-stranded DNA  
EDTA  Ethylene Diamine Tetraacetic Acid 
EGFR Epidermal Growth Factor Receptor 
EMBOSS European and Molecular Biology Open Software Suite 
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2 
EZH2 Enhancer of zeste homolog 2  
FCS Fetal Calf Serum 




Gene names are written italic 
Abbreviation Explanation 
  
FZD1 Frizzled Class Receptor 1 
g  gram 
GNAS GNAS complex locus 
GSK3b Glycogen Synthase Kinase 3b  
h  hour 
HA Hepatic adenoma  
HBV hepatitis B 
HBx HBV X gene, viral transcriptional activator 
HCC HepatoCellular Carcinoma 
HCV hepatitis C 
H-DN High-grade dysplastic nodules 
HEK cells Human Embryonic Kidney cells 
HFE Hemochromatosis gene 
Hg19 Human genome version 19 
HGF Hepatocyte growth factor  
HM  Hemochromatosis 
HNF1A Hepatocyte nuclear factor 1 homeobox A 
HRAS Harvey Rat Sarcoma Viral Oncogene Homolog 
indels the insertion or the deletion 
IGF insulin-like growth factor 
IGF-I insulin-like growth factor 1 
IGF-II  Insulin-Like Growth Factor 2 
IGV Integrative Genomic Viewer 
IL-6 interleukin 6 
IL6ST Interleukin 6 Signal Transducer 
Indels Insertions/deletions 
IRF2 Interferon regulatory factor 2 
IWP International Working Party  
JAK2 Janus Kinase 2 
JNK c-Jun N-terminal kinase  
JUN  Proto-Oncogene 
Kb Kilobase 
KDM6A Lysine (K)-Specific Demethylase 6A 
KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog 
LB Lysogeny broth  
L-DN low-grade dysplastic nodules 
LEF lymphoid enhancer-factor  
LT liver transplantation  
MAPK 1 Mitogen-Activated Protein Kinase 1 
MCT microwave coagulation therapy 
MET Proto-Oncogene, Receptor Tyrosine Kinase 
mg milligram 
ml milliliter 




Gene names are written italic 
Abbreviation Explanation 
  
MMP9 Matrix Metallopeptidase 9 
mt mitochondria 
mtDNA mitochondrial DNA 
MYC V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
n.d Underlying HCC are not defined  
NAFLD Non-alcoholic fatty liver disease  
NASH nonalcoholic steatohepatitis 
NBT Nitroblue tetrazolium  
nDNA nuclaer DNA 
NF1 Neurofibromin 1 
NF2 Neurofibromin 2 (Merlin) 
NFE2L2 Nuclear Factor, Erythroid 2-Like 2 
ng nanogram 
NGS next generation sequencing 
nm nanometer 
NOTCH1 Notch homolog 1 
NOTCH2  Notch homolog 2 
NOTCH3 Notch homolog 3 
NRAS  Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog 
NS5A Nonstructural protein 5A  
nt nucleotides 
OXPHOS Oxidative phosphorylation 
PBS Phosphate-Buffered Saline 
PCR Polymerase Chain Reaction 
PDGF the platelet-derived growth factors 
PDGFRA  Platelet-Derived Growth Factor Receptor, Alpha Polypeptide 
PEI Percutaneous Ethanol Injection  
PIK3CA Phosphatidylinositide-3-kinase, catalytic, alpha polypeptide 
PMS Phenazine methosulfate  
PTEN Phosphatase and tensin homolog  
qPCR quantitative real-time polymerase chain reaction 
RB Retinoblastoma 
RFA RadioFrequency Ablation  
RNA ribonucleic acid 
ROS Reactive Oxygen Species 
RPS6KA3 Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 3 
rRNA ribosomal RNA 
SAV Sequencing Analysis Viewer  
SDH Succinate dehydrogenase 
SH Steatohepatitis 
SIFT sorting tolerant from intolerant 
SMAD2 SMAD Family Member 2 
SMAD4 SMAD Family Member 4 




Gene names are written italic 
Abbreviation Explanation 
  
TACE Trans-Arterial ChemoEmbolisation  
TAE Trans-Arterial Embolisation  
TARE Trans-Arterial RadioEmbolisation 
TCF T Cell-Factor  
TE buffer Tris EDTA buffer 
TGF-β Transforming Growth Factor beta 
TKs Tyrosine Kinases  
TP53 Tumor protein p53 
tRNA  transfer RNA 
VEGF Vascular Endothelial Growth Factor  
VEGFR-2 Vascular Endothelial Growth Factor Receptor-2 
VEGFR-3 Vascular Endothelial Growth Factor Receptor-3 
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